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General Abstract 
Platelets are non-nucleated cell that play a central role in maintaining the haemostatic 
process. They also contribute to thrombotic events, and the initiation and progression 
of atherosclerosis. Antiplatelet medications such as aspirin have been shown to have 
a beneficial effect in the primary and secondary prevention of cardiovascular 
diseases. However, their use can have significant side effects, including 
gastrointestinal ulceration, gastritis and bleeding.  
 
It has been shown that vanilloid-like agents, including plant-derived vanilloids 
(capsaicin (CAP) and dihydrocapsaicin (DHC)), and endogenous vanilloids (N-
arachidonoyl-dopamine (NADA) and N-oleoyldopamine (OLDA)), individually 
inhibit in vitro aggregation in platelets obtained from healthy donors. Thus, the 
overall aim of this thesis was to investigate the possible mechanism(s) by which 
vanilloids inhibit platelet aggregation, both individually and in combination. This is 
important especially since some studies have shown that CAP has a gastro-protective 
effect against mucosal damage induced by aspirin, indomethacin and ethanol. 
Moreover, regular chilli consumption has been reported to decrease the incidence of 
peptic ulcers, control glucose and insulin levels, making chilli a potential 
nutraceutical.  
 
This thesis consists of six chapters. Chapter 1 is a review and critique of the literature 
on platelet structure and function, transient receptor potential vanilloid-1 (TRPV1) 
channels and cannabinoid (CB) receptors in health and disease, vanilloids and their 
clinical applications, the manifestations of systemic lupus erythematosus (SLE), and 
the role platelets in SLE. Chapters two through five present the related background, 
  XV 
research experiments and data generated that detail the mechanistic investigations of 
the inhibitory effects of vanilloids on platelet function. The last Chapter 6 is a 
comprehensive discussion of all the investigations conducted during candidature, and 
includes directions for future work stemming from this research.  
 
Vanilloid-like agents mediate their actions on neurons and other cells through 
TRPV1 channels and/or CB receptors. The aims of the investigations described in 
Chapter 2 were to firstly to confirm TRPV1 expression on human platelets, and then 
to determine whether vanilloid inhibition of in vitro platelet aggregation was receptor 
mediated, i.e., through TRPV1 channels, and/or CB1 or CB2 receptors. Platelets 
were obtained from healthy volunteers for all experiments unless otherwise stated. 
Expression of TRPV1 in platelets was confirmed, although to my knowledge, this is 
the first time this has been demonstrated using confocal microscopy. Furthermore, 
the inhibitory effects of vanilloids on in vitro platelet aggregation induced by 
collagen, Adenosine diphosphate (ADP) and arachidonic acid (AA) were found not 
to be TRPV1-, CB1- or CB2- receptor mediated. However, blocking TRPV1 and 
CB2 receptors appear to enhance OLDA and CAP inhibitory action on platelets.  
 
After excluding a definite role for TRPV1, CB1 and CB2 receptors in the action of 
vanilloid on platelets, other possible mechanisms were investigated in Chapter 3. My 
previous Masters work showed that the endovanilloids, OLDA and NADA, as well 
as the high concentrations (100-25 µM) of plant-derived vanilloid, CAP, 
significantly inhibit in vitro ADP-induced platelet aggregation. Furthermore, CAP, 
DHC and NADA inhibited AA-induced aggregation, whereas NADA and OLDA 
only inhibited aggregation induced by a low concentration of collagen (4 µg/mL, but 
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not 8 µg/mL). Thus, the focus of this thesis was whether vanilloids exert their action 
on platelets by interfering with 1) ADP receptors by measuring vasodilator-
stimulated phosphoprotein (VASP) phosphorylation level, dense- (5-
hydroxytryptamine (5-HT)) release, and/or α-granules (platelet factor 4 (PF4) and β-
thromboglobulin (β-TG)) release, and/or 2) the AA metabolic pathway in platelets. 
Furthermore, the effect of vanilloids on platelet-derived microparticles (PMP) was 
also determined. 
  
NADA significantly increased VASP phosphorylation (17% ± 2.2, p<0.05) 
compared to control (no treatment control), indicate a potential involvement of ADP 
receptor. In addition, OLDA also increased VASP phosphorylation by 13.4%± 2.7, 
p=0.12 but the result was not statistically significant. However, none of the 
vanilloids tested produced a significant effect on PF4, β-TG or 5-HT release from 
ADP-activated platelets. Under AA stimulation, thromboxane B2 (TXB2) formation 
decreased significantly in the presence of 50 µM CAP (10.7%, p<0.001), whereas in 
the presence of 50 µM DHC, the decrease in TXB2 was not significant (4.6%, 
p=0.8). In contrast, OLDA and NADA had no effect on TXB2 formation compared 
to AA alone.  In ADP- and AA-stimulated platelets, vanilloids had no effect on PMP 
release.  Taken together, these results suggest that NADA and possibly OLDA 
inhibits in vitro platelet aggregation through interference with the ADP receptor, 
P2Y12, as VASP phosphorylation increased significantly in its presence. Moreover, 
CAP and perhaps DHC, inhibit the AA pathway, as TXB2 formation was 
significantly decreased. Finally, no changes in circulating PMP in the presence of 
CAP, DHC, OLDA and NADA were observed, suggesting that they do not affect the 
pathway that leads to PMP formation. Although the precise mechanism(s) that 
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produce PMP is(are) not well understood, alterations in phospholipid symmetry and 
cytoskeleton rearrangement appear to be essential. 
 
Pepper fruits (chilli) are the main source of vanilloids, CAP and DHC, which are 
usually present in 60:40 ratio. In Chapter 4, the effects of CAP and DHC both 
individually, and in combination (CAP:DHC, 60:40), on AA-, ADP-, and collagen-
induced in vitro platelet aggregation were investigated and compared. Additionally, 
their effects on platelet count and TXB2 formation were determined to assess the 
combination toxicity toward platelets and their mechanism of action, respectively. 
Under AA stimulation, 12.5 µM CAP and DHC inhibited aggregation by 23.2% and 
25.3%, respectively compared to control (both p<0.01). Interestingly, combination of 
CAP and DHC (7.5:5 µM) produced further inhibition 57.5%, p<0.001, compared to 
control (no treatment control). However, CAP and DHC individually, and in 
combination, had no effect on ADP- or collagen-induced platelet aggregation. 
Incubation of platelets with vanilloids, individually or in combination, did not 
significantly affect the platelet count. The 60:40 CAP:DHC (7.5:5 µM) combination 
significantly inhibited (p<0.001) TXB2 formation compared to the individual 
vanilloids. These results indicate that CAP and DHC in combination act 
synergistically to inhibit the AA metabolic pathway. Therefore, the combination of 
chilli pepper-derived vanilloids exhibits a stronger antiplatelet effect than the 
individual vanilloids, which opens up a new opportunity for research. 
  
Finally, a pilot study was conducted that investigated the effect of vanilloid-like 
agents, CAP, DHC, OLDA and NADA (0-50 µM) on ADP-(5 µM) and collagen-(4 
µg/mL) induced aggregation of platelets obtained from SLE patients (Chapter 5). As 
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all patients were on non-steroidal anti-inflammatory drugs, AA-induced aggregation 
has been excluded. These patients have a higher risk of thrombotic events and the 
development of atherosclerosis compared to the general population that may be 
associated with enhanced platelet activation. CAP, DHC, OLDA and NADA, in 
contrast to their inhibitory effects on platelets from healthy individuals, had no effect 
on ADP-induced aggregation of platelets from SLE patients. Similarly, CAP, DHC 
and OLDA did not influence aggregation induced by collagen. However, NADA 
inhibited collagen-induced aggregation in a concentration-dependent manner (0 vs 
50 µM; %AUC, 44.8±6.5 vs 34.7±7.8, p<0.001) and (%MAX, 60.8±7.7% vs 
37.8±9.7%, p<0.001 n = 5). These results suggest that the pathway(s) through which 
CAP, DHC and OLDA inhibit platelet aggregation in healthy platelets may be 
impaired in SLE, and/or affected by the medications used to treat the manifestations 
of SLE. 
 
In summary, through these studies I have generated new data and knowledge on the 
mechanism of action of vanilloid-like agents on platelets and platelet aggregation. 
The major outcomes are as follows.  First, TRPV1 expression on platelets has been 
confirmed using confocal microscopy. Second, inhibition of in vitro platelet 
aggregation by vanilloid-like agents appears to be independent of a direct interaction 
with TRPV1 channels or CB receptors. Third, CAP and DHC appear to inhibit in 
vitro platelet aggregation by interfering with the AA-pathway, whereas NADA and 
OLDA do so by interfering with and/or blocking the ADP receptor, P1Y12. Fourth, 
CAP, DHC, NADA and OLDA have no effect on the release of PMP from ADP- and 
AA- stimulated platelets. Fifth, low concentrations of a CAP and DHC combination 
(60:40) have a greater inhibitory effect on in vitro platelet aggregation through the 
  XIX 
AA-pathway, compared to a higher concentration of the individual vanilloid. Finally, 
unlike findings in platelets from healthy individuals, only NADA appears to have an 
inhibitory effect on platelets from patients with SLE. The data presented in this thesis 
can be used as a basis for the design of future studies that may investigate the effect 
of vanilloid-like agents using in vivo models as well as on other patients with high 
risk of thrombosis and atherosclerosis to test the viability of chilli pepper as 
nutraceutical. 
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1.! Chapter 1: Literature Review 
1.1.!Introduction 
Platelets are essential for primary haemostasis and endothelium repair, however they 
also play a key role in chronic inflammation and atherosclerosis, the major cause of 
cardiovascular disease (CVD) (Zucker, 1980). Platelets participate in chronic 
inflammation by forming and extending atherosclerotic plaques (Lusis, 2000, Ross, 
1999). Therapeutic agents that suppress platelet aggregation are therefore beneficial 
in the prevention and treatment of CVD. 
The active principles of hot chilli peppers, capsaicin (CAP) and dihydrocapsaicin 
(DHC), as well as the endovanilloids, N-arachidonoyl-dopamine (NADA) and N-
oleoyldopamine (OLDA) have been reported to inhibit in vitro platelet aggregation 
(Almaghrabi et al., 2014, Adams et al., 2009, Raghavendra and Naidu, 2009), 
however, their precise mechanism(s) of action are yet to be determined.  
CAP, NADA and OLDA appear to exert their action through transient receptor 
potential vanilloid 1 (TRPV1)-dependent and -independent mechanisms in neuronal 
tissue (Caterina and Julius, 2001). TRPV1 is a non-selective cation channel that is 
stimulated by a wide variety of agents and physical factors, including plant-derived 
vanilloids (e.g. CAP), endovanilloids (e.g. OLDA and NADA), heat (> 43 0C) and 
acid (pH < 7) (Caterina and Julius, 2001, Zhong and Wang, 2008). Endovanilloids 
also have an affinity for cannabinoid (CB) receptors, CB1 and CB2, and are hence 
also termed endocannabinoids (Howlett et al., 2002).  TRPV1 channels, as well as 
CB1 and CB2 receptors, are expressed in platelets, although the precise role(s) of 
these receptors in platelet function is unclear (Harper et al., 2009, Deusch et al., 
  2 
2004, Catani et al., 2010).  
CVD and atherosclerosis are well-described clinical manifestations in autoimmune 
diseases such as systemic lupus erythematosus (SLE) (Ward, 1999, Gladman and 
Urowitz, 1987). The worldwide prevalence of SLE varies from 4.3 to 150 per 100 
000 population (Chakravarty et al., 2007, Pons-Estel et al., 2010, Jakes et al., 2012), 
with high prevalence in women in childbearing age and certain ethnic groups 
(Askanase et al., 2012, Maidhof and Hilas, 2012). SLE is a prototypic autoimmune 
disease characterised by a perturbed immune response against self, with the 
consequent production of autoantibodies. Some of these autoantibodies form immune 
complexes that are responsible for tissue inflammation that directly contribute to the 
development of several clinical manifestations of the disease (Ruiz-Irastorza et al., 
2001). In SLE, platelets are abnormally activated, which leads to the release of 
inflammatory mediators into the local environment. As a result, the adhesive and 
chemotactic properties of endothelial cells change and increase the risk of 
atherosclerosis, despite thrombocytopenia in some cases (Gawaz et al., 2005, West 
and Johnson, 1988). Understanding the mechanism(s) of action of vanilloids and 
endovanilloids compounds in platelets and how they might affect platelet activation 
in SLE patients is important, as these compounds may be developed as novel anti-
platelet nutraceutical agents.  
1.2.!Platelets 
Platelets are anuclear, small, irregularly shaped fragments of megakaryocyte 
cytoplasm (Avraham, 1993). Their main role is to maintain normal haemostasis and 
repair wounds (Hoak, 1988, Jurk and Kehrel, 2005), but they also contribute to other 
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pathophysiological events such as atherosclerosis, arterial thrombosis and acute 
thrombotic events.  
1.2.1.!Structure and Function 
Platelets are discoid in shape, with approximate dimensions of 2.0-9.0 by 0.5 µm, 
and an average volume of 7-11 femtolitres (fL). They typically circulate in the blood 
for approximately ten days at a concentration of 150 - 450 x 109/L (George, 2000). 
Moreover, they have multiple roles and contribute to many physiological and 
pathological processes such as haemostasis, thrombosis, wound repair, vessel 
constriction and clot retraction, tumour growth, host defense and inflammation 
(Ruggeri, 2002, Harrison, 2005).   
Although platelets are cell fragments, they contain many structures that are crucial 
for their function. These include mitochondria, which regulate the pro-thrombotic 
actions function of platelets and the initiation of apoptosis (Jobe et al., 2008, Vanags 
et al., 1997). An open canalicular system (OCS) serves as a two-way passageway for 
exchange of substances between granular contents of the platelet and the blood 
plasma, and as a reservoir of plasma membrane, membrane proteins, and receptors 
(Escolar and White, 1991, White, 1972). The dense tubular system plays an integral 
role in regulating platelet activation, as a main calcium releasing and sequestering 
organelle (White, 1972, Brass, 1984, Gerrard et al., 1976).  The plasma membrane 
cytoskeleton forms 30 percent of the total platelet proteins, which include actin and 
tubulin. The main function of the cytoskeleton is the maintenance of the discoid 
shape of resting platelets and rapid changes in shape in activated platelets. Moreover, 
the platelet cytoskeleton is responsible for cellular movements, such as transport of 
organelles across the platelet chromosome segregation during mitosis (Fox, 1993, 
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Olorundare et al., 1993, Fox, 2001). Furthermore, platelets have secretory granules, 
alpha (!) granules, dense granules, lysosomes and peroxisomes, which contain 
proteins that regulate angiogenesis, stimulate platelet adhesion, enhance vascular 
repair and promote cell-cell interaction (Figure 1-1) (Kamath et al., 2001, Fukami 
and Salganicoff, 1977, Stenberg et al., 1984, Siess, 1989). Furthermore, platelets 
express different receptors that modulate their function (De Botton et al., 2002).  
Platelets react to endothelial damage via tightly controlled functional responses, 
including adhesion, granule release, activation and aggregation, exposure of 
procoagulant surface, microparticle formation and clot retraction. As a result of these 
responses, a haemostatic plug forms to occlude the damage and prevent bleeding 
(Rodgers, 1999, Harrison, 2005). 
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Figure 1-1 Platelets structure and contents of secretory granules  
Substances released by platelets and their intra-platelet sources. Illustrated are some of the bioactive 
substances released from dense bodies, α-granules, lysosomes, cytoplasm, and platelet membrane. C1 
INH, C1 inhibitor; CTAP, connective tissue-activating peptide; HMWK, high-molecular-weight 
kininogen; PAI-1, plasminogen activator inhibitor 1; PDECGF, platelet-derived endothelial cell 
growth factor; PDGF, platelet-derived growth factor; TGF-β, transforming growth factor-β; and vWF, 
von Willebrand factor. The figure was sourced and modified from Hoffman et al. (2008).  
1.2.1.1.!Activation and Aggregation 
Platelet activation is divided into three overlapping stages: initiation, extension and 
perpetuation (Hoffman et al., 2008). The damaged endothelium exposes collagen, 
which attracts and then activates platelets via attachment to von Willebrand factor 
(vWF) multimers. A platelet monolayer forms over the exposed collagen that 
stimulates thrombin generation and subsequent platelet aggregation. Thrombin and 
collagen normally initiate in vivo platelet activation, however several agonists can 
stimulate in vitro platelet aggregation (Falati et al., 2003, Del Conde et al., 2005). 
Plasma 
membrane 
Mitochondria!
Actin!
Myosin!
Dense tubular 
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Microparticles!
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The platelet surface receptors, glycoprotein Ib/V/IX (GPIb-V-IX), integrin αIIbβ3 
(followed by intracellular signaling through α2β1) and GPVI, assist vWF-dependent 
binding of platelets. As a result, more platelets are attached to the damaged 
endothelium and create a surface for further platelet-platelet interaction (Massberg et 
al., 2003). Moreover, collagen receptors help to capture fast-moving platelets, which 
lead to platelet activation and cytoskeleton reorganisation. vWF propagates this 
process by increasing the affinity of the collagen binding site for platelets and 
stabilises the adhesion of platelets to exposed endothelium collagen (Massberg et al., 
2003, Nieswandt et al., 2001, Nieuwenhuis et al., 1985, Sixma et al., 1997, Kato et 
al., 2003). 
In thrombotic and inflammatory diseases, thrombin initiates platelet activation 
through proteolytic cleavage and stimulation of a subfamily of G Protein-Coupled 
Receptors (GPCRs) known as Protease-Activated Receptors (PAR1 and PAR4). The 
initiation stage of platelet activation is adequate to form a platelet plug, but not to 
arrest bleeding. The second phase of platelet activation is initiated when more 
platelets are attracted, activated and aggregated on the collagen-bound monolayer 
(Hoffman et al., 2008). Consequently, secretion of agonists such as thrombin, ADP 
and thromboxane A2 (TXA2) increases intra-platelet calcium, that in turn activates 
phospholipase C (PLC) and phospholipase A (PLA), recruiting further platelets to 
the injured endothelium. Phosphatidylinositol-4,5-bisphosphate (PIP2) is hydrolysed 
by PLCγ2, an isoform of PLC, to form diacylglycerol and 1,4,5- inositol triphosphate 
(IP3). IP3 opens Ca2+ channels in the platelet-dense tubular system, which increases 
cytosolic Ca2+ influx through the platelet plasma membrane. In contrast, PLA 
hydrolyses arachidonic acid (AA) from phospholipids in the platelet membrane, with 
cyclooxygenase-1 (COX-1) then converting AA to prostaglandin H2 (PGH2). 
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Thromboxane synthase generates TXA2 from PGH2, with thromboxane B2 (TXB2) 
subsequently produced by a non-enzymatic hydration of TXA2 (Figure 1-2) 
(Kulkarni et al., 2004, Nesbitt et al., 2003). 
 
Circulating or locally secreted catecholamines cause vasoconstriction and stimulate 
activation of platelets by propagating the effects of platelet agonists. Most platelet 
agonists exert their effect of extending the platelet plug through GPCRs, which are 
the largest family of membrane proteins in human genome (Fredriksson et al., 2003, 
Pierce et al., 2002, Vassilatis et al., 2003). Chemically different ligand groups, such 
as nucleotides, lipids, amines, ions, proteases and peptides can stimulate GPCRs 
(Bockaert et al., 2002). As a result of their ability to interact with an array of 
functionally diverse heterotrimeric guanine nucleotide-binding proteins (G proteins), 
activation of GPCRs by agonist(s) can stimulate different signaling pathways to alter 
cellular functions (Cabrera-Vera et al., 2003, Wettschureck and Offermanns, 2005). 
The plethoric versatility of G protein-mediated signaling may explain why it is well-
suited for its function as a primary mediator of the second phase of platelet activation 
in the haemostasis and thrombosis processes. These processes require rapid action 
and coordination of various mediators to activate and recruit more platelets into the 
developing thrombus (Offermanns, 2006). 
During the perpetuation stage, the platelet plug is stabilised to stop premature 
disaggregation. The aggregated platelets stabilise mainly by the cohesive strength of 
the binding between αIIbβ3 and fibrin, fibrinogen or vWF (Shattil and Newman, 
2004). In addition, there are other molecules that facilitate adhesion and intracellular 
signaling, apart from integrins such as junctional adhesion molecules (JAMs) 
(Muller, 2003, Bazzoni, 2003), signaling lymphocytic activation molecule (SLAM; 
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CD150) (Krause et al., 2000, Martin et al., 2001, Nanda et al., 2005) and platelet 
endothelial cell adhesion molecule 1 (PECAM-1; CD31) (Newman and Newman, 
2003). Activation of platelets is a very dynamic process where receptors and effector 
pathways regulate each stage of this process (Hoffman et al., 2008). 
 
1.2.1.2.!Platelets Adhesion Receptors 
Platelets normally circulate within the blood in an inactive state without interacting 
with other platelets or cells. Following exposure to stimulatory agonists or vascular 
injury, platelets become more adhesive.  Most adhesive proteins in platelets belong 
to the integrin group, a widely distributed family of heterodimeric cell surface 
molecules (having two subunits, ! and "), which share some functional, structural 
and immunochemical characteristics (Hynes, 1992, Fitzgerald et al., 1987). Each !-
subunit joins a "-subunit via a non-covalent bond, forming an efficient adhesive 
protein receptor. The major "-subunits expressed on platelets are "1 and "3 ("2 at low 
levels), along with five !-subunits (Philippeaux et al., 1996). The !IIb"3 integrin 
(GPIIb/IIIa) is unique to megakaryocytes/platelets and plays an important role in 
platelet aggregation and tumor cell-platelet interaction (Grossi et al., 1988, 
Boukerche et al., 1989, Honn et al., 1992). 
GPIb-V-IX is a platelet surface molecule that is involved in platelet adhesion as a 
receptor for vWF, but is not one of the integrin family (Andrews et al., 2003). vWF 
mediates reversible rapid adhesion of platelets which allows the rolling of platelets 
along the surface of the disrupted endothelium (Sadler, 2002). This rolling may 
temporarily bridge the platelet to subendothelial matrix contents until a more stable 
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adhesive bond is formed. The binding between GPIb-V-IX and vWF leads to 
intracellular signaling events that result in activation of !IIb"3 and platelet 
aggregation (Berndt et al., 2001, Savage et al., 1992). Furthermore, the role of GPIb-
V-IX in haemostasis is not limited to vWF, but also as a binding site for thrombin, 
which has an important function in the production of PMPs and procoagulant activity 
(Okumura and Jamieson, 1976, Moroi et al., 1982). 
Figure 1-2 Arachidonic acid pathway in platelets 
Cyclooxygenase-dependent arachidonic acid pathway in platelets. Thrombin, generated in vivo or ex 
vivo by several chemical or physical stimuli, activates its protease-activated receptors (PARs) 
increasing intraplatelet calcium, which triggers phospholipases (PL) A2-dependent cleavage of 
arachidonic acid (AA) from plasma membranes. AA is the enzymatic substrate of cyclooxygenase 
(COX)-1 and -2. COX-1-dependent AA path in platelets generates mainly TXA2, which amplifies 
platelet activation by binding to its platelet receptors (TPs). COX-2-dependent AA path in normal 
platelets is less prominent and generates mainly PGE2, which acts as a positive modulator of platelet 
response to other agonists by binding to its platelet receptors (EPs). TXA2 both in vivo or ex vivo is 
nonenzymatically hydrolised to TXB2, which is biologically inactive but stable, and can be measured 
in ex vivo assays or undergoes further hepatic enzymatic biotransformation in vivo. Image sourced 
from Rocca and Petrucci, 2012 without modifications (Rocca and Petrucci, 2012). 
 
Subendothelial collagen is a well-known potent platelet agonist that initiates platelet 
activation and adhesion. There are four collagen receptors, !2"1 and GPVI bind 
  10 
directly to collagen, and !IIb"3 and GPIb-V-IX bind to collagen through vWF. !2"1 
(also known as VLA-2 and platelet GPIa-IIa) is a member of the integrin adhesion 
receptor family and helps platelets to attach to endothelial exposed collagen 
(Hoffman et al., 2005, Hoffman et al., 2008, Clemetson et al., 1999). !2"1 mainly 
acts as a secondary receptor for collagen adhesion to platelets (Siljander et al., 2004). 
In contrast, GPVI serves primarily as a collagen receptor that directly interacts with 
the collagen and stimulates intracellular signaling cascades. The collagen-platelet 
interaction is a complicated process and the antiplatelet medications that target 
collagen receptor are limited to patients with high thrombotic and low bleeding risk, 
for a short period of time (Gachet, 2015, Franchi and Angiolillo, 2015).  
ADP is one constituent of platelet dense granules that are released in response to 
physiological platelet agonists, including collagen, TXA2 and thrombin. ADP also 
amplifies its own effects as well as those of other activators (Shankar et al., 2006, 
Maffrand et al., 1988). In addition, ADP is released passively by damaged 
endothelium and red blood cells that enhance platelet aggregation via integrin !IIb"3 
activation and subsequent fibrinogen binding (Mills, 1996). Adding ADP to platelets 
in vitro leads to TXA2 formation, phosphorylation of PIP2, raised cytosolic Ca2+ 
concentration, shape change, aggregation and granules release, as well as inhibition 
of cAMP formation (Daniel et al., 1986, Mills and Smith, 1972, Raha et al., 1993, 
Sage and Rink, 1986). 
Platelets have two ADP-dependent purinergic receptors, P2Y1 and P2Y12, members of 
the GPCR superfamily (Jantzen et al., 1999, Daniel et al., 1998). The third platelet 
purinergic receptor is P2X1, an ATP-gated Ca2+ channel (Daniel et al., 1998, 
MacKenzie et al., 1996). P2Y1 is responsible for activation of PLC, as well as the 
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production of diacylglycerol and IP. As a result of IP formation, Ca2+ is mobilised 
from cytosolic stores, activates protein kinase C (PKC) and causes phosphorylation 
of myosin light chains (Figure 1-3). These signaling events play an important role in 
agonist-induced platelet shape change. P2Y1 activation is sufficient to cause platelet 
shape change. However, to induce platelet aggregation both receptors need to be 
activated (Daniel et al., 1998, Daniel and Adelstein, 1976, MacKenzie et al., 1996). 
By blocking or deleting the P2Y1 receptor, ADP still can inhibit cAMP formation, 
but its ability to increase cytosolic Ca2+ concentration, and cause platelet shape 
change and aggregation, are significantly impaired. P2Y1-/- knockout mice have 
minimal increases in bleeding time and increased survival rate after administration of 
ADP. However, the responses to other platelet agonists are unaffected (Leon et al., 
2001, Leon et al., 1999). 
ADP binds to the P2Y12 receptor on the platelet surface, triggering signaling through 
G inhibitory protein to inhibit adenylyl cyclase and cAMP formation (Hollopeter et 
al., 2001, Zhang et al., 2001), leading to dephosphorylation of vasodilator-stimulated 
phosphoprotein (VASP) (Figure 1-3) (Cattaneo, 2007). VASP phosphorylation is 
directly proportional to the degree of P2Y12 antagonism (Cattaneo, 2007). Patients 
lacking functional P2Y12, have a mild hemorrhagic phenotype because their platelets 
do not aggregate normally in response to ADP (Cattaneo and Gachet, 1999, Nurden 
et al., 1995). In mice, deletion of either P2Y1 or P2Y12 impairs the response of 
platelets to low concentrations of thrombin, TXA2 and ADP, and prolongs bleeding 
time (Leon et al., 1999, Fabre et al., 1999). 
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1.2.1.3.!Granules 
Activation of platelets by ADP, collagen and thrombin trigger morphological 
changes in platelets that result in the movement of secretory granules to the cell 
centre and consequent fusion with the surface-connected canalicular system. As a 
result of granule-plasma membrane fusion, platelets release their granule components 
(Siess, 1989, Stenberg et al., 1984, Escolar and White, 1991). Platelets are full of 
secretory granules including α granules, dense granules, lysosomes and peroxisomes, 
which are important for platelet function (Figure 1-1) (Coppinger et al., 2004). 
 
The most abundant secretory granules in platelets are !-granules, forming 
approximately ~10% of platelet volume (Table 1-1). In addition, there are around 50-
80 !-granules per platelet with sizes ranging from 200-500 nm (Frojmovic and 
Milton, 1982). Platelet !-granules play roles in angiogenesis, antimicrobial activity, 
wound healing, atherosclerosis, inflammation, host defense, and malignancy (Blair 
and Flaumenhaft, 2009). 
Dense granules contain small particles, including calcium ions and serotonin, as well 
as nucleotides, including ADP and adenosine triphosphate (ATP). These contents 
promote localised vasoconstriction and activate other platelets so any change in 
granules release may affect normal haemostasis (Ren et al., 2008). Platelet 
peroxisomes and lysosomes contain catalase and hydrolytic enzymes such as 
cathepsins and hexosaminidase, which might play a role in platelet activation and 
clot remodeling (Ren et al., 2008, Kamath et al., 2001, Anitua et al., 2004). Each of 
these secretion events should be highly controlled to avoid the inappropriate release 
of granules contents.  
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1.2.1.4.!Microparticles 
Microparticles are heterogeneous, membrane-coated small vesicles with a diameter 
of 0.1-1 µm that are released from different cell types, including platelets. 
Microparticles contain a variety of intracellular components such as DNA, RNA and 
cytoplasmic proteins, and express proteins derived from their original cell source. 
They are released from plasma membranes by a process called ‘exocytic budding’ 
following cell activation or apoptosis. Formation of microparticles is an active 
process, being constantly produced by cells. In this process, the normal asymmetry 
of membrane lipids is misplaced, which causes phosphatidylserine to be on the outer 
layer of the microparticle membrane. As a result, annexin V, which is commonly 
used to detect and quantify microparticles, is allowed to bind to phosphatidylserine 
(Distler et al., 2005, Wolf, 1967). Several markers have been used to determine the 
origins of microparticles such as platelets (CD41a/b, CD42a/b and CD61), 
endothelial cells (CD144, CD105, CD146, CD51, CD62E AND CD31+/CD42a-) 
and erythrocytes (CD235a) (Gelderman and Simak, 2008, Jimenez et al., 2003, Jy et 
al., 2004). 
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Figure 1-3 ADP pathway in platelet aggregation.  
Activation of the P2Y1 receptor leads to an alteration in shape and initiates a weak and transient phase 
of platelet aggregation. The binding of ADP to the Gq-coupled P2Y1 receptor activates phospholipase 
C (PLC), which generates diacylglycerol (DAG) and inositol triphosphate (IP3) from 
phosphatidylinositol biphosphate (PIP2). Diacylglycerol activates protein kinase C (PKC) leading to 
phosphorylation of myosin light chain kinase (MLCK-P) and IP3 leads to mobilisation of intracellular 
calcium. The P2Y1 receptor is coupled to another G-protein, G12, which activates the “Rho” protein 
and leads to the change in platelet shape. The binding of ADP to the Gi-coupled P2Y12 receptor 
liberates the Gi protein subunits αi. β and γ, resulting in stabilisation of platelet aggregation. The αi 
subunit inhibits adenylyl cyclase (AC) and, thus, reduces cyclic adenosine monophosphate (cAMP) 
levels, which diminishes cAMP-mediated phosphorylation of vasodilator-stimulated phosphoprotein 
(VASP-P). The status of VASP-P modulates glycoprotein (GP) IIb/IIIa receptor activation. The 
subunit βγ activates the phosphatidylinositol 3-kinase (PI3K), which leads to GP IIb/IIIa receptor 
activation through activation of a serine-threonine protein kinase B (PKB/Akt) and of Rap1b GTP 
binding proteins. Prostaglandin E1 (PGE1) activates AC, which increases cAMP levels and status of 
VASP-P. Solid arrows indicate activation; dotted arrows indicate inhibition. Image sourced from 
(Angiolillo et al., 2007) without modifications. 
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Table 1-1 Platelet Alpha Granules Contents and Functions 
Functions Contents References 
Chemokines  CXCL1 (GRO-α), CXCL4 (platelet factor 4), 
CXCL5 (ENA-78), CXCL7 (PBP, β-TG, 
CTAP-III, NAP-2), CXCL8 (IL-8), CXCL12 
(SDF-1α), CCL2 (MCP-1), CCL3 (MIP-1α), 
CCL5 (RANTES 
 
(Brandt et al., 2000, Gleissner et al., 2008) 
Growth factors  Vascular endothelium growth factor (VEGF), 
Platelet-derived growth factor (PDGF), 
Fibroblast growth factor (FGF), Epidermal 
growth factor (EGF), Hepatocyte growth factor 
(HGF), Insulin-like growth factor (IGF) 
 
(Rendu and Brohard-Bohn, 2001, Nurden et al., 
2008) 
Angiogenesis inhibitors  TSP-1 
 
(Jimenez et al., 2000) 
Pro angiogenic mediators  Angiopoietin, CXCL12 (SDF-1α), Matrix 
metalloproteinases     (MMP-1, -2, and -9) 
 
(Karshovska et al., 2007, Massberg et al., 2006) 
Complement and complement binding 
proteins  
Complement C3, Complement C4 precursor (Maynard et al., 2007) 
Adhesive receptors  GPIbα-IX-V (major receptor for fibrinogen), 
Integrin αIIbβ3, GPVI (collagen receptor) 
 
(Berger et al., 1996, Suzuki et al., 2003) 
Membrane bound proteins  Integrins (e.g., αIIb, α6, β3), Immunoglobulin 
family receptors (e.g. GPVI, Fc receptors, 
PECAM), Leucine-rich repeat family receptors 
(e.g., GPIb-IX-V complex), Tetraspanins (e.g., 
CD9), Other receptors (CD36, Glut-3), P-
selectin 
(Suzuki et al., 2003, Nurden et al., 2004, Niiya 
et al., 1987, Maynard et al., 2007, Berger et al., 
1993) 
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Coagulation factors and co-factors  Factors V, Factors XI, Factor XIII (Rendu and Brohard-Bohn, 2001, Hayward et 
al., 1995, Jeimy et al., 2008, Kiesselbach and 
Wagner, 1972) 
Inactive precursor  Thrombin, Prothrombin, High molecular weight 
kininogens, Plasminogen 
(Maynard et al., 2007, Rendu and Brohard-
Bohn, 2001) 
Inhibitory proteases  Plasminogen activator inhibitor-1 (PAI-1), α2-
antiplasmin 
(Rendu and Brohard-Bohn, 2001) 
Anticoagulants Antithrombin, C1-inhibitor (Blair and Flaumenhaft, 2009) 
Adhesion molecules Fibrinogen, Von Willebrand factor (vWF), 
Fibronectin, Vitronectin, Thrombospondin 
(Cramer et al., 1988, Gralnick et al., 1985) 
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Platelet-derived microparticles (PMP) represent subcellular elements for signaling 
between cells, and intercellular communication in inflammation. PMP are able to 
trigger coagulation in vitro due to the expression of tissue factor on their surface 
(Shimura et al., 1996, Schecter et al., 2000, Nieuwland et al., 1997, Joop et al., 
2001), and by providing a negatively charged surface (phosphatidylserine) for the 
prothrombinase complex (factors Va and FXa) to assemble (Gilbert et al., 1991, 
Hamilton et al., 1990, Hoffman et al., 1992). The prothrombinase complex catalyses 
the conversion of the inactive zymogen prothrombin to the enzyme thrombin. 
Furthermore, tissue factor (the trigger of the tissue factor pathway) and vWF 
multimers (which facilitates platelet aggregation), have been detected on circulating 
PMP (Morel et al., 2011b). Moreover, PMP promote cyclooxygenase-2 (COX-2) 
expression in endothelial cells, which leads to an increase in prostaglandin 
production and vasodilation (Barry et al., 1997, Barry et al., 1998).  
Microparticles from different origins have been proposed as future prognostic, 
diagnostic or predictive biomarkers for several diseases, as they change composition, 
phenotype and number in a variety of pathological conditions (Gyorgy et al., 2011, 
Ramacciotti et al., 2010, Rautou et al., 2011, van der Zee et al., 2006). Increased 
levels of circulating PMP are associated with prothrombotic diseases such as 
myocardial infarction (van der Zee et al., 2006), sickle cell anemia (Shet et al., 
2003), heparin-induced thrombocytopenia (Hughes et al., 2000) and inflammation 
(Daniel et al., 2006, Pereira et al., 2006, Pamuk et al., 2006). In prototypic 
autoimmune diseases such as SLE, it has been shown that SLE patients have elevated 
levels of PMP, which are associated with an increased potential for thrombin 
generation (Pereira et al., 2006). As microparticles contain DNA, or RNA, or both, it 
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has been suggested that they might act as autoadjuvants to activate macrophages, 
lymphocytes and dendritic cells (DC), stimulate cytokine and chemokine production 
(Piccin et al., 2007, Ratajczak et al., 2006, Beyer and Pisetsky, 2010). In rheumatoid 
arthritis, microparticles appear to contribute directly to synovial inflammation, and 
recently it has been found that PMP in synovial fluid might exacerbate arthritis 
(Berckmans et al., 2002, Boilard et al., 2010). 
1.2.2.!The Role of Platelets in Atherosclerosis 
Atherosclerosis is a systemic inflammatory disease influenced by blood cells, 
including platelets, which accumulate in the intima of large and medium-sized 
arteries (Ross, 1999, Lusis, 2000). Injury to the endothelium causes endothelial 
dysfunction that changes the normal homeostatic properties of the endothelium, from 
an anticoagulant to procoagulant, releasing growth factors, cytokines and vasoactive 
molecules. Atherosclerotic lesions begin to grow and progress on dysfunctional 
endothelium.  
Platelets mediate atherosclerotic lesion formation by releasing their granule contents 
and microparticles following adhesion and activation, in addition to forming free AA 
that can be converted into TXA2 or leukotrienes. TXA2 is a potent platelet agonist 
and vasoconstricting agent, while leukotrienes amplify the inflammatory response 
(Ross, 1999). Indeed, it has been reported that platelet-derived proinflammatory 
factor deposition on monocytes and on the vascular wall, lead to increased monocyte 
recruitment, activation of monocyte integrins and exacerbation of atherosclerotic 
lesions (Huo et al., 2003, Chesterman and Berndt, 1986). In addition, inhibition of 
platelet adhesion decreases leukocyte infiltration and weakens the development of 
atherosclerotic plaques in the cholesterol-fed apolipoprotein E-deficient (ApoE-/-) 
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mouse (Huo et al., 2003). In conclusion, the contents released from platelet granules 
during the release reaction play a major role in the development of atherosclerosis.  
1.3.!Cannabinoid Receptors  
Cannabinoid (CB) receptors are so named as they are activated by cannabinoids such 
as delta-9-tetrahydrocannabinol (THC) (Howlett et al., 1988). The two CB receptors 
described to date, CB1 and CB2, are different in their predicted amino acid sequence 
and signaling mechanisms. Both however, are coupled through G protein (GPCRs) to 
adenylyl cyclase and mitogen-activated protein kinase (Rueda et al., 2000). 
CB1 receptors are present mainly in central and peripheral neurons, with a major 
function to inhibit neurotransmitter release (Childers and Deadwyler, 1996, Pertwee, 
2001). In contrast, the CB2 receptor is predominantly expressed on immune cells and 
affects many functions of the immune response, including modulation of cytokine 
release (Zhu et al., 2000). Platelets express CB1, and to lesser extent CB2, receptors, 
although their roles in platelet function are unclear (Deusch et al., 2004, Catani et al., 
2010). 
1.3.1.!Cannabinoid Receptors in Disease  
The CB system is able to modulate immune function through the CB2 receptor that is 
expressed by macrophages, NK cells, T cells and B cells, in addition to its important 
role in neuronal regulation through the CB1 receptor (Klein et al., 2003). In the 
healthy central nervous system (CNS), CB1 and CB2 receptors are normally 
undetectable (Buckley et al., 2000, Galiegue et al., 1995, Munro et al., 1993). 
However, CB1 and CB2 expression changes in relation to cell activation (Carlisle et 
al., 2002, Garcia-Ovejero et al., 2009).  For example, CB2 receptor expression is 
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provoked in the spinal cord, and in chronic pain models related to peripheral nerve 
injury, which are associated with the presence of activated microglial cells (Zhang et 
al., 2003). 
Neuritic plaque-associated astrocytes and microglia in patients with Alzheimer’s 
disease contain activated microglial cells with raised CB2 receptor expression, 
whereas the expression of CB1 receptors remains unchanged (Benito et al., 2003). It 
has been found that the cannabinoid system and microglial cells are also associated 
with CNS inflammation in multiple sclerosis (Compston and Coles, 2002).   
Furthermore, the expression of CB2 receptors in CNS is dramatically upregulated in 
experimental autoimmune encephalomyelitis associated with infiltrating 
macrophages and resident microglia (Ponomarev et al., 2005). It has been reported 
that low doses of THC act through CB2 receptors to reduce the progression of 
atherosclerotic plaques in a murine knockout model of atherogenesis, via suppression 
of macrophage recruitment (Steffens et al., 2005). In any case, the selective presence 
of cannabinoid receptors in different human cells suggest that the modulation of their 
activity may have potential therapeutic implications (Pertwee, 2006).  
1.3.2.!Endogenous Cannabinoids (Endocannabinoids) 
Endocannabinoids are AA derivatives and part of the eicosanoid family (Blankman 
et al., 2007). They are the endogenous ligands for CB receptors and a part of 
endocannabinoid system as well as the enzymes for ligand biosynthesis and 
degradation for molecules, such as fatty acid amide hydrolase (FAAH) and 
monoacylglycerol lipase (Freund et al., 2003, Mackie, 2006).  
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The main endocannabinoids, 2-arachidonoylglycerol (2-AG) and anandamide (AEA) 
activate CB receptors, and in the case of AEA, TRPV1 channels (Figure 1-4). 
Moreover, it has been reported that platelets are able to metabolise 2-AG and AEA 
(Maccarrone et al., 1999, MacCarrone et al., 2001, Braud et al., 2000, Gkini et al., 
2009, Varga et al., 1998). Both 2-AG and AEA act as platelet agonists however, the 
literature relating to the actions of endocannabinoids in platelets is controversial. It 
has been reported that 2-AG activates human platelets through CB1 and CB2 
receptors, as blocking these receptors inhibited the 2-AG stimulatory effect on 
platelets (MacCarrone et al., 2001). In contrast, another study reported that 2-AG 
induced platelet aggregation through a CB1- and CB2-independent mechanism 
(Keown et al., 2010). The reasons for these conflicting findings are unknown, 
however, it might be due to using different experimental models e.g., platelet rich 
plasma (PRP) versus whole blood in aggregation studies, as well as different CB1 
and CB2 receptor antagonists.   
2-AG and AEA hydrolysis generates AA, which is the major substrate of 
cyclooxygenase (Nakahata, 2008). It has been reported that AEA activates platelets 
from rabbits, but this was insensitive to CB1 antagonist and inhibited completely by 
a COX1 inhibitor (Braud et al., 2000). Another study has shown the same effect 
using human platelets. However, inhibiting COX1 did not have an effect on platelet 
activation suggesting that AEA activation may be mediated through cannabinoid 
receptor-dependent mechanisms (Maccarrone et al., 1999).    
THC activates platelets by increasing GPIIb/IIIa expression, as well as P-selectin and 
2-AG levels (Deusch et al., 2004). Finally, in addition to AEA, there are other 
endocannabinoids that act also as an endovanilloids (discussed later in 1.6.1 
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Endogenous Vanilloids), such as N-oleoyldopamine (OLDA) and N-arachidonoyl-
dopamine (NADA) (Figure 1-5).  
 
Figure 1-4 Chemical Structures of Endogenous Cannabinoids  
Anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) (Tomida et al., 2004). 
 
 
Figure 1-5 Chemical Structures of Endovanilloids/Endogenous Cannabinoids 
N-oleoyldopamine (OLDA) and N-arachidonoyl-dopamine (NADA) (Chu et al., 2003). 
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1.4.!Transient Receptor Potential Vanilloid Channel-1  
The Transient Receptor Potential Vanilloid Channel-1 (TRPV1) channel, also 
referred to as the CAP receptor (Roberts et al., 2004), is a non-selective cation 
channel that is stimulated by a wide variety of agents. These include plant-derived 
vanilloids (e.g. CAP and resiniferatoxin (RTX)), endogenous vanilloid-like lipids 
(e.g. OLDA and NADA), acid (pH < 7) and heat (> 43 0C) (Caterina and Julius, 
2001, Zhong and Wang, 2008). The TRPV1 channel is widely distributed throughout 
the peripheral nervous system, central nervous system and non-neuronal tissue 
(Sanchez et al., 2001). 
There are several amino acids and amino acid sequence motifs in the TRPV1 
channels protein that have defined functions, such as mediating the actions of CAP 
(Kuzhikandathil et al., 2001, Tominaga and Tominaga, 2005, Welch et al., 2000), 
heat activation (Gunthorpe et al., 2000), phosphorylation (Rathee et al., 2002, Dai et 
al., 2004), modulation by lipids (Ahern, 2003, Chuang et al., 2001), multimerisation 
(Smith et al., 2002), proton action (Jordt et al., 2000), permeability (Caterina et al., 
1997, Mohapatra et al., 2003) and desensitisation (Szallasi and Blumberg, 1999) 
(Figure 1-6, describes these features in more detail). 
Capsaicin is lipophilic, which allows it to pass through the cell membrane and acts 
on binding sites on the intracellular domain of TRPV1, providing a possible 
explanation for the lag time between capsaicin intake and pungent sensation (Jung et 
al., 1999). TRPV1 has a similar structure to voltage-gated K+ channels, involving the 
six-TM topology. As specified by the contemporary helix-packing models of the 
voltage-gated K+ channels, the first, second and third TM domains are placed on the 
lipid-facing side of the tetrameric channel complex. In contrast, the fifth and sixth 
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TM domains are placed nearer to the pore-forming channel core. Presuming TRPV1 
is similar to helix packing, the capsaicin lipophilic moiety might bind to the second 
and third TM domains on the channel-lipid interface.  The vanilloid moiety might 
interact with residues around Tyr 511 in the cytosolic region, therefore binding the 
cytosolic tail with two TM domains (Kuzhikandathil et al., 2001, Tominaga and 
Tominaga, 2005, Welch et al., 2000). 
 
Figure 1-6 Critical residues involved in TRPV1 function.   
TRPV1 has six transmembrane domains and a short, preforming hydrophobic stretch between the fifth 
and sixth transmembrane domains. TRPV1 topology highlighting residues implicated in the 
activation, sensitisation, desensitisation, gating properties or permeation of the channel. CAP passes 
through the cell membrane to its binding sites in the intracellular domain. Phosphatidylinositol (4,5)-
bisphosphate (PIP2) binds to the indicated region in the carboxyl (C) terminus. Calmodulin (CaM) 
binds to both C- and amino (N)-termini. Image sourced from (Nagy et al., 2014) without 
modifications. 
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1.4.1.!TRPV1 in Disease 
Upregulation of TRPV1 channel expression occurs on certain pathological 
conditions, which may provide a basis for the use TRPV1 channels antagonists as 
potential therapeutic agents (Cortright and Szallasi, 2004). For example, abnormal 
expression of TRPV1 channels by neurons that do not normally express the TRPV1 
channels has been linked to the development of neuropathic pain and inflammatory 
hyperalgesia (Hudson et al., 2001, Rashid et al., 2003). Indeed, the expression of 
TRPV1 in dorsal root ganglia increased following dorsal root ganglia avulsion injury 
(e.g. central axotomy) (Smith et al., 2002).  
 
A number of disorders are correlated with increased aberrant expression of TRPV1 
for example: in the respiratory system, airway neurons express TRPV1 upon 
exposure to allergen leading to release neuropeptides, which increase airway 
secretions and submucosal edema, alter smooth muscles tone, and stimulate immune 
and inflammatory cellular responses (Bessac and Jordt, 2008, Lieu et al., 2012). In 
nasal mucosa allergic inflammation, mucosal expression of TRPV1 increases 
(Samivel et al., 2016), as do TRPV1 channel expression in mononuclear cells of end-
stage kidney disease patients (Saunders et al., 2009). 
 
The number of TRPV1-like immunoreactive fibers increases in patients’ colon with 
active inflammatory bowel disease and irritable bowel syndrome and in a rectal 
biopsy from patients with fecal urgency and rectal hypersensitivity (Chan et al., 
2003, Yiangou et al., 2001, Akbar et al., 2010). Furthermore, patients with 
neurogenic detrusor over-activity have an increased expression of TRPV1 and were 
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effectively treated with TRPV1 agonists, CAP or RTX (Chancellor and de Groat, 
1999). 
 
High fat fed TRPV1 knockout mice were protected against obesity-induced 
hypertension and glucose intolerance compared to high-fat-fed wild-type mice 
(Marshall et al., 2013). In summary, disease-related changes in the expression of 
TRPV1 have been described in human, however, the mechanism(s) regulating 
TRPV1 gene expression in diseased conditions are unknown. Therefore, better 
understanding of these mechanisms will have implications for drug development.   
1.5.!Vanilloids 
Vanilloids are compounds that contain a vanillyl group and include endogenous 
agents (endovanilloids) that are primarily AA derivatives, and plant-derived 
vanilloids, with the most well-known being capsaicinoids, the active ‘hot’ 
constituents of chilli peppers.   
1.5.1.!Endogenous Vanilloids 
Endogenous AA derivatives activate TRPV1 channels and CB receptors to varying 
degrees, and include at least three types of lipids: N-acylethanolamines [N-
oleoylethanolamine, AEA, N-linoleoylethanolamine] (Zygmunt et al., 1999, Ross, 
2003); unsaturated N-acyldopamines [OLDA, NADA] (Chu et al., 2003, Huang et 
al., 2002) and lipoxygenase products [e.g., leukotriene B4, 12-(S)- and 15-(S)-
hydroperoxyeicosatetraenoic] (Hwang et al., 2000).  
NADA was originally characterised in the striatum of bovine brain, and the areas 
with the highest concentrations in rat nervous system include the cerebellum, 
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striatum and hippocampus, whereas the lowest concentration is found in the dorsal 
root ganglion (Huang et al., 2002). In addition, NADA has nanomolar affinity for 
TRPV1 channels on sensory neurons, which leads to the release of calcitonin gene-
related peptide and substance P (Huang et al., 2002), and also possesses the same 
affinity for CB1 receptors (Bhave et al., 2002). NADA was the first endovanilloid 
identified in mammals with similar efficacy and potency at TRPV1 channels 
comparable to that of CAP (Huang et al., 2002). OLDA is the most selective and 
potent endogenous vanilloid at the TRPV1 channels, and might function as a central 
or peripheral mediator of TRPV1 channel activation. Moreover, OLDA is 50 times 
more effective at TRPV1 channels compared to CB1 receptors. Also it is more potent 
than CAP by 30 times (Chu et al., 2003, Szolcsanyi et al., 2004). Moreover, OLDA 
is quite stable and remains for long periods (hours) in bio-membranes, potentially 
activating receptors for extended periods (Zajac et al., 2006). 
Importantly, NADA and OLDA inhibit in vitro platelet aggregation induced by ADP 
and collagen in a concentration-dependent manner, and both are more potent than 
CAP and DHC (Almaghrabi et al., 2014). Moreover, since platelets have CB1 and 
CB2 receptors (Deusch et al., 2004, Catani et al., 2010) and FAAH (Maccarrone et 
al., 1999), a prominent component of endocannabinoid system, the possibility that 
endocannabinoids/endovanilloids can modulate platelet function is a distinct 
possibility.  
1.5.2.!Plant Derived Vanilloids 
The placental tissues of Capsicum fruit contain capsaicinoids (Kozukue et al., 2005, 
Thompson et al., 2005a, Thompson et al., 2005b, Garces-Claver et al., 2006). CAP 
and DHC are the two major capsaicinoids that are responsible for the ‘pungency’ of 
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chilli peppers (Bennett and Kirby, 1968, Kosuge and Furuta, 1970). The relative 
proportions of CAP:DHC in many common pepper varieties is 60:40 (Garces-Claver 
et al., 2006). Besides CAP and DHC, at least nine other capsaicinoids have been 
found to form in peppers including, norcapsaicin, nordihydrocapsaicin, 
homocapsaicin,  homodihydrocapsaicin, homocapsaicin II, homodihydrocapsaicin II, 
N-vanillyl nonanamide, N-vanillyl octanamide, and N-vanillyl decanamide (Reilly et 
al., 2001a, Reilly et al., 2001b, Davis et al., 2007, Mueller-Seitz et al., 2008). 
Capsaicinoids are synthesised by condensation of vanillylamine and fatty acids, 
mainly in the pepper placenta (Thiele et al., 2008, Curry et al., 1999), are stable in 
nonpolar and polar solvents, and highly lipophilic (Tanaka et al., 2009).  
It is well known that capsaicinoids exert their actions by stimulating TRPV1 
channels, and the mechanism is now well described (Luo et al., 2011). In the nervous 
system, capsaicinoids act as a natural irritant and selectively activate TRPV1 
channels on sensory neurons, which convey noxious sensations to the central nervous 
system. Activated TRPV1 channels allow sodium and calcium ions to move through 
the sensory neuron membrane, resulting in depolarisation and nociceptive responses. 
These are followed by a long-lasting refractory period and desensitisation of the 
neuron (Wang and Woolf, 2005, Gerner et al., 2008, Kissin, 2008, Knotkova et al., 
2008). Each analog binds to and activates TRPV1 channels with different potency, 
and is dependent on a 3-methxy-4-hydroxybenzylamine ring (vanilloid) and alkyl 
chain structure (Hayes et al., 1984, Walpole et al., 1993a, Walpole et al., 1993c, 
Walpole et al., 1993b). CAP, nonivamide and DHC are the most pungent and potent 
vanilloids in Capsicum (Reilly and Yost, 2006). 
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1.5.3.!Clinical Applications of Plant-Derived Vanilloids 
Capsaicinoids have extensive pharmacological properties, however their clinical 
application is to date limited by their high toxicity and low selectivity (Luo et al., 
2011). Some examples of the physiological and pharmacological effects of plant-
derived vanilloids, and their potential clinical applications, are discussed below. 
As an analgesic, administration of CAP locally or orally reduces pain in rheumatoid 
arthritis, inflammatory heat, noxious chemical hyperalgesia, and neuropathic pain 
(Fraenkel et al., 2004, Raber et al., 2015). In oncology studies, CAP has been shown 
to reduce the size of MDAMB231 breast cancer masses in mice (Thoennissen et al., 
2010) and was able to destroy cultured prostate cancer cells, while DHC was 
reported to enhance autophagy in cultured human HCT116 colon cancer cells (Oh et 
al., 2008, Thoennissen et al., 2010, Yang et al., 2010). Moreover, it has been found 
in clinical studies and animal experiments that capsaicinoids suppress obesity by 
decreasing body fat accumulation (Shin and Moritani, 2007, Reinbach et al., 2009). 
Capsaicinoids have also gastroprotective effects in various animal models, where 
gastric ulcers were induced by hydrochloric acid, aspirin, ammonia, indomethacin or 
ethanol (Szolcsanyi and Bartho, 2001, Mozsik et al., 2007).  
CVD such as atherosclerosis, myocardial infarction and coronary heart disease are 
associated with significant morbidity and mortality, and there is growing evidence 
that capsaicinoids have many beneficial effects on the cardiovascular system (Harada 
and Okajima, 2009, Peng and Li, 2010). CAP-sensitive sensory nerves that are rich 
in TRPV1 channels are densely distributed in the cardiovascular system. Activation 
of TRPV1 channels by exogenous agonists has been reported to exert hypotensive 
effects and protective effects against cardiac injury by stimulating the formation and 
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release of neurotransmitters such as calcitonin gene-related peptide (CGRP) and 
substance P (Zvara et al., 2006, Peng and Li, 2010). Thus, TRPV1 channels are a 
target for drug development and therapy to treat CVD.  
 
It is believed that low-density lipoprotein (LDL) oxidation is the initiating factor for 
the growth and progression of atherosclerotic plaques. Serum total cholesterol and 
lipid peroxide levels in high fat fed rats are reduced following CAP treatment, in an 
in vivo study (Manjunatha and Srinivasan, 2006, Manjunatha and Srinivasan, 2007). 
In addition, it has been found that CAP and DHC were able to raise LDL resistance 
to oxidation in vitro by slowing the initiation of oxidation and/or delaying the 
oxidation rate (Ahuja et al., 2006a). Regular consumption of chilli for four weeks in 
humans increased the resistance of serum lipoproteins to oxidation (Ahuja and Ball, 
2006) as well as reducing hyperinsulinaemia and hyperglycaemia (Ahuja et al., 
2006b, Chaiyasit et al., 2009). Indeed, a recent large prospective cohort study in 
China (~500,000 participants), reported that regular spice intake significantly 
reduced all-cause mortality, in particular, ischemic heart disease and diabetes, which 
was attributed primarily to chilli constituents (Lv et al., 2015). Finally, the 
antioxidant property of capsaicinoids makes them a useful preventive tool for CVD 
and in particular atherosclerosis and coronary heart diseases (Luo et al., 2011). 
Although the clinical application of CAP has been restricted to pain management, 
these other observations support further research into additional uses for CAP and 
other vanilloids in cancer, obesity, CVD and gastrointestinal ulcers.     
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1.5.4.!Toxicity of Plant-Derived Vanilloids 
The desensitising and cytotoxic properties of capsaicinoids have been well 
documented in peripheral sensory neurons (Aδ and C-fiber) and applied for chronic 
pain treatment (Szallasi and Blumberg, 1999, Wood et al., 1988). Furthermore, it has 
been found that activation of TRPV1 channels expressed by cultured neurons 
isolated from rat dorsal root ganglia enhanced cell death (Szallasi and Blumberg, 
1999). In neurogenic inflammation, CAP stimulates TRPV1 channels- and calcium- 
dependent release of substance P, and neuropeptides from the airway tissue neurons 
to promote inflammatory responses to potentially harmful stimuli (Veronesi and 
Oortgiesen, 2006, Veronesi et al., 1999). Therefore, TRPV1 antagonists might be the 
future treatment for respiratory inflammation. 
 
Capsaicinoids are known to cause coughing, severe irritation and respiratory 
inflammation in experimental human and animal models. This has been 
demonstrated through studies that have demonstrated that CAP and neuropeptide 
synergistically enhanced the production of inflammatory mediators (tumor necrosis 
factor, interlukin-6 and -8) from normal human bronchiolar epithelial cells, human 
bronchiolar epithelial cells (BEAS-2B), and the human lung adenocarcinoma cell 
line (A549) (Quay et al., 1998, Veronesi et al., 1999, Veronesi et al., 2000). 
Furthermore, activation of TRPV1 channels on respiratory epithelial cells by 
capsaicinoids initiates the production of pro-inflammatory cytokines that promote 
host defense responses and may lead to cell death. Capsaicin-induced cell death was 
greater in the BEAS-2B and A549 cell-lines with high TRPV1 channels expression, 
suggesting that TRPV1 channels might be the key mediator of CAP effect (Reilly et 
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al., 2003). Finally, CAP might have a potential role in cancer prevention (Yang et al., 
2010, Surh, 2002, Oh et al., 2008). 
1.6.!Vanilloids and Platelets 
This section discusses the studies that have investigated the effects of vanilloids on 
in vivo and in vitro platelet aggregation, and their potential mechanism/s of action 
(Table-1-2). It has been found that plant-derived vanilloids, CAP and DHC, as well 
as endovanilloids, OLDA and NADA, inhibited in vitro ADP-induced platelet 
aggregation in a concentration-dependent manner (Almaghrabi et al., 2014). The 
effects of both classes of vanilloids on aggregation induced by ADP were not shown 
to be TRPV1-dependent or through the destruction of platelets (Almaghrabi et al., 
2014). Additionally, plant-derived vanilloids inhibited AA-induced aggregation 
while endovanilloids inhibited collagen-induced platelet aggregation (Almaghrabi et 
al., 2014). A study using canine platelets reported that CAP inhibited in vitro platelet 
aggregation induced by collagen in a concentration-dependent manner, but this 
inhibition was not mediated through TRPV1 channels as A-993610, the TRPV1 
antagonist, had no effect (Mittelstadt et al., 2012). 
 
Adams et al. (2009) found that CAP inhibits in vitro platelet aggregation in a 
concentration-dependent manner, while DHC exhibits a bimodal effect on platelet 
aggregation, stimulating at 3.125 µM, and inhibiting from 25-100 µM. Furthermore, 
CAP inhibited in vitro platelet aggregation induced by AA dramatically compared to 
other agonists, ADP, calcium ionophore and collagen, through inhibition of the 
COX1 enzyme in platelets (Raghavendra and Naidu, 2009). Previous studies 
suggested that the anti-platelet effect of CAP was not through specific membrane 
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receptors, but through the insertion into the plasma membrane of platelets, changing 
membrane their ionic permeability and/or fluidity (Hogaboam and Wallace, 1991).  
In contrast to previous studies, Sandor et al., (2014), examined the effect of oral 
administration of 400 µg CAP + 500 mg aspirin and 800 µg CAP + 500 mg aspirin 
on 15 healthy males, compared to aspirin and CAP alone, in the first clinical human 
trial on the effect of CAP on platelet aggregation in vivo. Blood was drawn before 
and after administration of the drugs, platelet aggregation was then induced by 
adrenaline and measured using optical aggregometry. The authors showed that oral 
CAP did not influence the inhibitory effect of aspirin on platelet aggregation induced 
by adrenaline, compared to aspirin alone. Furthermore, CAP (400 and 800 µg) by 
itself did not have any effect on in vitro platelet aggregation (Sandor et al., 2014).  
Harper et al. (2009) reported the presence of TRPV1 channel in human platelets, and 
that CAP is able to induce a concentration-dependent increase in Ca2+ release and 
Ca2+ influx from intracellular platelets stores, that was suppressed by different 
TRPV1 antagonists (5-iodo-resiniferatoxin and AMG 9810) (Harper et al., 2009). 
Furthermore, Harper et al. (2009) has suggested that TRPV1 contributes to the 
activation of platelets induced by ADP and thrombin by promoting endovanilloids 
formation in response to platelets agonists. These findings are in conflict with other 
recent and earlier studies, which demonstrated that capsaicinoids inhibit, rather than 
activate, platelet aggregation (Adams et al., 2009, Almaghrabi et al., 2014, 
Mittelstadt et al., 2012, Raghavendra and Naidu, 2009, Hogaboam and Wallace, 
1991).  
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The reasons for the discrepant results across these studies are not known, however, it 
may be due to a variety of reasons such as; species, as platelets from various species 
have different sensitivity to several platelets agonists (Nylander et al., 2006), and the 
concentrations of platelet agonists employed, as the magnitude of aggregation 
response is concentration-dependent (Maayani et al., 2003). In addition, there were 
differences in incubation times. The anti-haemostatic effects of capsaicinoids may 
potentially prevent and/or decrease the incidence of CVD risk. However, the exact 
mechanism(s) responsible for the effect of vanilloid-like agents on platelet 
aggregation are not well understood, and their effect on platelets from patients with 
high risk of thrombosis and atherosclerosis such as SLE patients, is unknown.  
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Table 1-2 Summary of studies on the effects of vanilloid/s on platelet aggregation in reverse chronological order   
Studies Origin of 
platelets 
Agonist/s Incubation 
time 
Vanilloid/s and/or 
endovanilloids 
The effect/s on platelet aggregation Mechanism/s of action 
Sandor et al. 
(2014) 
Human  Epinephrine (10 
µM) 
 400 µg CAP + 500 mg 
aspirin (ASA) 
800 µg CAP + 500 mg 
ASA 
Oral CAP did not influence the 
inhibitory effect of ASA on platelet 
aggregation induced by epinephrine 
compared to ASA alone 
 
 
Almaghrabi et 
al. (2014) 
Human  ADP (5 and 10 
µM) 
 
Collagen (4 and 
8 µg/mL) 
 
AA (300 and 
400 µg/mL) 
No 
incubation 
3.125, 6.25, 12.5, 25, 
50 and 100 µM of 
CAP, DHC, OLDA and 
NADA, dissolved in 
Ethanol 
OLDA and NADA completely inhibited 
ADP-induced aggregation 
CAP and DHC inhibited ADP-induced 
aggregation but to a lesser extent 
NADA & OLDA inhibited the 
aggregation induced by 4ug/mL collagen 
CAP & DHC completely inhibited AA-
induced aggregation and NADA too but 
not to the same extend 
 
The effect of CAP & OLDA on 
ADP-induced aggregation are 
not TRPV1 mediated 
TRPV1 antagonist is SB452533 
CAP, DHC, OLDA and NADA 
are not cytotoxic to the platelets 
Ethanol alone has no effect on 
platelet aggregation 
Mittelstadt et 
al. (2012) 
Dog Collagen (2 
µg/mL)  
3 minutes 
incubation  
3, 10 and 30 µg/mL of 
CAP  
CAP inhibited collagen-induced platelet 
aggregation in a concentration dependent 
manner 
The effect of CAP on collagen-
induced aggregation are not 
TRPV1 mediated 
TRPV1 antagonist is A-993610 
 
Adams et al. 
(2009) 
Human ADP (5 µM)  No 
incubation 
25, 50 and 100 µM of 
CAP and DHC, 
dissolved in Ethanol 
CAP inhibited ADP-induced platelet 
aggregation induced by ADP in a 
concentration dependent manner. 
DHC has bimodal effect, low 
concentration of DHC enhanced the 
aggregation, while higher concentration 
inhibited the aggregation 
 
The effects of CAP and DHC 
are unlikely to be mediated 
through interference with ADP 
receptors, as the platelets shape 
did not change after the 
exposure to CAP and DHC 
* Harper et al. 
(2009) 
 
Human  ADP (50 µM)  
 
Thrombin (0.5 
U mL-1) 
Five seconds 100 µM of CAP CAP evoked platelet aggregation, a 
response that was inhibited in a 
concentration dependent manner by 5’-
iodo-RTX (TRPV1 antagonist) 
CAP (100 µM) evoked a concentration 
dependent manner increase in [Ca2+]i in 
fura-2-loaded platelets  
TRPV1 is present in human 
platelets and CAP enhances 
platelet aggregation through 
TRPV1 channel  
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Raghavendra 
et al. (2009) 
 
Human ADP (50 µM)  
 
Collagen (0.5 
mg/mL)  
 
AA (1 mM)  
5 minutes 
incubation   
 
 
100 and 200 µM CAP, 
dissolved in DMSO. 
 
CAP inhibited AA-induced platelet 
aggregation in a concentration dependent 
manner, complete inhibition was shown 
with 60 µM CAP 
100 µM CAP completely inhibited 
collagen-induced platelet aggregation  
200 µM CAP inhibited ADP-induced 
aggregation by 58%  
DMSO did not show any effect on 
platelet aggregation 
  
15 µM CAP inhibited TXB2 
formation by 70%, using HPLC 
method 
Hogaboam et 
al. (1991) 
Rabbits Thrombin (60-
100 mU/mL) 
 
Calcium 
ionophore (1-5 
µM) 
 
Platelets-
activating factor 
(35-200 pg/mL) 
Incubated 
 
10-320 µM of CAP, 
dissolved in DMSO 
 
CAP inhibited thrombin-, calcium 
ionophore- and platelets-activating 
factor-induced aggregation in a 
concentration dependent 
CAP did not have any effect on 
the shape change of the platelets 
in response to thrombin. 
The ability of lipophilic 
molecule to alter the fluidity of 
the plasma membrane, and 
allowing calcium to stream into 
the neuron. Any change any 
platelets fluidity leads to 
inhibition of aggregation 
induced by ADP or thrombin 
All the studies have used Platelet Aggregometry (PRP) to measure the effects of vanilloid/s on platelet aggregation except * Harper et al. (2009) study used 
[Ca2+]i  influx.   
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1.7.!Systemic Lupus Erythematosus (SLE) 
SLE is a multisystem autoimmune and chronic inflammatory disorder affecting 
mainly women of childbearing age. Patients with SLE can present with a wide array 
of clinical manifestations, including malar rash, polyarthritis, nephropathy, in 
addition to haematological manifestations (Gaubitz, 2006). SLE patients have a 
significantly increased risk of venous and arterial thrombosis (Ruiz-Irastorza et al., 
2001). Moreover, SLE patients exhibit a high tendency to develop accelerated 
atherosclerosis that may lead to premature CVD (Ruiz-Irastorza et al., 2001, Salmon 
and Roman, 2001). Indeed, the incidence of myocardial infarction in SLE is 50-fold 
higher compared to sex- and age-matched healthy individuals (Manzi et al., 1997). 
Cardiovascular events, infection, SLE-associated organ damage, and disease activity 
are the main causes of mortality in SLE patients (Jacobsen et al., 1999). The 
treatment approach for SLE patients depends on signs, symptoms and severity of the 
disease. Common medications used in the treatment of SLE are: non-steroidal anti-
inflammatory drugs, anti-malarial medications, steroids, immunosuppressive agents 
and monoclonal antibodies (Maidhof and Hilas, 2012).   
1.7.1.!Pathophysiology and Hematological Manifestations of SLE 
Pathogenic autoantibodies are the main cause of tissue damage in SLE. Anti-double-
stranded DNA (dsDNA) antibodies are thought to be the most important factors in 
the pathogenesis of SLE (Ter Borg et al., 1990, Isenberg et al., 2007). However, 
these antibodies are now considered to be one of many other SLE autoantibodies, 
and they are useful in the disease confirmation in the clinical setting when SLE is the 
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most likely diagnosis. Moreover, anti-double-stranded DNA antibodies have limited 
value in disease activity monitoring and flare up prediction (Fu et al., 2015).  
Interferon alpha (INFα) plays an important role in the progression of SLE as it 
stimulates DC differentiation (Blanco et al., 2001, Banchereau and Pascual, 2006). 
The activation of DC leads to the release of autoantibodies against nuclear antigens 
and DNA, as well as stimulating B and T cells (Blanco et al., 2001, Banchereau and 
Steinman, 1998, Chan et al., 2012, Duffau et al., 2010). 
Activated T cells initially express CD40L, a type II transmembrane protein and 
ligand for CD40, which induces dendritic-cell and B-cell activation. The soluble 
form of CD40L (sCD40L) is abundant in the serum from SLE patients and reflects 
disease activity (Goules et al., 2006). The main sources of sCD40L are platelets and 
PMP, and sCD40L has the ability to stimulate antigen-presenting cells such as DC 
(Elzey et al., 2003, Mehling et al., 2001, Nomura et al., 2012, Solanilla et al., 2005, 
Jurk and Kehrel, 2005). Serum from SLE patients has been shown to induce platelet 
activation to a greater extent compared to serum from healthy individuals, suggesting 
that sCD40L is responsible for this activation (Duffau et al., 2010).  
There is evidence to support that immune complexes (DNA-anti-DNA and/or RNP-
anti-RNP) are responsible for platelet activation via the FcγRIIA receptor (Duffau et 
al., 2010). As a result, activated platelets and DC enhance IFN-α secretion. In 
platelets isolated from SLE patients IFN-α controls up-regulation of multiple mRNA 
and proteins, and thus the modulation of platelet and megakaryocyte activity (Lood 
et al., 2010).  Antibody production is a complicated process that involves key factors 
of the immune system, and these findings demonstrate the important role of IFN-α in 
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SLE and show that platelets can directly propagate the SLE inflammatory response 
(Boilard et al., 2012, Rahman and Isenberg, 2008).   
Hematological problems are common in SLE patients and can affect both blood cells 
and the coagulation pathway, either due to the disease course itself and/or by the side 
effects from medications. The major manifestations include thrombocytopaenia, 
anaemia, and leucopaenia (Harvey et al., 1954, Howe and Lynch, 1987, Kaplan et 
al., 1987, Harris et al., 1985). Despite thrombocytopaenia, SLE patients have a 
higher risk of developing thrombosis, which further increases in the presence of 
antiphospholipid antibodies (APL) (West and Johnson, 1988).  Anaemia occurs 
frequently due to chronic disease and autoimmune haemolytic anaemia (Dubois and 
Tuffanelli, 1964).  
1.7.2.!Role of Platelets in SLE 
Platelets have a proinflammatory role in atherosclerosis as they release inflammatory 
mediators into the local environment upon activation, and change the adhesive and 
chemotactic properties of endothelial cells (Gawaz et al., 2005). Activated platelets 
may affect the development of atherosclerotic plaques by releasing adhesive ligands 
such as P-selectin, which are expressed on platelet membranes to mediate 
endothelium-platelet interactions (Celi et al., 1997). P-selectin signaling stimulates 
macrophages and monocytes to release growth factors and chemoattractants 
(Ruggeri, 2002).  
Platelets are highly effective immune cells that mediate a wide range of immune 
responses. In addition, CD40L is highly expressed by platelets and PMP, and it has 
the ability to activate antigen-presenting cells, such as DC (Mehling et al., 2001, 
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Nomura et al., 2012, Solanilla et al., 2005, Elzey et al., 2003, Mobarrez et al., 2016, 
Jurk and Kehrel, 2005). In SLE, sCD40L levels are high, which leads to activation of 
DC and autoantibody production (Figure 1-7) (Desai-Mehta et al., 1996, Goules et 
al., 2006). Therefore, platelets might be a new active player in the pathogenesis of 
SLE through CD40L (Duffau et al., 2010, Mobarrez et al., 2016, Boilard et al., 
2012). 
There is significant evidence of platelet activation in SLE, as reflected by increased 
circulating levels of PMP, platelet and/or leukocyte aggregates, surface and soluble 
P-selectin, and TXB2 (Ferro et al., 1999, Nagahama et al., 2001, Tam et al., 2003, 
Joseph et al., 2001, Sellam et al., 2009). Finally, complement could also contribute to 
platelet activation in SLE, as the accumulation of complement fragment C4d and 
inflammatory cytokines on the platelet surface, has been reported (Gori et al., 2009, 
Batal et al., 2012, Navratil et al., 2006, Peerschke et al., 2010). 
Antiplatelet medications are effective in the prevention of thrombotic events 
(Vandvik et al., 2012), with aspirin prescribed to SLE patients for primary 
prophylaxis of thrombosis (Arnaud et al., 2015, Arnaud et al., 2014). However, 
aspirin use is associated with many side effects, such as increased gastric injury and 
bleeding (Singh and Triadafilopoulos, 1999, Derry and Loke, 2000, Ivey et al., 1980, 
Weil et al., 1995).  As stated earlier, studies on healthy humans, dogs and rabbits 
platelets have shown that the naturally occurring vanilloid, CAP, can inhibit in vitro 
platelet aggregation (Raghavendra and Naidu, 2009, Mittelstadt et al., 2012, 
Almaghrabi et al., 2014, Adams et al., 2009, Hogaboam and Wallace, 1991), 
however the effect of CAP and other vanilloid-like agents on platelets from SLE 
patients, is not currently known. 
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1.8.!Summary and Aims of the Project  
This thesis is a continuation of my previous Masters work, and is presented as series 
of stand-alone manuscripts for publication, and therefore there is a small amount of 
repetition related to the methods. Previously, I have shown that plant-derived 
vanilloids, CAP and DHC, and endovanilloids, OLDA and NADA, inhibited in vitro 
ADP-induced platelet aggregation, and CAP, DHC and NADA inhibited AA-
induced aggregation (Almaghrabi et al., 2014). Moreover, only endovanilloids 
showed an effect on aggregation induced by a low concentration (4 µg/mL) of 
collagen, and thus the collagen pathway was not of interest in the current study 
(Almaghrabi et al., 2014). Although the effects of vanilloids and endovanilloids on in 
vitro platelet aggregation have been described, the exact mechanism of inhibition of 
platelet aggregation is unknown. Previous studies investigated the possible 
mechanism of action of CAP using platelets from healthy individuals, but not other 
vanilloids or endovanilloids. 
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Figure 1-7 Activation of DC and autoantibody production. 
Platelets activated by circulating immune complexes express surface CD40L, which promotes platelet 
aggregation, binding to myeloid DC to induce their maturation and binding to plasmacytoid DC to 
promote IFN-α secretion. Abbreviations: CD40L, CD40 ligand; DC, dendritic cell; sCD40L, soluble 
CD40 ligand; SLE, systemic lupus erythematosus. Image sourced from (Boilard et al., 2012) without 
modifications. 
Vanilloid-like agents exert their action in neuronal tissue through TRPV1, CB1 and 
CB2 receptors, and only a single study has previously shown that TRPV1 is 
expressed by platelets using Western Blot. Hence, TRPV1 expression by platelets 
was investigated using, confocal microscopy, and then whether the inhibitory effects 
of vanilloids are through TRPV1, CB1 and CB2 receptors were determined. 
Thereafter, whether vanilloids inhibited platelet aggregation was investigated by 
interfere/block ADP receptors, P2Y1 and/or P2Y12, by measuring granules release, 
and VASP phosphorylation status, respectively. Furthermore, TXB2 levels were 
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measured to determine if the inhibitory effect of vanilloids was through suppression 
of AA pathway. Finally, microparticle release was measured to investigate whether 
vanilloids suppress platelet aggregation by interfering with their release. 
 
After speculating the mechanism of action of individual vanilloids, it was interesting 
to know if effect of a combination of CAP and DHC as they occur naturally in 
Capsicum is different compared to the individual vanilloids. Finally, patients who 
have a high risk of thrombosis and atherosclerosis, SLE patients, were studied as part 
of a small pilot study to investigate whether vanilloids have any effect, on 
abnormally hyperactive platelets of SLE patients. 
 
The aims were to: 
The overarching aim of this study was to investigate the mechanism of action of 
plant-derived vanilloids and endovanilloids, and determine the effects of these agents 
on platelets from SLE patients. The specific aims were to: 
1.! Determine whether TRPV1 channels are expressed by platelets. 
2.! Investigate the effects of vanilloids and TRPV1 channels and, cannabinoid 
CB1 and CB2 receptors antagonists on platelets count, and whether the 
inhibition of platelet aggregation by vanilloids is mediated through TRPV1 
channels and/or CB1 and CB2 receptors. 
3.! Determine whether vanilloids inhibit in vitro platelet aggregation by 
interfering with one or more of the following: a) the arachidonic acid (AA) 
metabolic pathway and subsequent thromboxane B2 formation (TXB2); b) 
adenosine diphosphate (ADP)-induced-dense (5-hydroxytryptamine (5-HT)) 
release via the P2Y1 receptor; c) ADP-induced-α-granules (platelet factor 4 
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(PF4) and/or β-thromboglobulin (β-TG)) release via the P2Y1 receptor; d) 
vasodilator-stimulated phosphoprotein (VASP) phosphorylation through the 
P2Y12 receptor. 
4.! Investigate the effect of vanilloids on platelets microparticles (PMP) 
formation. 
5.! Determine the effect of the combination of CAP and DHC on AA-, ADP- and 
collagen-induced aggregation and TXB2 formation. 
6.! Investigate the effect of vanilloids on the aggregation of platelets from SLE 
patients.
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2.! Chapter 2: The Inhibition of Platelet Aggregation by Vanilloid-
like Agents is Not Mediated by Transient Receptor Potential 
Vanilloid-1 Channels or Cannabinoid Receptors 
 
Part of this chapter has been published as: 
Almaghrabi, SY, Geraghty, DP, Ahuja, KDK and Adams, MJ 2016. Inhibition of 
platelet aggregation by vanilloid-like agents is not mediated by transient receptor 
potential vanilloid-1 channels or cannabinoid receptors. Clin Exp Pharmacol 
Physiol, 43, 606-11. 
 
2.1.!Abstract 
Vanilloid-like agents, including CAP, N-arachidonoyl-dopamine (NADA) and N-
oleoyldopamine (OLDA) inhibit platelet aggregation, however, little is known about 
the precise mechanism(s) of action. The aims of the chapter were to; 1) to confirm 
the presence of transient receptor potential vanilloid-1 (TRPV1) channels in 
platelets, 2) determine the effect of vanilloid-like agents on in vitro platelet count, 
and 3) investigate whether the effects of vanilloids on collagen-, arachidonic acid 
(AA)- and ADP-stimulated platelets are mediated by TRPV1 and/or cannabinoid 
(CB1 and CB2) receptors. 
 
Using confocal microscopy, the presence of TRPV1 was confirmed in platelets. 
Incubation of platelets with each of the individual vanilloids, CAP, NADA and 
OLDA, or with TRPV1 (SB452533), CB1 (AM251) and CB2 (AM630) antagonists, 
for up to two hours did not significantly affect the platelet count. OLDA and NADA 
significantly inhibited collagen-induced aggregation by 23% and 85%, respectively. 
SB452533 50 µM and 10 µM significantly (both p<0.05) enhanced the anti-
aggregating effect of OLDA by 39% and 14%, respectively, compared to OLDA 
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alone. CAP and NADA significantly inhibited AA-induced aggregation by 56% and 
26%, respectively. CAP anti-aggregating effect was enhanced in the presence of 
SB452533 and AM630 (both 50 µM) by 26.5%, p=0.38 and 30.8%, p=0.19, 
respectively compared to CAP only, however, the results were not statistically 
significant. AM251 and AM630 did not affect inhibitory effects of CAP and OLDA 
on aggregation induced by ADP. 
 
The results suggest that the inhibitory effect of vanilloids on platelet aggregation is 
independent of TRPV1, CB1 and CB2 receptors. However, blocking these receptors 
may boost vanilloids anti-aggregating effect. Further research on the antiplatelet 
activity of vanilloids that focus on mechanisms other than those associated with 
vanilloid receptors are presented in Chapter 3. 
2.2.!Introduction 
Platelets play a central role in haemostasis and the development of thrombosis by 
forming adhesive aggregates (Harker et al., 1976, Zucker, 1980). Agents that 
suppress platelet aggregation are beneficial in the prevention and treatment of 
cardiovascular diseases (CVD). The active principles of spices such as capsaicin 
(CAP), from hot chilli peppers, have been reported to affect in vitro platelet 
aggregation (Almaghrabi et al., 2014, Raghavendra and Naidu, 2009, Adams et al., 
2009, Harper et al., 2009).  
  
CAP, other capsaicinoids, and endovanilloids including, N-arachidonoyl-dopamine 
(NADA) and N-oleoyldopamine (OLDA), act through transient receptor potential 
vanilloid-1 (TRPV1) in neuronal tissue (Zhong and Wang, 2008), a non-selective 
cation channel with some preference for Ca2+ (Caterina et al., 1999). Endovanilloids 
  47 
also have affinity for cannabinoid (CB) receptors, and are hence termed 
endocannabinoids (Hu et al., 2009). TRPV1, CB1 and CB2 receptors are expressed 
by platelets (Deusch et al., 2004, Catani et al., 2010). One study has shown that 
TRPV1 channels are present on platelets using Western blotting (Harper et al., 
2009), however no information is available on the precise role(s) of these channel on 
platelet function.  
 
Studies have demonstrated variable effects of CAP on platelet function, including 
both inhibition (Raghavendra and Naidu, 2009, Adams et al., 2009) and 
enhancement of aggregation (Harper et al., 2009). Recently, we demonstrated that 
CAP as well as OLDA and NADA, inhibit ADP-induced in vitro platelet aggregation 
through a TRPV1-independent mechanism (Almaghrabi et al., 2014). OLDA and 
NADA also suppressed collagen-induced aggregation, while CAP and NADA 
inhibited aggregation induced by arachidonic acid (AA) (Almaghrabi et al., 2014). 
Although vanilloid-like agents have been shown to affect platelet aggregation, the 
mechanism(s) are not well understood, and unlikely to be due to direct toxic effect 
on platelets (Almaghrabi et al., 2014).  
 
Therefore the aims of this study were to; 1) determine whether TRPV1 channels are 
expressed by platelets, using confocal microscopy, 2) determine the effects of 
vanilloids, endovanilloids and receptor antagonists on platelet count, and 3) 
investigate whether the action of vanilloids/endovanilloids on collagen-, AA- and 
ADP-induced aggregation is through TRPV1, CB1 and/or CB2 receptors. 
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2.3.!Materials 
ADP, AA and collagen were obtained from Helena Laboratories (Beaumont, Texas, 
USA). CAP, NADA, OLDA; the TRPV1 antagonist SB452533 (N-(2-
Bromophenyl)-N'-[2-[ethyl(3-methylphenyl)amino]ethyl]-urea); the CB1 antagonist 
AM251(N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-
pyrazole-3-carboxamide); and the CB2 antagonist AM630 (6-Iodo-2-methyl-1-[2-(4-
morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone) were obtained 
from Tocris (Bristol, UK). ProLong® Gold Antifade Reagent and Anti-rabbit IgG 
(H+L), F(ab')2 Fragment (Alexa Fluor® 647 Conjugate) were obtained from Cell 
Signaling Technology (Boston, MA, USA). Vanilloid receptor 1 (H-150) was 
obtained from Santa Cruz Biotechnology (Texas, USA). Dako antibody diluent was 
obtained from Dako (Glostrup, Denmark). 
!Methods 
This study was approved by the Tasmanian Health and Medical Human Research 
Ethics Committee (approval number: H00011414). Informed written consent was 
obtained from all participants. 
Venous blood samples were collected from healthy volunteers (aged 18-65 years), 
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who had avoided aspirin and antiplatelet medications for at least 10 days and dietary 
chilli for at least two days. The protocol of isolation of human platelets from whole 
blood has been used from Abcam® website. Briefly, blood was collected into citrate-
phosphate-dextrose buffer (CPD) (16 mM citric acid, 90 mM sodium citrate, 16 mM 
NaH2PO4, 142 mM dextrose, pH 7.4) as anticoagulant (1:9 ratio of anticoagulant to 
whole blood). Whole blood was centrifuged at 200g for 20 minutes at room 
temperature (RT) to obtain PRP. HEP buffer (140 mM NaCl, 2.7 mM KCl, 3.8 mM 
HEPES, 5 mM EGTA, pH 7.4) was added to PRP in 1:1 ratio (v/v), containing 
prostaglandin E1 (PGE1, 1 µM final concentration) to prevent platelet activation. 
PRP was centrifuged at 100g for 15 minutes, to pellet red and white blood cells. The 
supernatant was then transferred into new plastic tubes and centrifuged at 800g for 
15–20 minutes to pellet the platelets. The platelet pellet was rinsed with platelet wash 
buffer (10 mM sodium citrate, 150 mM NaCl, 1 mM EDTA, 1% (w/v) dextrose, pH 
7.4) by gently adding wash buffer and removing it slowly with a transfer pipette. The 
pellet was resuspended in Tyrode’s buffer (134 mM NaCl, 12 mM NaHCO3, 2.9 
mM KCl, 0.34 mM Na2HPO4, 1 mM MgCl2, 10 mM HEPES, pH 7.4), containing 5 
mM glucose and freshly added BSA (3 mg/mL). The concentration of platelet was 
adjusted to 1–3 x 108 /mL using Tyrode’s buffer.  
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Glass slides were coated with 100 µg/mL fibrinogen in phosphate buffer saline 
(PBS) overnight at 4°C. They were then blocked with bovine serum albumin (BSA) 
(5mg/mL) in PBS for 2 hours at RT. Then 1 mL of platelet suspension was added to 
the slides and allowed to adhere to the blocked slides for 60 minutes at 24°C. The 
slides were then fixed in 4% paraformaldehyde for 10 minutes at RT, and then 
washed three times with PBS using a transfer pipette. The slides were incubated with 
primary antibody (Anti-TRPV1) (1:200 dilution) for 120 minutes, and then a 
fluorescent secondary antibody (Alexa Fluor 647-conjugated goat anti-rabbit) (1:500 
dilution) for 60 minutes. Platelets were mounted using ProLong® Gold Antifade 
Reagent. Controls included unstained cells to allow for autofluorescence, and 
secondary antibody only to check for nonspecific fluorescence. These slides were 
visualized with the laser set at 405 nm to generate bright field images. An UPAL 
SAPO 60× objective was used and all images were acquired using an Olympus 
FV1200 Confocal Microscope (Tokyo, Japan) using the same setting and thus 
comparable. 
Venous blood was collected by venipuncture using minimal stasis from twenty 
healthy volunteers (aged 18-65 years) (Table 2-1). Each experiment used platelets 
from four volunteers. All participants had no previously diagnosed haemostatic 
abnormality. A total of 20 mL of whole blood was collected into 3.2% sodium citrate 
anticoagulant tubes (1:9 ratio of anticoagulant to whole blood). Subjects avoided 
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aspirin and antiplatelet medications for at least 10 days and dietary chilli for at least 
two days, prior to collection. Samples were centrifuged at 150g for 10 minutes at 
room temperature to obtain PRP. The remaining blood was then centrifuged at 2000g 
for 20 minutes at room temperature to obtain platelet poor plasma (PPP). 
 
Table 2-1 participants’ characteristics table 
Age Gender Age Gender 
35 Female 36 Female  
32 Female 51 Female  
29 Female 35 Female  
20 Female 39 Male  
24 Female 45 Male  
24 Female 24 Male  
33 Female 28 Male  
32 Female 27 Male  
44 Female 43 Male  
48 Female 25 Male  
25 Female 21 Male 
44 Female  24 Male  
The effect of vanilloids on in vitro platelet count was determined using a Sysmex 
1000i analyser (Roche Diagnostics, Sydney, NSW, Australia) with PRP adjusted to 
250 x 109/L using PPP from the same subject. PRP was used to mimic the same 
condition of the aggregation experiment (Platelet Aggregometry). CAP, OLDA and 
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NADA (each 50 and 3.125 µM) and SB452533, AM251 and AM630 (each 50 µM) 
were added separately to PRP and the platelet count measured every 15 minutes for 
two hours (n=4, separate subjects). PRP with buffer was used as the blank. Data are 
presented as percent of platelet count normalised to platelet count at time zero. 
A four-channel AggRAM platelet aggregometer (Helena Laboratories, Beaumont, 
Texas, USA) was used to conduct all experiments as described previously (Adams et 
al., 2009, Ahuja et al., 2009, Ahuja et al., 2012). ADP, AA, collagen, CAP, NADA 
and OLDA were prepared as previously described (Almaghrabi et al., 2014). Briefly, 
ADP and AA were dissolved in deionized water and stored in 1M aliquots at -20°C 
until needed and collagen was ready to use. Aliquots of agonists were thawed and 
diluted in normal saline (pH 7.1) to produce final concentration of ADP (5 µM), AA 
(300 µg/mL) and collagen (4 µg/mL). CAP and OLDA were dissolved in 100% 
ethanol and stored as 0.1M aliquots at -20°C.  NADA was stored as 11.37 x 103 µM 
aliquot at -20°C. Aliquots of all vanilloids were diluted as required in normal saline 
(pH 7.1) to provide final concentrations 50 µM. SB452533 and AM251 were 
dissolved in 100% ethanol and stored in 10 and 100 mM aliquots, respectively, 
whereas AM630 was dissolved in DMSO and stored in 100 mM aliquots. All 
aliquots were stored at -20°C then diluted using normal saline buffer (pH 7.1), to 
provide final concentrations of 10 and 50 µM for experiments. PPP from the same 
sample was used as the blank for each experiment and to adjust the platelet count of 
PRP to 250 x 109/L. ADP (5 µM), collagen (4 µg/mL) or AA (300 µg/mL), were 
added to PRP (225 µL) to initiate aggregation in the presence and absence of 
TRPV1, CB1 or CB2 antagonists (10, 50 µM), with/out vanilloid (50 µM). 
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Aggregation was recorded for 10 minutes, with aggregometry data generated by the 
HemoRAM 1.1.0. Software package (Helena Laboratories, Beaumont, Texas, USA). 
Parameters included percentage of the maximum aggregation (%MAX) and 
percentage of the area under the aggregation curve (%AUC). The values for %MAX 
and %AUC were similar for each experiment, thus only %MAX data (normalised to 
control, (i.e., agonist only) are presented in figures 2, 3, 5 and 6. Each data set is 
presented as the mean of four experiments, using platelets from four separate 
subjects. 
Data were plotted using GraphPad Prism (version 5; San Diego, CA, USA). All data 
for comparison between different concentrations of vanilloids with/without receptor 
antagonists was initially analysed using ANOVA/linear regression (Stata version 13, 
StataCorp, LP, USA).  However, residuals from this model did not conform to the 
assumptions of linear regression. Therefore, ordinal logistics regression analysis was 
used for the comparisons, as this model does not require the assumptions of linear 
regression to be true. Post-estimation Holm test analysis was then used to adjust p 
values for multiple comparisons. P values < 0.05 were considered statistically 
significant. 
2.5.!Results 
The presence of TRPV1 channels on platelets  
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Confocal microscopy demonstrated that TRPV1 channels were present in platelets 
(Figure 2-1 B,C), with variable expression between, and within, individual platelets. 
Both secondary antibody (Figure 2-1 D) and unstained cells (Figure 2-1 E) controls 
did not express TRPV1. The anti-TRPV1 antibody (sc-20813) has been cross-
validated by immunodetection in human prostate carcinoma (Czifra et al., 2009), 
inflamed gingival tissues (Ozturk and Yildiz, 2011) and a synovial joints in a rat 
model of osteoarthritis pain (Kelly et al., 2015). 
The effect of vanilloid-like agents and TRPV1, CB1 and CB2 
antagonists on platelet count 
Incubation of platelets individually with CAP, OLDA or NADA (each 50 µM), or 
SB452533, AM251 and AM630 (each 50 µM) for two hours had no statistically 
significant effect on platelet count, relative to buffer control (Figure 2-2). Similar 
results were observed with CAP, OLDA and NADA (each 3.125 µM).  
Effect of TRPV1, CB1 and CB2 antagonists on collagen-, AA- or 
ADP-induced aggregation 
50 µM of SB452533 (TRPV1 antagonist), AM251 (CB1 antagonist) and AM630 
(CB2 antagonist) alone had no significant effect on aggregation induced by collagen, 
AA or ADP (Figure 2-3). Similar results were observed with 10 µM SB452533, 
AM251 and AM630. Ethanol (solvent for SB452533 and AM251, as well as the 
vanilloid-like agents capsaicin, OLDA and NADA), and DMSO (solvent for 
AM630) also had no effect on platelet aggregation at the final concentrations tested 
(data not shown). 
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Figure 2-1 Immunodetection of TRPV1 channels on human platelets using confocal microscopy. 
All the images are from the same sample, A) Bright field image using 405 nm laser; B) TRPV1 
staining of platelets using 647 nm channel; C) merged image of 405 nm and 647 nm channels; D) 
secondary antibodies only; E) unstained cells. Scale bar= 40 pixels. Original magnification is x 60. 
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Figure 2-2 50 µM CAP, OLDA, NADA, SB452533 (TRPV1 antagonist), AM251 (CB1 
antagonist) and AM630 (CB2 antagonist) had no effect on platelet count over two hours of 
incubation relative to buffer control. 
Data are presented as percent of platelet count (normalised to platelet count at time zero). Mean ± 
SEM; n=4. 
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Figure 2-3 Effects of 50 µM SB452533 (TRPV1 antagonist), AM251 (CB1 antagonist) and 
AM630 (CB2 antagonist) on collagen-, AA- and ADP-induced aggregation. 
Data are presented as percent maximum aggregation (normalised to aggregation in the absence of 
antagonist). Mean ± SEM; n=4. 
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Effect of blocking TRPV1, CB1 and CB2 receptors on the inhibitory 
action of OLDA and NADA on collagen-induced platelet aggregation  
OLDA and NADA (50 µM) significantly inhibited aggregation induced by collagen 
by 23%, p<0.005 and 85%, p<0.005, respectively (Figure 2-4). The inhibitory effect 
of 50 µM OLDA was not affected by AM251 or AM630 (Figure 2-4 A). However, 
50µM SB452533 significantly enhanced the anti-aggregating effect of OLDA (39% 
compared to the effect of OLDA only, p<0.05; Figure 2-4 A and 2-5). A similar 
effect was observed when 10 µM SB452533 and 50 µM OLDA were combined. The 
inhibition produced by 50 µM NADA was not affected by SB452533, AM251 or 
AM630 (10 and 50 µM) (Figure 2-4 B).  
Effect of blocking TRPV1, CB1 and CB2 receptors on the inhibitory 
action of CAP and NADA on AA-induced platelet aggregation 
CAP and NADA (50 µM) significantly inhibited AA-induced platelet aggregation by 
56%, p<0.005 and 26%, p<0.05, respectively (Figure 2-6). Moreover, 50 µM of 
SB452533 and AM630 enhanced the anti-aggregating effect of CAP by 26.5%, 
p=0.38 and 30.8%, p=0.19, respectively, compared to CAP only, however the results 
were not statistically significant. The anti-aggregating effect of CAP in presence of 
SB452533 (10 µM), AM630 (10 µM), and AM251 (10 and 50 µM) did not change. 
SB452533, AM251 and AM630 did not have a statistically significant effect on 
NADA anti-aggregating effect (Figure 2-6). 
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Figure 2-4 Effects of SB452533 (TRPV1 antagonist), AM251 (CB1 antagonist) and AM630 (CB2 
antagonist) on (50 µM) OLDA and NADA inhibition of collagen-induced platelet aggregation. 
Data are presented as percent maximum aggregation (normalised to aggregation in the absence of 
vanilloid and antagonist). Mean ± SEM; n=4. *p<0.05 compared to control (i.e. 0 µM of antagonist). 
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Figure 2-5 Representative aggregation curves (percent aggregation) showing the effect of a 
TRPV1 antagonist (SB452533) on the inhibitory effect of OLDA on 4µg/mL collagen-induced 
aggregation.  
Green (4µg/mL collagen); brown (4µg/mL collagen + 50 µM OLDA); red (4µg/mL collagen + 50µM 
SB452533); blue (4µg/mL collagen + 50 µM OLDA + 50µM SB452533) (n=1). 
 
Effect of blocking CB1 and CB2 receptors on the inhibitory action of 
CAP and OLDA on ADP-induced platelet aggregation 
CAP and OLDA (50 µM) significantly inhibited ADP-induced aggregation by 31%, 
p<0.05 and 37%, p<0.005, respectively (Figure 2-7). The anti-aggregating effect of 
CAP and OLDA did not change in the presence of AM251 and AM630 (10 and 50 
µM) (Figure 2-7). 
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Figure 2-6 Effects of SB452533 (TRPV1 antagonist), AM251 (CB1 antagonist) and AM630 (CB2 
antagonist) on (50 µM) CAP and NADA inhibition of AA-induced platelet aggregation. 
Data are presented as percent maximum aggregation (normalised to aggregation in the absence of 
vanilloid and antagonist). Mean ± SEM; n=4. 
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Figure 2-7 Effects of AM251 (CB1 antagonist) and AM630 (CB2 antagonist) on (50 µM) CAP 
and OLDA inhibition of ADP-induced platelet aggregation. 
Data are presented as percent maximum aggregation (normalised to aggregation in the absence of 
vanilloid and antagonist). Mean ± SEM; n=4. 
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2.6.!Discussion 
To the best of my knowledge this is the first study to confirm the presence of TRPV1 
channels on platelets using confocal microscopy, and then to investigate the role of 
TRPV1 channels, and CB1 and CB2 receptors, on the inhibition of platelet 
aggregation produced by vanilloids and endovanilloids. In this chapter, TRPV1 
channels were confirmed to be expressed by platelets, thus its role in the vanilloid 
inhibition of platelet aggregation could be investigated. Aggregation was induced 
using three platelet agonists, collagen, AA and ADP, in combination with the 
presence of vanilloids and/or endovanilloids that previously shown to inhibit 
aggregation (Almaghrabi et al., 2014). The vanilloids, endovanilloids and receptor 
antagonists used in this study had no direct effect on platelet count, to rule out the 
toxic effects of these agents on platelets. Moreover, potent receptors antagonists, 
SB452533 (TRPV1 antagonist), AM251 (CB1 antagonist) and AM630 (CB2 
antagonist) each had no effect on platelet aggregation induced by collagen, AA and 
ADP, indicating that blocking these receptors individually has no effect on platelet 
aggregation. 
 
There was no difference in collagen-induced aggregation profile of platelets in 
presence of NADA or OLDA with/without CB1 and CB2 receptors antagonists. This 
suggested that the inhibitory effects of OLDA and NADA on aggregation do not 
appear to be mediated through these receptors.  However, blocking TRPV1 channels 
(with 50 and 10 µM of SB452533) significantly enhanced the inhibitory effect of 
OLDA but had no effect on NADA. In AA-induced aggregation, CAP in presence of 
50 µM TRPV1 and CB2 antagonists showed a greater non-significant inhibitory 
effect on platelet aggregation compared to CAP alone. Moreover, the inhibitory 
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influences of NADA on AA-induced aggregation did not appear to be due to a direct 
interaction with TRPV1, or the CB1 and CB2 receptors. Similar effects were 
observed with AM251 (CB1 antagonist) and AM630 (CB2 antagonist) on 
aggregation induced by ADP, as they did not interfere with the anti-aggregating 
action of CAP and OLDA. Therefore, blocking the TRPV1 channel and CB2 
receptor may not impede but enhance vanilloids inhibitory action. However, CB1 
receptor appears to have no role in vanilloids effect on platelets. 
 
It has previously been shown that OLDA and NADA inhibited aggregation induced 
by collagen, while CAP and NADA suppressed AA-induced aggregation 
(Almaghrabi et al., 2014). Moreover, CAP (Adams et al., 2009, Almaghrabi et al., 
2014) as well as the endovanilloid, OLDA, inhibit ADP-induced in vitro platelet 
aggregation, but this effect appeared to be independent of TRPV1 channels 
(Almaghrabi et al., 2014). Furthermore, the inhibitory effects of vanilloids and 
endovanilloids did not appear to be mediated by the direct destruction of platelets 
(Almaghrabi et al., 2014). TRPV1 channels, and CB1 and CB2 receptors, are known 
to mediate the action of CAP and endovanilloids in several tissues, including 
neuronal tissue, prostate cells and others (Walker et al., 2005, Van der Aa et al., 
2003). However, the role(s) of TRPV1 channels, as well as CB1 and CB2 receptors, 
expressed by platelets remain unclear (Deusch et al., 2004, Harper et al., 2009, 
Catani et al., 2010). 
 
In the current study, TRPV1 channels were shown to be present on platelets using 
confocal microscopy. However, the inhibitory effects of vanilloids and 
endovanilloids on in vitro platelet aggregation, at least in regard to collagen-, AA- 
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and ADP- induced aggregation of human platelets, are not mediated via TRPV1, nor 
the CB1 or CB2 receptors. Interestingly, blocking the TRPV1 channels enhanced the 
inhibitory effect of OLDA in collagen-induced aggregation, and CAP in AA-induced 
aggregation, which could be due to reduced Ca2+ influx [Ca2+]i and intracellular Ca2+ 
release from platelets and thus greater reduction in Ca2+-mediated aggregation 
(Clapham, 2003, Montell et al., 2002, Moran et al., 2004). Moreover, CB receptors 
are coupled through Gi protein and inhibit adenylyl cyclase and cAMP formation 
(Rueda et al., 2000, Childers and Deadwyler, 1996). Thus, blocking CB2 in presence 
of CAP in AA-induced aggregation may lead to increase the cAMP formation and 
further inhibition of platelet aggregation.  
 
Although the exact mechanism for the effects of vanilloids and endovanilloids on 
non-neuronal tissue remains unclear, CAP has been shown to suppress the AA 
pathway and thromboxane A2 formation (Raghavendra and Naidu, 2009) through 
complete abrogation of AA-induced aggregation (Almaghrabi et al., 2014, 
Raghavendra and Naidu, 2009). Furthermore, CAP and endovanilloids have been 
shown to inhibit ADP-induced aggregation (Almaghrabi et al., 2014), an effect 
postulated to be mediated by the blocking of platelet ADP receptors, and consistent 
with the demonstration that a two to three fold increase in cAMP completely inhibits 
ADP-induced aggregation (Haslam et al., 1978). Moreover, it has been demonstrated 
that CAP is incorporated into phospholipid membranes, resulting in changes to lipid 
packing and alterations to their thermotropic properties (Aranda et al., 1995). It may 
be that inhibition of platelet aggregation by vanilloid-like agents could be through 
incorporation into phospholipid membranes.   
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It is acknowledged that this study has a number of limitations. Firstly, PRP was used 
to determine in vitro aggregation in response to various agents, which may not 
accurately reflect in vivo platelet function. Secondly, relatively high concentrations 
of vanilloids/endovanilloids and receptor antagonists were used. However, 50 µM of 
CAP, OLDA, NADA and the antagonists had no effect on platelet count, and I have 
previously shown that 50 µM CAP, NADA, OLDA have no effect on platelet 
viability (Almaghrabi et al., 2014). In rat, 1.24-24.4 percent of the administrated dose 
of CAP was detected in blood 1-24 hours after oral administration of 30 mg/kg body 
weight CAP. The maximum concentration of 24.4 percent was seen after one hour 
and then gradually decreased to 1.24 percent after 24 hours (Suresh and Srinivasan, 
2010). Finally, there may be variable responses of platelets from individual subjects 
related to agonists and/or vanilloids. 
 
In conclusion, the current study demonstrated that platelets express TRPV1 channels 
and vanilloids/endovanilloids and their respective antagonists have no effect on 
platelet count. Blocking TRPV1 channels, and CB1 and CB2 receptors alone had no 
effect on platelet aggregation. However, blocking TRPV1 and CB2 receptor in a 
combination with OLDA and CAP appears to enhance vanilloids inhibitory effect. 
Thus further investigation in these receptors role/s in platelets is warranted. Platelets 
play an important role in contributing to the formation of atherosclerotic lesions, a 
major contributing factor to the development of CVD. Naturally occurring 
antiplatelet compounds such as vanilloid-like agents may potentially exhibit fewer 
adverse effects, e.g., gastrointestinal disturbances, than existing medications and may 
be useful as an adjuvant or alternative to conventional antiplatelet medications. 
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Further research is warranted to determine the precise mechanism(s) of action of 
vanilloids/endovanilloids and their suitability for therapeutic application. 
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3.! Chapter 3: Inhibition of Vanilloid-Induced in vitro Platelet 
Aggregation is Dependent on VASP Phosphorylation and 
Thromboxane Biosynthesis but Independent of Platelet Granule 
Release 
3.1.!Abstract 
The mechanism by which vanilloids, including plant-derived vanilloids (capsaicin 
(CAP) and dihydrocapsaicin (DHC)), and endogenous vanilloids (N-arachidonoyl-
dopamine (NADA) and N-oleoyldopamine (OLDA)), inhibit platelet aggregation is 
not known. The aims of this study were to determine whether vanilloids inhibit in 
vitro platelet aggregation by interfering with one or more of the following: 1) 
vasodilator-stimulated phosphoprotein (VASP) phosphorylation, 2) adenosine 
diphosphate (ADP)-induced dense (5-hydroxytryptamine (5-HT)) release, 3) α-
granules (platelet factor 4 (PF4) and β-thromboglobulin (β-TG)) release, and 4) the 
arachidonic acid (AA) metabolic pathway and subsequent thromboxane B2 
formation (TXB2). In addition, the effect of vanilloids on platelet-derived 
microparticles (PMP) formation/release was investigated.  
 
Platelets were obtained from venous blood of healthy volunteers. VASP 
phosphorylation was measured (ELISA) after incubation of platelets with 3.125 and 
50 µM CAP, DHC, NADA and OLDA. 5-HT, PF4 and β-TG release from dense and 
α-granules were measured (ELISA), in the presence and absence of 3.125, 25 and 
100 µM of each of the vanilloids on platelets treated with 10 and 5 µM ADP. 
Platelets were treated with AA (300 µg/mL) in the absence and presence of 3.125 
and 50 µM CAP, DHC, NADA and OLDA, TXB2 formation determined (ELISA). 
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PMP release was measured in the presence and absence of vanilloids (50 µM) in 
ADP- and AA-activated platelets by flow cytometry.  
 
NADA increased VASP phosphorylation significantly (17% ± 2.2, p<0.05) 
compared to control (no treatment control), and OLDA had a non-significant effect 
on VASP phosphorylation (13.4% ± 2.7, p=0.12). Vanilloids did not significantly 
affect the release of PF4, β-TG or 5-HT from ADP-activated platelets. CAP (50 µM) 
significantly inhibited TXB2 formation from AA-activated platelets (10.7%, 
p<0.001) and to a lesser extent DHC (50 µM; 4.6%; p=0.91). None of the vanilloids 
had a statistically significant effect on PMP release from ADP- and AA-stimulated 
platelets. 
 
The results of this study suggest that the inhibitory effect of NADA on in vitro 
platelet aggregation might be through interference with the ADP receptor, P2Y12, as 
VASP phosphorylation increased significantly in its presence. Furthermore, CAP 
may inhibit platelet aggregation by suppressing the AA metabolic pathway. The 
inhibitory effects of CAP, DHC, OLDA and NADA on in vitro platelet aggregation 
do not appear to be mediated through inhibition of the P2Y1 ADP receptor, as dense- 
and α-granules release were not affected. Finally, the inhibition of aggregation by 
vanilloids is not related to a reduction in PMP formation/release.    
3.2.!Introduction 
Platelets are small anucleate cell fragments that originate from megakaryocyte 
cytoplasm and play a crucial role in the hemostatic process and in thrombus 
formation (Zucker, 1980). There are many endogenous agonists that activate platelets 
and act through various signaling pathways. In vivo, thrombin and collagen initiate 
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platelet activation, however several other agonists can also stimulate platelets in 
vitro, including adenosine diphosphate (ADP) and arachidonic acid (AA) (Del Conde 
et al., 2005, Falati et al., 2003). 
 
The activation of platelets through collagen glycoprotein receptors (!2"1 and GPVI) 
leads to the release of thromboxane A2 (TXA2) and ADP (Clemetson et al., 1999, 
Maffrand et al., 1988) via phospholipase C (PLC) activation. As a result of PLC 
activation, the cytosolic Ca2+ concentration increases leading to activation of 
phosphokinase C (PKC) and then phospholipase A (PLA) (Lemons et al., 2000, Jurk 
and Kehrel, 2005). PLA then mediates AA release from phospholipid membranes, 
cyclooxygenase-1 (COX-1) converts AA into prostaglandin H2 (PGH2), and the 
latter converts to TXA2 via TXA2 synthase (Stassen et al., 2004, Patrono, 1994). 
However, TXA2 has a short half-life and undergoes non-enzymatic hydration to 
form thromboxane B2 (TXB2), which is more stable and measurable (Catella et al., 
1986). 
 
Platelets express two ADP receptors, P2Y1 and P2Y12, which belong to the purinergic 
class of G-protein-coupled receptors (GPCRs) (Daniel et al., 1998, Jantzen et al., 
1999). Activation of P2Y1 enhances the cytosolic Ca2+ concentration that leads to the 
release of the contents of !- and dense-granules (Daniel et al., 1998, Siess, 1989). 
ADP binds to the P2Y12 receptor on the platelet surface and signals via Gi inhibitory 
protein to inhibit adenyl cyclase, cAMP formation and dephosphorylation of 
vasodilator-stimulated phosphoprotein (VASP) (Cattaneo, 2007). VASP is an 
intracellular platelet protein, which is unphosphorylated at the basal state and plays a 
significant role in negatively regulating adhesive events that are involved in platelet 
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aggregation (Halbrugge et al., 1990, Waldmann et al., 1987, Aszodi et al., 1999).  
 
Platelet derived microparticles (PMP), which are shed fragments of the plasma 
membrane of platelets, are the most abundant microparticles (MP) in the circulation 
(~70% to 90% of total) (Horstman and Ahn, 1999, Joop et al., 2001, Berckmans et 
al., 2001). PMP are typically characterised by size (<1 µm), as well as expression of 
either GPIb or αIIbβ3 receptors (Flaumenhaft et al., 2009). In general, MP consist of a 
phospholipid bilayer, which encloses transmembrane receptors and proteins, and 
exposes intracellular components including transcription factors, enzymes and 
mRNA derived from MPs parent cells (VanWijk et al., 2003). The circulating level 
of PMP is a marker of platelet activation (Abrams et al., 1990, Morel et al., 2011a, 
Keuren et al., 2006). PMP have important physiological roles, including as signaling 
structures between cells (Morel et al., 2004). In addition, PMP participate in the 
pathogenesis of atherosclerosis and thrombus formation, by providing a catalytic 
phospholipid surface for the assembly of blood coagulation factors. Furthermore, 
they expose phosphatidylserine and express tissue factor, thereby promoting 
thrombin generation and amplification of coagulation (Tan and Lip, 2005, Lee et al., 
1993, Mallat et al., 2000, Lacroix et al., 2013). The significant roles of PMP in the 
development of thrombosis and atherosclerosis make them a potentially attractive 
therapeutic target for the treatment and/or prevention of cardiovascular diseases 
(CVD) (Abrams et al., 1990, Morel et al., 2011a, Keuren et al., 2006, Azevedo et al., 
2007, Hartopo et al., 2016).  To date, nothing is known about the effect of vanilloids 
on these biomarkers (i.e., PMP) of thrombosis.  
 
Agents that suppress platelet activation and aggregation are well known for their 
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importance in preventing and treating CVD. Natural compounds such as the active 
ingredient of the hot chilli pepper have been studied as potential antiplatelet agents 
(Adams et al., 2009, Almaghrabi et al., 2014, Mittelstadt et al., 2012, Raghavendra 
and Naidu, 2009, Hogaboam and Wallace, 1991). Hot chilli peppers contain 
capsaicinoids, a group of compounds that give them their characteristic pungent 
taste. The two major capsaicinoids responsible for pepper pungency are capsaicin 
(CAP) and dihydrocapsaicin (DHC) (Kozukue et al., 2005, Curry et al., 1999). CAP, 
DHC and endogenous vanilloid-like lipids (‘endovanilloids’), e.g., N-
oleoyldopamine (OLDA) and N-arachidonoyldopamine (NADA), inhibit in vitro 
ADP- and AA-induced platelet aggregation (Adams et al., 2009, Almaghrabi et al., 
2014, Raghavendra and Naidu, 2009). In addition, CAP and endovanilloids exert 
their action in sensory neurons by activating transient receptor potential vanilloid-1 
(TRPV1) and cannabinoid receptors (CB) (Caterina et al., 1999, Hu et al., 2009). 
TRPV1 and CB receptors are present in/on platelets but neither CAP nor 
endovanilloids act through these receptors to inhibit platelet aggregation (Harper et 
al., 2009, Deusch et al., 2004, Mittelstadt et al., 2012), as I have earlier shown in 
Chapter 2. Therefore, the precise mechanism/s of action of vanilloids and 
endovanilloids on platelet aggregation remain to be elucidated. 
 
In this study, whether vanilloids inhibit in vitro platelet aggregation by interfering 
with one or more of the following was investigated: 1) ADP-induced VASP 
dephosphorylation, 2) ADP-induced dense (5-hydroxytryptamine (5-HT)) release, 3) 
ADP-induced α-granules (platelet factor 4 (PF4) and β-thromboglobulin (β-TG)) 
release, 4) the AA metabolic pathway and subsequent TXB2 formation. Furthermore, 
the effects of vanilloids on the formation/release of PMP were also determined.   
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3.3.!Materials 
ADP and AA were purchased from Helena Laboratories (Beaumont, Texas, USA). 
CAP, NADA and OLDA were obtained from Tocris (Bristol, UK). DHC, 1.1µm and 
0.8µm carboxylate and amine modified latex (polystyrene) beads, were obtained 
from Sigma-Aldrich (St Louis, USA). The following ELISA kits were used: TXB2 
(Abcam, Melbourne, Australia), 5-HT, PF4 and β-TG (Uscn Life Science Inc, 
Wuhan, China), VASP (Diagnostica Stago, Melbourne, Australia). Hank’s Balanced 
Salt Solution (HBSS) was obtained from Thermo Fisher Scientific (Victoria, 
Australia). BV421 anti-human CD41b and PE anti-human CD42a antibodies were 
bought from BD Biosciences (Victoria, Australia). 
3.4.!Methods 
Ethics 
This study was approved by the Tasmanian Health and Medical Human Research 
Ethics Committee (approval number: H00011414). Informed written consent was 
obtained from all participants. 
Sample collection 
Venous blood was collected by venipuncture using minimal stasis from healthy 
volunteers (aged 18-65 years). All participants had no previously diagnosed 
haemostatic abnormality. Subjects avoided aspirin and antiplatelet medications for at 
least 10 days and dietary chilli for at least two days, prior to collection. 
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Vanilloids and platelets agonist preparation  
CAP, DHC, OLDA and NADA, and platelet agonists, ADP and AA, were prepared 
as previously described in Chapter 2.  
Effects of vanilloids and endovanilloids on VASP phosphorylation 
status 
VASP dephosphorylation/phosphorylation status was determined using ELISA in the 
absence and presence of 3.125 and 50 µM of CAP, DHC, NADA and OLDA 
according to manufacturer’s instructions (Appendix 3). The concentration of ADP 
used in these kits is unknown and when I contacted the company they declined to 
disclose such information. The blood was incubated with the reagents for 10 minutes. 
The measurement of VASP phosphorylation, expressed as platelet reactivity index 
(PRI), mirrors the degree of P2Y12 receptor inhibition, i.e., the lower the PRI, the 
higher the inhibition of the P2Y12 receptor. The PRI was calculated using optical 
density (OD) at 450 nm in the presence of prostaglandin E1 alone [PGE1], or PGE1 
and ADP simultaneously [PGE1+ ADP], using this formula:  
PRI% = (OD[PGE1] – OD[PGE1+ADP]/ OD[PGE1] – OD(blan)) x100. 
Effects of vanilloids and endovanilloids on 5-HT, PF4 and β-TG 
release from platelets 
The release of dense and α-granules from platelets treated with 5 and 10 µM ADP in 
the absence and presence of 3.125, 25 and 100 µM of CAP, DHC, NADA and 
OLDA was measured using ELISA kits for 5-HT, PF4 and β-TG, according to 
manufacturer’s instructions (Appendix 4-6). Vanilloids were incubated with platelets 
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for 10 minutes. Data are presented as percent 5-HT, PF4 and β–TG normalised to 
their concentration with ADP only (i.e. no treatment control). 
Effects of vanilloids and endovanilloids on TXB2 release from 
platelets 
TXB2 is a stable metabolite of TXA2 (Catella et al., 1986). The measurement of 
TXB2 release from platelets treated with AA (300 µg/mL) in the absence and 
presence of 3.125 and 50 µM of CAP, DHC, NADA and OLDA was performed 
using a TXB2 ELISA kit according to manufacturer’s instructions (Appendix 7). 
Platelets were incubated for 10 minutes with vanilloids. Data are presented as 
percent TXB2 concentration normalised to TXB2 concentration in plasma with AA 
only (i.e. no treatment control). 
Effects of vanilloids and endovanilloids on the release of Platelet-
derived microparticles  
Preparation of microparticles  
Venous whole blood was collected by venipuncture from four volunteers (aged 18-
65) with 21-gauge needles. Samples were collected into acid citrate dextrose 
anticoagulant (ratio blood:anticoagulant 9:1) and processed within two hours. All 
experiments were conducted as previously described (van der Heyde et al., 2011).  
Briefly, blood was centrifuged at 150g for 10 minutes to generate platelet rich 
plasma (PRP). Platelets were purified by washing PRP using Ca2+ and Mg2+ free 
Tyrode’s buffer (140mM NaCl, 3 mM KCl, 47 mM NaH2PO4, 1.2mM NaHCO3, 1 
mg mL–1 glucose, pH 7.4). Tyrode’s buffer was sterile-filtered with 0.2 µm filter, to 
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reduce the background noise (Dey-Hazra et al., 2010). The platelet count was 
determined using a Sysmex 1000i analyser (Roche Diagnostics, Sydney, Australia) 
and adjusted to 1x 106/mL using Tyrode’s buffer. Platelets were then activated and 
incubated for 15 minutes with ADP (5 µM) or AA (300 µg/mL) in the presence and 
absence of CAP, DHC, NADA or OLDA (final concentrations 50 µM). Samples 
were then centrifuged at 5000g for 15 minutes, and the cell-free supernatant rich in 
MP, including PMP, transferred to a separate tube.  
 
Flow cytometry 
The MP rich supernatant (10 µL) was added into flow cytometry tubes, labeled with 
5 µL of CD41b-BV421 and CD42a-PE and incubated in the dark for 25 minutes. 
Subsequently, 500 µL of Hank’s Balanced Salt Solution (HBSS) was added then the 
samples subjected to flow cytometry. Data were acquired using an Attune® Acoustic 
Focusing Cytometer (Life Technologies, Grand Island, USA). Fluorescence and 
scatter signals were calibrated with Attune™ Performance Tracking Beads (Thermo 
Fisher Scientific, Victoria, Australia). Latex beads, 1.1 and 0.8 µm, were run and 
used to set the upper limit of the population to analyse with FSC <1.0 µm (Figure 3-1 
a).  PMP were gated by their size (<1.0 µm) and positivity for anti-CD41b and -
CD42a (Figure 3-1 b,c). For each sample there were eight controls including, PRP, 
MP plasma only, MP + ADP, MP + AA, MP + CAP, MP + DHC, MP + OLDA and 
MP + NADA, as the biological comparison controls are the most appropriate to set 
positive/negative limits (Maecker and Trotter, 2006).  
Statistical analysis 
One-way ANOVA was performed using GraphPad Prism. Holm-Šidák was used to 
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adjust p-values for multiple comparisons. P < 0.05 was considered statistically 
significant (version 7; San Diego, CA, USA). Analysis of the flow data was 
performed using dot plot that was collected from fluorescence data acquired in the 
logarithmic mode from 10,000 events analysed in each sample. Final analysis was 
performed using FlowJo (version 7/9, Oregon, U.S.A.). Data were plotted using 
GraphPad Prism (version 7; San Diego, CA, USA) and expressed as the percentage 
of fluorescence-positive MP and normalised to MP plasma only.  
3.5.!Results 
 
The effect of vanilloids and endovanilloids on VASP 
phosphorylation  
NADA (50 µM) significantly reduced the PRI (increased VASP phosphorylation) by 
17% ± 2.2, p<0.05 compared to control (no treatment control) (control PRI = 98.9%), 
whereas OLDA decreased the PRI, but this was not statistically significant (13%± 
2.7, p=0.12). CAP and DHC had minimal effect on VASP phosphorylation (Figure 
3-2).   
The effect of vanilloids and endovanilloids on the release of 5-HT, 
PF4 and β-TG from platelets 
Relative to ADP alone, neither plant-derived vanilloids (CAP and DHC), nor 
endogenous vanilloids (NADA and OLDA) (3.125, 25 and 100 µM) had a significant 
effect on 5-HT, PF4 or β-TG release on ADP-activated platelets (Figure 3-3). 
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Figure 3-1  
(a) Forward and side scatter gating showing the 0.8 and 1.1 µm beads and the upper limit of the MP 
gate. (b) Dot plots graph of plasma that has not been completely depleted in platelets, MP and 
platelets can be easily distinguished using 1 µm limit. (b) Double staining of MP plasma using CD41a 
and CD42b.   
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Figure 3-2 Effect of CAP, DHC, NADA and OLDA on VASP phosphorylation status. 
Data are presented as percent of platelet reactivity index (PRI), n=6, * p < 0.05. 
 
The effect of vanilloids and endovanilloids on the release of TXB2 
from platelets 
TXB2 release was decreased significantly in the presence of CAP (50 µM; 10.7%, 
p<0.001) following stimulation with AA (Figure 3-4). DHC (50 µM; 4.6%) 
decreased TXB2 release but this result was not statistically significant (p=0.80). 
However, 3.125 µM CAP and DHC had no effect on TXB2 formation. Furthermore, 
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neither OLDA nor NADA (3.125 and 50 µM) had an effect on TXB2 compared to 
AA alone (no treatment control) (Figure 3-4). 
The effect of vanilloids and endovanilloids on the release of platelet 
microparticles 
A gate was set to include only events showing FSC <1 µm beads. If the MP were 
stained, then another gate was set to include only events with fluorescence intensity 
higher than that detected with unstained MP. 
 
In comparison to MP only plasma, ADP stimulated a slight increase in MP 
generation from platelets in the presence and absence of vanilloids (Figure 3-5A and 
3-6A). The quantities of CD41b and CD42a positive PMP (indicative of glycoprotein 
GPIIb and integrin alpha IIb, and GPIX, respectively) remained unchanged after 
exposure to ADP (5 µM). Although CAP, DHC, OLDA and NADA (50 µM) alone 
decreased the number of CD41b and CD42a positive PMP (~24%), the decreases 
were not statistically significant (Figure 3-5B and 3-6B).  
 
In comparison to ADP (5 µM) alone, plant-derived vanilloids and endovanilloids had 
no effect on MP generation by ADP-stimulated platelets (Figure 3-5A and 3-6A). 
Moreover, CAP did not change the generation of CD41b/CD42a positive PMP 
whereas DHC slightly increased it (Figure 3-5B). NADA non-significantly increased 
the CD41b and CD42a positive PMP by 17.2% (p=0.91) while OLDA had no effect 
(Figure 3-6B).  
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In comparison to MP only plasma, AA (300 µg/mL) stimulated a slight increase in 
MP generation in the absence and presence of CAP and DHC (Figure 3-7A), but 
none were statistically significant. Generation of PMP (CD41b/CD42a positive) was 
reduced (~25%) by AA, CAP and DHC alone (Figure 3-7B).  Interestingly, PMP 
generation increased in the presence of AA+CAP and AA+DHC by 37.3% (p=0.24) 
and 11% (p=0.99), respectively, compared to AA only (Figure 3-7B).   
 
A similar pattern was observed for NADA and OLDA, i.e., slight increases in MP 
generation with AA or vanilloids alone (Figure 3-8A), but there was a non-
significant reduction in PMP generation by NADA and OLDA alone, and in 
combination with AA (Figure 3-8B). Results obtained in these experiments are 
summarised in Table 3-1. 
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Figure 3-3 Effect of CAP, DHC, NADA and OLDA on 5-HT, PF4 and β–TG release. 
Data are presented as percent of 5-HT, PF4 and β–TG concentration normalised to their concentration 
with ADP only (i.e. no treatment control). Results are the mean ± SEM, n=4. Some error bars are too 
small to be seen. 
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Figure 3-4 Effect of CAP, DHC, NADA and OLDA on TXB2 formation. 
Data are presented as percent of TXB2 concentration normalised to TXB2 concentration with AA 
only (i.e. no treatment control). Results are the mean ± SEM, n=5, *p<0.001. Some error bars are too 
small to be seen. 
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Figure 3-5 (A) The percent of MP in <1 µm gate of MP plasma only, ADP-activated platelets, 
capsaicin (CAP), dihydrocapsaicin (DHC), ADP+CAP and ADP+DHC. (B) The percent of 
CD41b+ and CD42a+ platelet derived microparticles (PMP) of (A) samples. 
Data are presented as percent of MP and PMP normalised to MP plasma only (i.e. 0 µM ADP and 
vanilloids). Results are the mean ± SEM, n=4. 
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Figure 3-6 (A) The percent of MP in <1 µm gate of MPs plasma only, ADP-activated platelets, 
N-oleoyldopamine (OLDA) and N-arachidonoyl-dopamine (NADA), ADP+OLDA and 
ADP+NADA. (B) The percent of CD41b+ and CD42a+ platelet derived microparticles (PMP) of 
(A) samples. 
Data are presented as percent of MP and PMP normalised to MP plasma only (i.e. 0 µM ADP and 
vanilloids). Results are the mean ± SEM, n=4. 
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Figure 3-7 (A) The percent of MP in <1 µm gate of MP plasma only, AA-activated platelets, 
capsaicin (CAP), dihydrocapsaicin (DHC), AA+CAP and AA+DHC. (B) The percent of CD41b+ 
and CD42a+ platelet derived microparticles (PMP) of (A) samples. 
Data are presented as percent of MP and PMP normalised to MP plasma only (i.e. 0 µM AA and 
vanilloids). Results are the mean ± SEM, n=4. 
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Figure 3-8 (A) The percent of MP in <1 µm gate of MP plasma only, AA-activated platelets, N-
oleoyldopamine (OLDA) and N-arachidonoyl-dopamine (NADA), AA+OLDA and AA+NADA. 
(B) The percent of CD41b+ and CD42a+ platelet derived microparticles (PMP) of (A) samples. 
Data are presented as percent of MP and PMP normalised to MP plasma only (i.e. 0 µM AA and 
vanilloids). Results are the mean ± SEM, n=4. 
MP Count
50
100
150
%
 M
P
MP only
AA 300µg/mL
OLDA 50µM
AA 300µg/mL + OLDA 50µM
NADA 50µM
AA 300µg/mL + NADA 50µM
A
CD41b+ & CD42a+ 
50
100
150
%
 P
M
P
B
  88 
Table 3-1 Summary of ADP- and AA-generated microparticles (MP) in the presence and absence of vanilloid-like agents, labeled with antibodies to GPIIb 
(CD41b) and GPIX (CD42a) 
 Total % of MP < 1 µm CD41b+/CD42a- CD41b-/CD42a+ CD41b+/CD42a+ CD41b-/CD42a- 
MP only 40.2±4.1 27.7±3.2 14.8±2.7 30.2±3.3 27.2±2 
ADP 43.7±3.5 19.3±4.5 23.1±3.4 30.4±4.5 27.1±3.8 
AA 42.7±0.8 20.3±1.9 22.1±1.7 22.4±2 35.3±0.9 
CAP 43.5±3.9 20.3±3.2 25.3±4.8 22.4±4.9 31.8±4 
ADP+CAP 45.3±3 17.2±1.9 23.2±2.1 28.3±3.1 31.3±2.5 
AA+CAP 43.4±4.4 17.9±4.3 23.8±6.7 33.7±6.4 24.6±4.9 
DHC 44.4±1.8 20.8±3.7 30.9±2.8 22.1±3.2 26.2±3.9 
ADP+DHC 43.9±3.9 18.8±3.4 18.4±3.4 35.7±4.6 27.1±5.5 
AA+DHC 41.8±1.6 20.9±1.7 25.8±3.3 25.7±3.8 27.6±3.5 
OLDA 44.1±3.4 24.4±2.2 24.9±1.8 23.4±4.5 27.3±4.3 
ADP+OLDA 43.4±2.2 20.2±3 21.6±3.5 28.7±3.1 29.5±5 
AA+OLDA 45.9±2.2 21.3±2.9 30.2±0.7 24.4±2.2 24.2±4.1 
NADA 40.5±2.6 19.8±3.2 26.7±4 22.9±3 30.5±5.2 
ADP+NADA 42.4±3 15.5±2.4 27.2±0.7 25.3±1.9 32.1±2.9 
AA+NADA 43.5±3 25.5±2.8 17.7±3.7 27.3±4.2 29.6±3.5 
Data are expressed as the percentage of MP <1 µm and fluorescence-positive MP (mean ± SEM; n=4). Variable expression of glycoprotein GPIIb and Integrin 
alpha IIb, and GPIX were detected in ADP- and AA-derived MP in the presence and absence of vanilloid-like agents, as assessed by CD41b and CD42a, 
respectively.  
  89 
3.6.!Discussion  
The present data suggest that the inhibitory effect of endovanilloids and plant-
derived vanilloids on in vitro platelet aggregation is caused at least in part through 
blocking the P2Y12 receptor and inhibiting the AA metabolic pathway, respectively. 
Plant-derived vanilloids, CAP and DHC, and endogenous vanilloids, NADA and 
OLDA, did not appear to mediate their inhibitory effects on platelet aggregation 
through blocking the P2Y1 ADP receptor, as dense- and α-granules release were not 
affected. Finally, the inhibitory effect of vanilloids appears to be independent of 
changes in PMP formation/release. 
 
The precise mechanism(s) of action of endogenous and plant-derived vanilloids on 
platelet aggregation remain to be clarified, although numerous hypotheses have been 
proposed, particularly for CAP. A previous study showed that CAP inhibits 
cyclooxygenase-1 (COX-1), which may result in inhibition of platelet aggregation 
(Raghavendra and Naidu, 2009). Furthermore, it has been suggested that CAP 
inhibits aggregation by inserting into platelet plasma membranes, changing its 
permeability and fluidity (Hogaboam and Wallace, 1991). 
 
I have previously shown that plant-derived vanilloids and endovanilloids inhibit 
ADP-induced platelet aggregation, with both vanilloid classes (apart from OLDA) 
producing a similar effect on AA-induced aggregation (Almaghrabi et al., 2014). 
These inhibitory effects were not mediated through TRPV1 channels, nor CB1 or 
CB2 receptors (Chapter 2). Based on these findings, I attempted to determine the 
mechanism(s) that might explain inhibition of platelet aggregation by vanilloid-like 
agents. The collagen pathway was not investigated as I have previously shown that 
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only the endovanilloids, NADA and OLDA, have an inhibitory effect on aggregation 
induced by a low concentration of collagen (4 µg/mL), which was not observed at the 
higher concentration (8 µg/mL) (Almaghrabi et al., 2014). 
 
Firstly, VASP phosphorylation status and the measurement of platelet granule 
release were used to determine whether vanilloids act through blocking the ADP 
receptors, P2Y12, and/or P2Y1, respectively. It was demonstrated that NADA 
stimulated phosphorylation of the targeted protein, VASP, by interfering 
with/blocking the P2Y12 receptor, which leads to increased cAMP formation. To a 
lesser extent, OLDA showed a non-significant stimulatory effect on VASP 
phosphorylation. Elevated levels of cAMP interfere with platelet activity by 
inhibiting fibrinogen receptor activation, cytoskeleton rearrangements, degranulation 
and expression of pro-inflammatory signaling molecules (Schwarz et al., 2001).  In 
addition, increased cAMP levels are associated with reduced binding ability of 
thrombin to its receptor (Lerea and Glomset, 1987, Lerea et al., 1987). In my 
previous study, the effect of CAP was investigated using 5 and 10 µM ADP to 
stimulate platelet aggregation (Almaghrabi et al., 2014). However, the ADP 
concentration in VASP kit was unavailable as the company refused to disclose this 
information. Therefore, the ADP concentration provided in the VASP kit may be 
higher than 10 µM, which may provide an explanation as to why no effect on VASP 
phosphorylation in the presence of CAP effect was observed. Moreover, DHC 
showed no effect on the phosphorylation status of VASP, as it had no effect on ADP-
induced aggregation (Almaghrabi et al., 2014). Plant-derived vanilloids and 
endovanilloids do not seem to exert their action through interference to the ADP 
receptor, P2Y1, as they had no effect on dense- (5-hydroxytryptamine (5-HT)), α-
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granules (platelet factor 4 (PF4) or β-thromboglobulin (β-TG)) release. 
 
Subsequently, the possibility that inhibition of platelet aggregation was due to the 
inhibition of TXA2 production in the AA pathway was investigated. Thromboxane 
A2 is an important mediator of platelet aggregation and AA markedly increases 
TXB2, the stable metabolite of TXA2 (Catella et al., 1986). CAP significantly 
reduced TXB2 formation, in agreement with the study of Raghavendra and Naidu 
(2009), which reported a significant reduction in TXB2 from washed platelets in the 
presence of CAP. Moreover, DHC showed non-significant inhibition of TXB2 
formation. These results are in agreement with my earlier work as CAP and DHC 
showed a strong inhibitory effect on AA-induced aggregation (Almaghrabi et al., 
2014). OLDA had no effect on TXB2 formation, which was expected since it did not 
inhibit AA-induced aggregation (Almaghrabi et al., 2014). Whereas NADA showed 
an inhibitory effect with AA-induced aggregation (Almaghrabi et al., 2014) but not 
on TXB2 formation. In platelets, AA converts to TXA2 and the latter is a potent 
inducer of aggregation causing granule release of its contents such as ADP to 
amplify aggregation. Therefore, NADA may block ADP receptors, P2Y12, and inhibit 
platelet aggregation. 
 
Finally, PMP generation increases upon platelet activation, which is associated with 
increased risk of CVD (Abrams et al., 1990, Morel et al., 2011a, Keuren et al., 2006, 
Azevedo et al., 2007, Hartopo et al., 2016). Currently used antiplatelet medications, 
abciximab and clopidogrel, inhibit PMP formation in vitro and ex vivo, respectively, 
whereas epoprostenol prevents PMP generation in vitro (Reverter et al., 1996, 
Tamburrelli et al., 2011, VanWijk et al., 2003, Behan et al., 2005). Hence, the effect 
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of vanilloids on PMP formation/release was investigated in the present study. 
Contrary to expectations, the presence of vanilloids had an effect, but not statistically 
significant, on the levels of CD41b/CD42a-positive PMP derived from ADP- and 
AA-stimulated platelets. Although the results were not significant NADA and OLDA 
seem to dampen PMP formation in ADP-stimulated platelets. This is noteworthy 
because NADA is able to inhibit platelet aggregation induced by different agonists 
(Almaghrabi et al., 2014) and inhibit PMP formation. However, NADA slightly 
increased PMP formation in AA-stimulated platelets while OLDA showed no effect. 
Interestingly, the effects of CAP and DHC on PMP formation were non-significantly 
exacerbated in the presence of the agonists, ADP and AA, which conflicts with their 
previously demonstrated antiplatelet effects (Adams et al., 2009, Almaghrabi et al., 
2014). Increased PMP levels are associated with platelet activation (Abrams et al., 
1990, Morel et al., 2011a, Keuren et al., 2006) and involved in the pathogenesis of 
atherosclerosis and thrombus formation (Tan and Lip, 2005, Lee et al., 1993, Mallat 
et al., 2000, Lacroix et al., 2013). However, the reason for this effect is unclear and it 
raises a question about whether or not CAP, DHC and possibly NADA would be safe 
to use as antiplatelet agents, especially in patients with hyperactive platelets. 
 
Although this study has achieved most of its initial aims, the main limitation was the 
relatively small sample size. However, the data from this chapter has generated new 
experimental data on some of the potential mechanisms by which vanilloids inhibit 
platelet aggregation. In addition, higher concentrations of the platelet agonists, ADP 
and AA, could have been used in PMP experiments. Concentrations of all agonists 
and vanilloids were kept consistent across all experiments to allow comparison of the 
effect of vanilloids on platelets across different studies. Further studies could 
  93 
include: investigate whether endovanilloids interfere with collagen receptor(s) as 
they also inhibited collagen-induced platelet aggregation. 
 
In conclusion, plant-derived vanilloids, CAP and DHC, and endogenous vanilloids, 
OLDA and NADA, inhibited in vitro platelet aggregation induced by AA and ADP. 
NADA and possibly OLDA may exert their inhibitory action through blocking the 
ADP receptor, P2Y12, whereas, CAP and possibly DHC via inhibiting AA metabolic 
pathway. None of the vanilloids inhibited aggregation through the P2Y1 ADP 
receptor, as the release reaction from dense- and α-granules was not affected. 
Moreover, no changes in the quantity of PMP released in the presence of vanilloids 
were observed. The mechanism of action of vanilloids should be further investigated 
as they have a potent antiplatelet effect and appear to inhibit platelet aggregation 
through different pathways. 
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4.! Chapter 4: Synergistic Inhibitory Effect of Capsaicin and 
Dihydrocapsaicin on In Vitro Platelet Aggregation and 
Thromboxane Formation  
 
4.1.!Abstract 
Capsaicinoids, including capsaicin (CAP) and dihydrocapsaicin (DHC), the pungent 
principles of pepper fruits, individually inhibit in vitro platelet aggregation. 
However, their effects when present in the relative proportions that they are found 
naturally, i.e., ~60% CAP and ~40% DHC, are not known. The aims of this study 
were to compare the effects of CAP and DHC alone, and in combination, on in vitro 
platelet aggregation, platelet count and thromboxane B2 formation (TXB2). 
 
Venous blood was collected from healthy participants in citrate tubes to obtain 
platelet-rich and platelet–poor plasma. The effects of 12.5 and 6.25 µM CAP and 
DHC individually, and in combination (CAP:DHC, 60:40) on arachidonic acid (AA) 
(300 µg/mL)-, ADP (5 µM)-, and collagen (4 µg/mL)-induced in vitro platelet 
aggregation, were investigated. Platelet count was determined pre- and post-
incubation with 12.5 µM CAP and DHC, and in combination (60:40 ratio). TXB2 
formation from platelets treated with AA (300 µg/mL) in the absence and presence 
of 12.5 µM and 6.25 µM CAP and DHC individually, and in a 60:40 combination, 
was measured by ELISA. 
 
Compared to control, CAP and DHC (12.5 µM) inhibited AA-induced aggregation 
by 23.2% and 25.3%, respectively (both p<0.01). In combination, CAP and DHC 
exhibited further inhibition in AA-induced aggregation (CAP:DHC, 3.75:2.5 µM, 
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36.5%, p=0.01; CAP:DHC, 7.5:5 µM, 57.5%, p<0.001), compared to control. In 
contrast to AA-induced aggregation, neither CAP nor DHC individually, or in 
combination, significantly inhibited ADP- or collagen-induced aggregation. 
Incubation of platelets with CAP and DHC (12.5 µM), and in combination for up to 
2 hours did not significantly affect the platelet count. In addition, the 60:40 
CAP:DHC (7.5:5 uM) combination significantly inhibited (p<0.001) TXB2 
formation, compared to the individual capsaicinoids. 
 
The present study shows that the combination of CAP and DHC in the proportions 
they are usually present in pepper fruits, produces a significantly greater inhibitory 
effect on AA-induced platelet aggregation and subsequent TXB2 formation, 
compared to the individual capsaicinoids. These results warrant further investigation 
to determine whether they may be exploited for therapeutic benefit. 
4.2.!Introduction  
Pepper fruits (Capsicum) are one of the most consumed foods worldwide. These 
fruits contain capsaicinoids, which give them a characteristic pungent taste. 
Capsaicin (CAP) and dihydrocapsaicin (DHC) are the major capsaicinoids (Bennett 
and Kirby, 1968, Kosuge and Furuta, 1970) and are usually present in a 60:40 ratio 
(Garces-Claver et al., 2006) (Table 4-1).  
 
Individually, CAP and DHC have strong inhibitory effects on arachidonic acid (AA)-
induced in vitro platelet aggregation, and to a lesser extent on ADP-induced platelet 
aggregation (high concentrations 100-25 µM of CAP) (Almaghrabi et al., 2014). In 
contrast, neither CAP nor DHC appear to have an inhibitory effect on collagen-
induced aggregation (Almaghrabi et al., 2014). The inhibitory action of capsaicinoids 
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on platelet aggregation could potentially be applied to the prevention and/or 
treatment of thrombosis and atherosclerosis. 
 
Previous studies investigated the effects of CAP and DHC individually on platelet 
aggregation (Almaghrabi et al., 2014, Adams et al., 2009, Raghavendra and Naidu, 
2009). The aim of this study was to determine the effect of CAP and DHC 
individually, and in combination (in the relative proportions found in pepper fruits), 
on in vitro platelet aggregation, platelet count and TXB2 formation. 
 
Table 4-1 Concentrations of Capsaicin and Dihydrocapsaicin in Different Capsicum Genotypes.  
Determined by the HPLC-ESI/MS(TOF) Method Developed [Values Are Means ± SE (n ) 3)] 
(Garces-Claver et al., 2006). 
 
Genotype Capsaicin 
(mg kg-1 of dry weight) 
Dihydrocapsaicin 
(mg kg-1 of dry weight) 
Yolo Wonder Not detected Not detected 
Agridulce 8.7 ± 0.1 8.3 ± 0.8 
Sweet Chinense 16.5 ± 0.2 12.9 ± 1.8 
Mild Habanero 17.7 ± 1.6 13.4 ± 2.4 
Perennial 164 ± 7 192 ± 8 
Tabasco 3785 ± 235 2461 ± 80 
Orange Habanero 6639 ± 348 3727 ± 179 
 
4.3.!Materials 
ADP, AA and collagen were purchased from Helena Laboratories (Beaumont, Texas, 
USA). Capsaicin was obtained from Tocris (Bristol, UK). DHC was obtained from 
Sigma-Aldrich Pty. Ltd (NSW, Australia). The TXB2 ELISA kits were purchased 
from Abcam (Melbourne, Australia). 
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4.4.!Methods 
Ethics 
This study was approved by the Tasmanian Health and Medical Human Research 
Ethics Committee (approval number: H00011414). Informed written consent was 
obtained from all participants. 
Sample collection and processing 
Venous blood was collected from four healthy volunteers (aged 18-65 years), who 
avoided aspirin and antiplatelet medications for at least 10 d, and dietary chilli for at 
least two days, prior to collection. Samples were centrifuged at 150g for 10 min at 
room temperature to obtain platelet rich plasma (PRP). The remaining blood was 
then centrifuged at 2000g for 20 min at room temperature to obtain platelet poor 
plasma (PPP). 
Platelet aggregation 
Platelet aggregation was performed as described in Chapter 2 section 2.4. AA (300 
µg/mL), ADP (5 µM), and collagen (4 µg/ mL) were added separately to PRP (225 
µl) to initiate aggregation in the presence and absence of CAP and DHC. CAP and 
DHC were investigated individually at 12.5 µM and 6.25 µM  (final concentration), 
and in combination in a ratio of 60:40 (CAP:DHC; 7.5:5 and 3.75:2.5). Aggregation 
was recorded for 10 min, with aggregometry data generated by the HemoRAM 1.1.0. 
Software package (Helena Laboratories, Beaumont, Texas, USA). Percentage of area 
under curve (%AUC) was recorded and normalised to control (i.e. agonist only). 
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Platelet count 
Platelet counts were determined using a Sysmex 1000i analyser (Roche Diagnostics, 
Sydney, Australia) with PRP adjusted to 250 x 109/L using PPP from the same 
subject. CAP, DHC (both individually tested at 12.5 µM), and a combination of 7.5 
µM CAP and 5 µM DHC, were added separately to PRP, and the platelet count 
measured every 15 min for 2 hours (n = 4 subjects). PRP with buffer was used as a 
blank. Data are presented as percent of platelet count normalised to platelet count at 
time zero. 
Measurement of thromboxane B2 
Thromboxane B2 release from platelets treated with AA (300 µg/mL) in the absence 
and presence of 12.5 and 6.25 µM of CAP and DHC and a 60:40 combination was 
measured using a ELISA kit according to manufacturer’s instructions (Appendix 7). 
Platelets were incubated for ten minutes with capsaicinoids. Data are presented as 
percent of TXB2 concentration normalised to TXB2 concentration of AA only (i.e. 0 
µM capsaicinoid). 
Statistical analysis 
Data were plotted using GraphPad Prism (version 6; San Diego, CA, USA). Data 
were compared for AUC differences between control, individual capsaicinoids and 
combination of CAP and DHC using ANOVA/linear regression (Stata version 13, 
StataCorp, LP, USA). The Holm test was used to adjust p-values for multiple 
comparisons. P values < 0.05 were considered statistically significant. 
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4.5.!Results 
The effect of CAP and DHC on platelet aggregation 
Aggregation data (%AUC) was normalised to control, i.e., platelet agonist only. CAP 
and DHC (12.5 µM) individually inhibited (both p<0.001) AA-induced platelet 
aggregation by 23.2% and 25.3%, respectively (Figure 4-1A). The combination of 
7.5 µM CAP and 5 µM DHC produced even greater inhibition (57.5%, p<0.0001) 
compared to the control (Figure 4-1 A). Similarly, the combination of CAP and DHC 
in 3.75 µM: 2.5 µM, significantly reduced aggregation (36.5%, p<0.01) compared to 
control (Figure 4-1 A). Additionally, the combination of CAP and DHC (7.5:5 µM) 
inhibited AA-induced aggregation more than CAP or DHC alone, by 34.3% and 
32.2% (both p<0.05), respectively (Figure 4-1 A). 
 
Although CAP, DHC and the combination of CAP and DHC led to lower ADP-
induced platelet aggregation compared to control (Figure 4-1 B), the results were not 
statistically significant when adjusted for multiple comparisons. Collagen-induced 
platelet aggregation was not significantly different between control, CAP, DHC, or 
CAP and DHC in combination (Figure 4-1 C). 
The effect of CAP and DHC on platelet count 
Incubation of platelets with CAP and DHC (individually at 12.5 µM), and in 
combination (CAP:DHC, 7.5:5 µM), for 2 h had no statistically significant effect on 
platelet count relative to buffer control (Figure 4-2).  
The effect of CAP and DHC on TXB2 formation 
  100 
The combination of CAP:DHC (7.5:5 µM) significantly inhibited TXB2 formation  
by 4.4% (p<0.001), compared to the control and individual capsaicinoids (12.5 µM) 
(Figure 4-3 A). However, 12.5 µM and 6.25 µM of individual CAP and DHC, and 
the combination (3.75:2.5 µM) had no statistically significant effect on TXB2 
formation (Figure 4-3).  
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Figure 4-1 The effects of capsaicin (CAP), dihydrocapsaicin (DHC) and their combination on 
arachidonic acid (AA)- (A and B), ADP- (C and D) and collagen- (E and F) induced platelet 
aggregation. 
Data are presented as percent area under curve normalised to aggregation in the absence of 
capsaicinoid. Results are the mean ± SEM of 4 experiments. *p<0.05, **p<0.001 compared to control 
(i.e. 0 µM of capsaicinoid) and to each column. 
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Figure 4-2 12.5 µM of CAP, DHC, and the combination of CAP:DHC (60:40) have no effect on 
platelet count over 2 hours of incubation. 
Data are presented as percent of platelet count (normalised to platelet count at time zero). Mean ± 
SEM; n = 4. 
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Figure 4-3 The effects of capsaicin (CAP), dihydrocapsaicin (DHC) and their combination on 
TXB2 formation. 
Data are presented as percent of TXB2 concentration normalised to TXB2 concentration with AA 
only (i.e. 0 µM capsaicinoid). Results are the mean ± SEM, n=4. **p<0.001 compared to control (i.e. 
0 µM of capsaicinoid) and to each column. Some error bars are too small to be seen. 
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4.6.!Discussion  
This study demonstrated that the combination of CAP and DHC produces greater 
inhibition of in vitro AA-induced aggregation compared to either agent alone, 
suggesting that these molecules act synergistically. The combined effects of CAP 
and DHC were greater at lower concentrations, than those used for CAP and DHC 
individually. In contrast, at the concentrations tested, CAP and DHC individually, 
and in combination, had no significant effect on ADP- or collagen-induced 
aggregation. The capsaicinoids and their combination used in this study had no direct 
effect on platelet count. Furthermore, it was demonstrated that the combination of 
CAP and DHC act through inhibition of the AA pathway, as TXB2 formation 
decreased significantly in the presence of both CAP and DHC. 
 
The inhibitory effects of CAP and DHC (individually) on platelet aggregation 
demonstrated in the current study are similar to what have previously been reported 
by our laboratory, in that they are concentration dependent (Almaghrabi et al., 2014, 
Adams et al., 2009) and not due to direct toxicity of CAP and DHC on platelets 
(Almaghrabi et al., 2014). Although inhibition of in vitro platelet aggregation by 
capsaicinoids has been observed using agonists including AA, ADP and collagen, the 
degree of inhibition is dependent on the agonist used (Raghavendra and Naidu, 2009, 
Almaghrabi et al., 2014, Adams et al., 2009). For example, 12.5 µM CAP and DHC 
individually inhibited AA-induced aggregation (Almaghrabi et al., 2014), whereas 
ADP-induced aggregation was inhibited at concentrations greater than 25 µM 
(Almaghrabi et al., 2014, Adams et al., 2009). Similarly, the inhibitory effect of CAP 
on collagen-induced aggregation varies across studies, which may be due to 
differences in CAP concentration, the species source of platelets, and/or 
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methodological differences, e.g., incubation times (Almaghrabi et al., 2014, 
Raghavendra and Naidu, 2009). Moreover, collagen is a more potent agonist than 
AA or ADP (Holmsen, 1977) and so may require higher concentrations of CAP or 
DHC than those used in the current study to produce inhibition of platelet 
aggregation in vitro.  
 
The combination of CAP and DHC had a greater inhibitory effect on AA-induced 
platelet aggregation and TXB2 formation, compared to CAP and DHC individually. 
Our data supports the finding that the inhibitory effect of these capsaicinoids may be 
through suppression of thromboxane A2 synthesis in the AA pathway (Raghavendra 
and Naidu, 2009). This was reflected by a 70% reduction in thromboxane B2 (the 
stable metabolite of thromboxane A2) synthesis from washed platelets in the 
presence of 15 µM CAP (Raghavendra and Naidu, 2009). 
 
There are two possible explanations for the enhanced antiplatelet effect of combined 
CAP and DHC on the AA pathway. First, each capsaicinoid in the combination may 
inhibit different enzymes in AA pathway, for example cyclooxyganase-1 and/or 
thromboxane synthase, which may lead to decreased TXA2 formation and 
subsequently TXB2. An alternative explanation may be that CAP and DHC act 
synergistically on one of the enzymes to inhibit TXA2 formation. However, the exact 
mechanism of the synergistic inhibitory effect of combined CAP and DHC is 
unknown and warrants further investigation. 
 
The effect of CAP on the gastrointestinal tract has been extensively investigated due 
to the perception that chilli causes gastric injury and peptic ulcers. However, recent 
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research challenges this perception as low dose CAP has a gastro-protective effect 
through increased mucosal secretion, and prevention of gastric mucosal damage 
caused by indomethacin, ethanol and /or aspirin (Mozsik, 2014, Szabo et al., 2013, 
Yeoh et al., 1995).  Moreover, it has been reported that individuals who regularly 
consume chilli have a lower incidence of peptic ulcers than those who eat chilli less 
frequently (Kang et al., 1995).  
 
Aspirin is the most commonly used anti-platelet therapy, but causes side effects such 
as increased gastric injury and bleeding (Singh and Triadafilopoulos, 1999, Derry 
and Loke, 2000). However, combined intake of chilli and aspirin was associated with 
lower gastric injury, compared to aspirin alone, as detected by endoscopic tests 
performed six hours following their ingestion (Yeoh et al., 1995). Although CAP 
inhibits in vitro platelet aggregation (Adams et al., 2009, Almaghrabi et al., 2014, 
Raghavendra and Naidu, 2009), a recent study reported no additional inhibition 
across a 24 hour period in participants who ingested aspirin with CAP, compared to 
those who were given only aspirin (Sandor et al., 2014). In light of our results in the 
current study showing enhanced inhibition of platelet aggregation with a 
combination of CAP and DHC, and studies indicating the beneficial effects of chilli 
peppers on the gastric mucosa (Yeoh et al., 1995, Kang et al., 1995), it will be 
prudent to investigate the combined effects of CAP, DHC (or chilli) and aspirin, 
against aspirin only, on platelet aggregation.  
 
In conclusion, combining CAP and DHC in proportions found in pepper fruits, led to 
a greater inhibition of AA-induced platelet aggregation and TXB2 formation, 
compared to individual agents. Moreover, this combination has no effect on platelet 
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count. To my knowledge, this is the first study to report synergistic effects of a 
mixture of capsaicinoids on platelet aggregation. Further investigations are warranted 
to determine the in vivo/ex vivo effect of the chilli pepper on platelet aggregation and 
to assess whether it may be exploited for therapeutic benefit. 
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5.! Chapter 5: The Effects of Vanilloid-like Agents on Platelet 
Aggregation from Patients with Systemic Lupus Erythematosus: 
A Pilot Study 
5.1.!Abstract 
Patients with systemic lupus erythematosus (SLE) have a higher risk of thrombotic 
events and cardiovascular disease (CVD) than the general population and are 
associated with poorer health outcomes. The risk of thrombosis is decreased with 
antiplatelet medication. We have found that vanilloid-like agents, including plant-
derived vanilloids, capsaicin (CAP) and dihydrocapsaicin (DHC), and endogenous 
vanilloids, N-arachidonoyl-dopamine (NADA) and N-oleoyldopamine (OLDA), 
inhibit in vitro platelet aggregation in healthy individuals. Plant-derived vanilloids 
may decrease the risk of thrombosis and CVD. The aim of this pilot study was to 
investigate the effects of a range of vanilloid-like agents on in vitro platelet 
aggregation using platelets isolated from patients with SLE. 
 
Venous blood was collected from five female patients previously diagnosed with 
SLE. ADP (5 µM), collagen (4 µg/mL), and arachidonic acid (AA) (300 µg/mL)-
induced platelet aggregation was determined using platelet rich plasma (PRP; 
250x109/L) in the absence and presence of the plant-derived vanilloids (CAP and 
DHC) and the endocannabinoid/endovanilloid agents (OLDA and NADA). 
Maximum aggregation (%MAX), area under curve (%AUC) and slope of platelet 
aggregation were determined. 
 
Capsaicin, DHC, OLDA and NADA had no effect on ADP-induced aggregation. 
Similar results were observed with collagen for CAP, DHC and OLDA. However, 
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NADA had a significant inhibitory effect on collagen-induced aggregation (0 vs 50 
µM; %MAX, 100±7.7% vs 62.2±9.7%, p<0.001; %AUC, 100±6.5% vs 77.5±7.8%, 
p<0.001). Arachidonic acid failed to induce aggregation, as all patients were on 
aspirin and/or other non-steroidal anti-inflammatory drugs (NSAID). The present 
study using SLE patients’ platelets shows that NADA inhibits in vitro collagen-
induced aggregation, while CAP, DHC and OLDA have no effect on ADP- and 
collagen-induced aggregation. Determining the effect of NADA on a larger number 
of SLE patients and further investigation on how to increase its formation/secretion, 
as an endogenous vanilloid, is warranted. 
5.2.!Introduction 
Systemic lupus erythematosus (SLE) is an autoimmune connective tissue disease, 
characterised by the production of antibodies to cell nucleus components. Some of 
these autoantibodies form immune complexes that are responsible for tissue 
inflammation that directly contribute to the development of different clinical 
manifestations of the disease (Ruiz-Irastorza et al., 2001). Patients with SLE present 
with various symptoms, such as arthritis, rash, thrombocytopenia, anemia, nephritis 
and psychosis. Despite frequently developing thrombocytopenia, SLE patients 
paradoxically have a higher risk of thrombotic complications, which further 
increases in the presence of antiphospholipid antibodies (West and Johnson, 1988). 
Atherosclerosis and CVD are also well-described clinical manifestations (Ward, 
1999, Gladman and Urowitz, 1987). Indeed, the incidence of myocardial infarction 
in SLE is 50-fold higher compared to sex- and age-matched healthy individuals 
(Manzi et al., 1997).  
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Platelets have a proinflammatory role in atherosclerosis, and in SLE are abnormally 
activated and release inflammatory mediators into the local environment, as well as 
change the adhesive and chemotactic properties of endothelial cells (Gawaz et al., 
2005). In addition, systemic inflammation in SLE can modify thrombotic responses 
by down-regulating anticoagulants, up-regulating procoagulants and inhibiting 
fibrinolysis, which may individually or collectively increase the risk of thrombus 
formation (Dahlback, 2012, Esmon and Esmon, 2011, Xu et al., 2010). 
Antiplatelet medications have proven effective in the prevention of thrombotic 
events (Vandvik et al., 2012) with aspirin prescribed to SLE patients for primary 
prophylaxis (Arnaud et al., 2015, Arnaud et al., 2014). However, aspirin use is 
associated with increased gastric injury and bleeding (Singh and Triadafilopoulos, 
1999, Derry and Loke, 2000, Ivey et al., 1980, Weil et al., 1995).  Several studies 
have shown that the naturally occurring vanilloid in the chilli pepper, capsaicin 
(CAP), inhibited in vitro aggregation of platelets from healthy humans, dogs and 
rabbits (Raghavendra and Naidu, 2009, Mittelstadt et al., 2012, Almaghrabi et al., 
2014, Adams et al., 2009, Hogaboam and Wallace, 1991). In contrast to aspirin, CAP 
has been shown to have a gastro-protective effect against aspirin-, ethanol-and 
indomethacin-induced gastric mucosal damage (Mozsik, 2014, Szabo et al., 2013, 
Yeoh et al., 1995). Furthermore, people who consume chilli on a regular basis have a 
lower incidence of peptic ulcer (Kang et al., 1995). In addition to CAP, there are 
other vanilloid-like agents including, the plant-derived vanilloid, dihydrocapsaicin 
(DHC) an analogue of CAP, and endogenous vanilloids, N-arachidonoyl-dopamine 
(NADA) and N-oleoyldopamine (OLDA). Previously, we have found that both plant-
derived and endogenous vanilloids inhibit in vitro platelet aggregation in healthy 
individuals (Adams et al., 2009, Almaghrabi et al., 2014). Whereas, to my 
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knowledge, no studies have been published that have investigated the effect of 
vanilloid-like agents on platelets from patients with high risk of atherosclerosis and 
thrombosis. The aim for this study was to therefore investigate the effects of plant-
derived and endogenous vanilloids on in vitro aggregation of platelets collected from 
patients with SLE. 
5.3.!Materials 
Adenosine diphosphate (ADP) and collagen were obtained from Helena Laboratories 
(Beaumont, TX, USA). CAP, NADA and OLDA were obtained from Tocris (Bristol, 
UK). DHC was obtained from Sigma-Aldrich (St Louis, USA). 
5.4.!Methods 
Ethics 
This study was approved by the Tasmanian Health and Medical Human Research 
Ethics Committee (approval number: H00011414). Informed written consent was 
obtained from all participants. 
Sample collection and processing 
The volunteers were five females (aged 48–75 years) diagnosed with SLE, who 
avoided dietary chilli for at least 2 days before providing blood samples. All subjects 
were taking different combinations of medications such as non-steroidal anti-
inflammatory drugs (NSAID), anti-malarial, chemotherapeutics and immune system 
suppressants. Venous blood was collected by venipuncture using minimal stasis from 
the patients. Whole blood (20 mL) was collected into 3.2% sodium citrate 
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anticoagulant tubes (1:9 ratio of anticoagulant to whole blood). Samples were 
centrifuged at 150g for 10 minutes at room temperature to obtain PRP. The 
remaining blood was then centrifuged at 2000g for 20 minutes at room temperature 
to obtain platelet poor plasma (PPP). 
Preparation of vanilloid-like agents 
CAP, DHC and OLDA were dissolved in 100% ethanol and stored as 0.1M aliquots 
at -20°C.  NADA was stored as 11.37 x 103µM aliquot at -20°C. Aliquots of all 
vanilloids were diluted as required in normal buffered saline (pH 7.1) to provide final 
incubation concentrations ranging from 3.125-50 µM. 
Preparation of platelet aggregation agonists 
ADP and AA were dissolved in deionised water and stored in 1M aliquots at -20°C 
until required. Collagen was provided as ready to use and stored at 4°C. Aliquots of 
agonists were thawed and diluted in normal buffered saline (pH 7.1) to produce final 
concentrations; ADP (5 µM), collagen (4 µg/mL) and AA (300 µg/mL). 
Platelet aggregometry 
Platelet aggregation was performed as described in Chapter 2 section 2.4. PRP (225 
µL) was activated with 25 µL of ADP (5 µM) or collagen (4 µg/mL), in the presence 
and absence of CAP, DHC, NADA or OLDA (final concentrations, 3.125-50 µM). 
Aggregometry data were generated by the HemoRAM 1.1.0. software package 
(Helena Laboratories, Beaumont, USA). Parameters included maximum percent of 
aggregation (%MAX, reflecting the intensity of aggregation responses) percent of 
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area under the curve (%AUC), slope (rate of aggregation) and lag time per second 
(reflecting the time from addition of the agonist until the aggregation commenced). 
These parameters of ADP-, and collagen-induced aggregation were normalised to 
control (i.e. agonist only). Each data set is presented as the mean of five experiments, 
using platelets collected from five separate volunteers. 
Statistical analysis 
Data were plotted using GraphPad Prism (version 7; San Diego, CA, USA). All data 
were analysed statistically with repeated measures ANOVA using general linear 
modelling (Stata version 13, StataCorp, LP, USA). Post-estimation Holm test 
analysis was then used to adjust p values for multiple comparisons. P values < 0.05 
were considered significant. 
5.5.!Results 
Summarised data for the effects of plant-derived vanilloids and endovanilloids on 
SLE patients’ platelet aggregation induced by ADP and collagen is presented in 
Table 5-1. Graphical representation of aggregation data (%MAX, %AUC, slope and 
lag time) is presented as data normalised to control, i.e., platelet agonist only 
(Figures 5-1- 5-4). 
 
 
!
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Effect of vanilloid-like agents on ADP-induced aggregation 
Plant-derived vanilloids, CAP and DHC, had no effect on MAX% and %AUC on 
ADP-induced platelet aggregation in comparison to control (no treatment control) 
(Figure 5-1). However, the slope of the aggregation curve was enhanced in the 
presence of CAP (0 vs 50 µM; slope, 100±7.4% vs 122.7±11.9%), but this effect was 
not statistically significant (Figure 5-1 C,F). Furthermore, the endovanilloids OLDA 
and NADA had no statistically significant effect on any of the measured parameters 
of platelet aggregation (Figure 5-2). 
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Table 5-1 Effect of vanilloids-like agents on ADP-, collagen-induced platelet aggregation from SLE patients. 
Agonist ADP (5 µM) 
 CON CAP 
(3.125 µM) 
CAP 
(12.5 µM) 
CAP 
(50 µM) 
CON DHC 
(3.125 µM) 
DHC 
(12.5 µM) 
DHC 
(50 µM) 
% MAX 61.3±9.2 59.38±8.4 61.12±7.8 59.5±8.1  64.1±7.5 62.4±7.3 63.5±8.1 63.9±6.8 
% AUC 48.5±8.3 46.3±8.1 39.1±10.2 46.9±7.5 51.6±6.8 48.3±6.8 50.6±7.5 51.1±6.1  
Slope 69.1±7.4 83.1±9.3 81.8±10.5 84.8±11.9  78.5±7.5 86.6±8.4 84.7±8.1 69.1±16.6  
Agonist ADP (5 µM) 
 CON NADA 
(3.125 µM) 
NADA 
(12.5 µM) 
NADA 
(50 µM) 
CON OLDA 
(3.125 µM) 
OLDA 
(12.5 µM) 
OLDA 
(50 µM) 
% MAX 63.9±7.6 61.9±7.6 61.7±8.7 59.4±7.1 61.4±7.5 61.3±7.3 63.3±7.5 63.4±7.1 
% AUC 49.8±7.6 48.4±6.8 48.8±7.9 45.9±6.9 48±6.9 48.4±7.2 50.4±7.1 50.2±6.7 
Slope 95.6±14.5 100.4±14.9 100.7±18.5 96.5±10.2 95.5±18 86.7±11.7 94.8±13.5 96.6±12.8 
Agonist Collagen (4 µg/mL) 
 CON CAP 
(3.125 µM) 
CAP 
(12.5 µM) 
CAP 
(50 µM) 
CON DHC 
(3.125 µM) 
DHC 
(12.5 µM) 
DHC 
(50 µM) 
% MAX 47.5±10.3 50.5±5.3 51.8±5.7 49.7±5.3 53±7.2 49.5±6.1 51.4±7.3 48.5±6.4 
% AUC 42.4±3.3 35.8±4.6 36.9±4.6 36.2±3.9 38.8±6.1 34.7±5.1 36.1±5.7 34.8±5.1 
Slope 27±5.4 26.2±4.5 25.1±4.8 24.5±3.5 24.1±5.5 25±4.2 23.9±4.9 20.2±3.6 
Lag time/s 6.36±4.8 28.9±10.1 41.9±21 8.6±4.3 36.3±25.4 48.4±24.2 48.3±22.9 29.8±24.7 
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Agonist Collagen (4 µg/mL) 
 CON NADA 
(3.125 µM) 
NADA 
(12.5 µM) 
NADA 
(50 µM) 
CON OLDA 
(3.125 µM) 
OLDA 
(12.5 µM) 
OLDA 
(50 µM) 
% MAX 60.8±7.6 48.5±7.2* 42.8±8.2* 37.8±9.7* 56.1±7.2 53.6±5.1 54.7±5.8 51±6.5 
% AUC 44.8±6.5 34.9±5.8* 30.4±6.7* 34.8±7.7* 40.7±5.7 38.5±4.1 39.6±4.9 37.9±5.1 
Slope 26.9±5.2 19.8±3.5 19.9±4.7 24.9±6.1 24.8±3.6 25.1±4.6 24.4±7.9 17.3±2.5 
Lag time/s 28.9±25.7 29.7±9 50.7±26.6 21.6±11.2 27.3±24.4 25.5±8.7 28.7±9.3 24.7±9.8 
Data are presented as percent maximum aggregation (%MAX), percent area under curve (%AUC), slope of the propagation phase of curve (slope) and lag time for 
collagen-induced aggregation (Lag time/s). Data are the mean ± SEM of 5 experiments for (3.125-50 µM) capsaicin (CAP), dihydrocapsaicin (DHC), N-
arachidonoyl-dopamine (NADA) and N-oleoyldopamine (OLDA). * P <0.001 compared to control (CON) (i.e. 0µM vanilloids).  
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Figure 5-1 Effect of plant-derived vanilloids on 5 µM ADP-induced platelet aggregation in SLE 
patients. 
Data are presented as percent maximum aggregation (%Max, normalised to aggregation in the 
absence of vanilloid to 100%) (A,D), percent area under curve (%AUC) (B,E) and slope of the 
propagation phase of curve (slope) (C,F). Bars are the mean ± SEM of 5 experiments, for capsaicin 
(CAP) and dihydrocapsaicin (DHC).  
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Figure 5-2 Effect of endovanilloids on 5 µM ADP-induced platelet aggregation in SLE patients. 
Data are presented as percent maximum aggregation (%Max, normalised to aggregation in the 
absence of vanilloid to 100%) (A,D), percent area under curve (%AUC) (B,E) and slope of the 
propagation phase of curve (slope) (C,F). Bars are the mean ± SEM of 5 experiments, for N-
arachidonoyl-dopamine (NADA) and N-oleoyldopamine (OLDA).  
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Effect of vanilloid-like agents on collagen-induced aggregation 
CAP and DHC did not affect any of the measured parameters of collagen-induced 
platelet aggregation (Figure 5-3). However, CAP prolonged the lag time at 3.125 µM 
and 12.5 µM, of SLE platelets (Figure 5-3 D), although this was not statistically 
significant. 
 
NADA had a significant inhibitory effect on collagen-induced aggregation (0 vs 50 
µM; %MAX, 100±7.7% vs 62.2±9.7%, p<0.001); (%AUC, 100±6.5% vs 77.5±7.8%, 
p<0.001) (Figures 5-4 E,F). However, NADA had no significant effect on the slope 
or lag time of collagen-induced aggregation. Moreover, OLDA did show any 
statistically significant effect on collagen-induced aggregation measured variables 
(Figure 5-4).  
Effect of vanilloids on platelets from healthy individuals 
Contrary to my earlier observations that plant and endogenous vanilloids inhibited 
agonist induced aggregation of healthy platelets (Almaghrabi et al., 2014), the 
platelets obtained from SLE patients did not show any change in presence of 
vanilloids and there were discrepancy in slope and lag time results. To ensure that 
these results were not due to an experimental error, I repeated the experiment in 
platelets obtained from four healthy volunteers (three females and one male; aged 
32–50 years). Vanilloids had the same inhibitory effect on platelet aggregation 
(Figure 5-5 and 5-6), as previously reported (Almaghrabi et al., 2014). 
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Figure 5-3 Effect of plant-derived vanilloids on 4 µg/mL collagen-induced platelet aggregation 
in SLE patients. 
Data are presented as percent maximum aggregation (%Max, normalised to aggregation in the 
absence of vanilloid to 100%) (A,E), percent area under curve (%AUC) (B,F), slope of the 
propagation phase of curve (slope) (C,G) and lag time/s (D,H). Bars are the mean ± SEM of 5 
experiments, for capsaicin (CAP) and dihydrocapsaicin (DHC). 
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Figure 5-4 Effect of endovanilloids on 4 µg/mL collagen-induced platelet aggregation in SLE 
patients. 
Data are presented as percent maximum aggregation (%Max, normalised to aggregation in the 
absence of vanilloid to 100%) (A,E), percent area under curve (%AUC) (B,F), slope, of the 
propagation phase of curve (slope) (C,G) and lag time/s (D,H). Bars are the mean ± SEM of 5 
experiments, for N-arachidonoyl-dopamine (NADA) and N-oleoyldopamine (OLDA). * P <0.05 
compared to control (i.e. 0µM vanilloids). 
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Figure 5-5 Effect of plant-derived vanilloids and endovanilloids on 5 µM ADP-induced platelet 
aggregation in healthy individuals. 
Data are presented as percent maximum aggregation (%Max, normalised to aggregation in the 
absence of vanilloid to 100%) (A,B,C,D). Bars are the mean ± SEM of 4 experiments, for capsaicin 
(CAP), dihydrocapsaicin (DHC), N-arachidonoyl-dopamine (NADA) and N-oleoyldopamine 
(OLDA). * P <0.05 compared to control (i.e. 0µM vanilloids). 
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Figure 5-6 Effect of plant-derived vanilloids and endovanilloids on 4 µg/mL collagen-induced 
platelet aggregation in healthy individuals. 
Data are presented as percent maximum aggregation (%Max, normalised to aggregation in the 
absence of vanilloid to 100%) (A,B,C,D). Bars are the mean ± SEM of 4 experiments, for capsaicin 
(CAP), dihydrocapsaicin (DHC), N-arachidonoyl-dopamine (NADA) and N-oleoyldopamine 
(OLDA). * P <0.05 compared to control compared to control (i.e. 0µM vanilloids). 
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5.6.!Discussion  
To my knowledge, this is the first study to investigate the effects of plant-derived 
vanilloids, CAP and DHC, and endovanilloids, OLDA and NADA, on in vitro 
aggregation of platelets from SLE patients. NADA inhibited collagen-induced 
aggregation but had no effect on ADP-induced aggregation. Furthermore, CAP, 
DHC, and OLDA had no effect on in vitro ADP- or collagen-induced platelet 
aggregation. For completion, platelet aggregation was initially investigated using AA 
as the agonist. However, all SLE patients were taking aspirin and/or other NSAID, 
and as these medications dampen platelet function through the AA pathway 
irreversibly inactivating COX-1 enzyme and TXA2 synthesis (Vane, 1971, Atkinson 
and Collier, 1980, Smith and Willis, 1971), the data for AA-induced in vitro 
aggregation was not included in this chapter. 
 
It has been previously reported that CAP, OLDA and NADA inhibit aggregation 
induced by ADP using platelets from healthy donors, while only endovanilloids 
inhibited collagen-induced aggregation (Almaghrabi et al., 2014, Adams et al., 
2009). In addition, CAP and DHC, as well as NADA, completely inhibited AA-
induced aggregation (Almaghrabi et al., 2014). The anti-aggregating effects of plant-
derived vanilloids and endovanilloids were independent of transient receptor 
potential vanilloid-1 (TRPV1) and cannabinoid (CB1 and CB2) receptors (Chapter 
2). Moreover, the effects of both classes of vanilloid-like agents on aggregation were 
shown not to be due to direct toxicity toward platelets (Almaghrabi et al., 2014). 
Instead, NADA was found to inhibit platelet aggregation by interfering with the ADP 
receptor, P2Y12, as phosphorylation levels of vasodilator-stimulated phosphoprotein 
(VASP) were significantly increased (Chapter 3). 
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Determining the effect of vanilloid-like agents on platelets from SLE is complicated 
as platelets are affected by the disease course itself, and/or medications. Platelets in 
SLE patients are abnormally activated, as reflected by increased levels of 
thromboxane B2, surface and soluble P-selectin, circulating platelet-derived 
microparticles, as well as platelet and/or leukocyte aggregates (Ferro et al., 1999, 
Nagahama et al., 2001, Tam et al., 2003, Joseph et al., 2001, Sellam et al., 2009). 
Furthermore, in SLE patients, interferon-α modulates platelet and megakaryocyte 
activity by up-regulating multiple mRNA and proteins (Lood et al., 2010). Moreover, 
plasma membranes of platelets isolated from SLE patients have been shown to be 
‘shaggy and rough’, unlike the smooth surface of normal platelets, which is 
presumably due to immune complex deposition on the surface (Andrianova et al., 
2016). Therefore, the pathway(s) through which vanilloid-like agents inhibit platelet 
aggregation in healthy platelets might be impaired, blocked or altered by SLE itself, 
or due to medications. In the present study CAP, DHC nor OLDA demonstrated an 
inhibitory effect toward platelets from SLE patients.  
 
Interestingly, NADA, that appears to act through blocking the P2Y12 receptor in 
healthy platelets (Chapter 3), inhibited aggregation of platelets from SLE patients in 
a concentration-dependent manner. Many studies have reported the potential 
contribution of the P2Y12 receptor in inflammatory diseases (Cattaneo, 2015, Gachet, 
2012, Steinhubl et al., 2007, Liverani et al., 2016). Furthermore, blocking this 
receptor with clopidogrel results in reduced the exposure of P-selectin and CD40 
ligand, decreased circulating inflammatory mediators (tumor necrotic factor-α (TNF- 
α) and C-reactive protein), and inhibits platelet-leukocyte aggregate formation 
(Cattaneo, 2015, Gachet, 2012, Steinhubl et al., 2007). In addition to the inhibitory 
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effect on platelet aggregation, NADA has also been shown to reduce the 
inflammatory response of human endothelial cells induced by exogenous and 
endogenous inflammatory agonists (Wilhelmsen et al., 2014). Furthermore, NADA 
inhibited TNF-α and interleukin-2 gene transcription and suppressed the associated 
signaling pathways, which mediate the activation of some transcriptions factors 
known to have an important role in the immune system (Sancho et al., 2004). 
Therefore, NADA may have important anti-inflammatory and anti-platelet properties 
that could have important implications for helping treat the symptoms of SLE.   
 
Activation of platelets by collagen is a complex process and involves several 
receptors, including GPIV, integrin K2L1, GPVI, p65 and a TIIICBP type III 
collagen receptor (Clemetson and Clemetson, 2001, Monnet and Fauvel-Lafeve, 
2000). In addition, co-stimulation of the ADP P2Y12 receptor and thromboxane A2 
receptor are also required for platelet aggregation and secretion induced by low 
concentrations of collagen (Atkinson et al., 2001, Roger et al., 2004). ADP mediates 
its effect through two purinergic receptors coupled to G proteins, P2Y1 and P2Y12. As 
already stated, NADA inhibits platelet aggregation through at least pathway 
interfering/blocking the ADP receptor (P2Y12) (Chapter 3). 
 
NADA was the only vanilloid that inhibited aggregation induced by collagen in SLE 
patients. The reason why NADA had an effect with collagen but not ADP is unclear, 
however it is interesting to speculate on possible reasons for this data. Although 
collagen receptors have not been investigated as possible targets for vanilloid action, 
NADA has been shown to produce an inhibitory effect on collagen-induced 
aggregation in healthy platelets (Almaghrabi et al., 2014). Therefore, NADA may 
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interfere with P2Y12 ADP receptor (Chapter 3) and collagen receptor/s. The effect of 
NADA was more prominent with collagen-induced aggregation using SLE platelets 
because the P2Y12 ADP receptor has been found to be down-regulated in SLE 
patients (Wang et al., 2004). Other possible explanations may be variations in 
receptor expression and function and/or alterations to intracellular signaling 
pathways in platelets from SLE patients’ platelets compared to healthy platelets that 
changed NADA’s molecular target.  
 
Several limitations of this study need to be considered.  Firstly, the small sample size 
might increase the risk of exaggerating treatment effects compared to larger sample 
size (Moher et al., 1998, Schulz et al., 1995). Secondly, the platelet count for 
aggregation experiments was standardised to 250 x 109/L in a PRP preparation and 
thus might not reflect the natural behaviors of platelets from SLE patients either with 
regard to platelet count or their interactions with other components of whole blood. 
As some patients have thrombocytopenia (Fayyaz et al., 2015, Jung et al., 2016), 
increasing the number of platelets might mask the actual effect of vanilloid-like 
agents. Finally, SLE patients were taking aspirin and/or other NSAIDs, and thus the 
effects of vanilloid-like agents on AA-induced aggregation could not be investigated.  
 
Future direction could include: 1) increase the number of patients as it may show the 
actual effect of vanilloids and decrease the discrepancy and variability between the 
data, 2) use a whole blood aggregometry technique, which does not need platelet 
count standardisation and probably more accurately mimics the in vivo conditions, 
and 3) determine the effect of vanilloids on AA-induced aggregation by measuring 
TXB2 formation.   
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In conclusion, the current pilot study showed that NADA had a significant inhibitory 
effect on aggregation induced by collagen on platelets from SLE patients. However, 
unlike those from the healthy individual the plant-derived vanilloids, CAP and DHC, 
as well as the endovanilloid, OLDA, had no effect on ADP- or collagen-induced in 
vitro platelet aggregation of SLE platelets. Capsaicin, DHC and OLDA had no effect 
on SLE platelets either because of the disease itself and/or the medications. This is 
the first study to generate pilot data on the effect of plant-derived vanilloids, CAP 
and DHC, and the endovanilloids, OLDA and NADA, on SLE platelet aggregation. 
The data generated provides the basis to further investigate the inhibitory effects of 
NADA toward platelets from a larger number of SLE patients and other patients with 
high risk of thrombosis. 
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6.! Chapter 6: Discussion  
 
In this thesis the possible mechanisms by which vanilloid-like agents including, 
plant-derived vanilloids and endovanilloids/endocannabinoids, inhibit aggregation of 
human platelets have been investigated. The reasons for conducting these 
experiments were that these agents produced significant inhibitory effects on platelet 
aggregation induced by several platelet agonists, which is unlike most available 
conventional antiplatelet medications that usually act through a single target. 
Therefore, a clear understanding of how vanilloid-like agents act on platelets, i.e., 
through vanilloid receptors (e.g., TRPV1, CB1, CB2), other platelet receptors (e.g., 
P2Y1, P2Y12) and/or signaling pathways (e.g., AA pathway), may provide a basis to 
consider using these compounds, either alone or in combination, as therapeutic 
options as anti-aggregation agents. As antiplatelet medications have been shown to 
have a beneficial effect in the primary and secondary prevention of CVD, developing 
novel anti-platelet drugs with fewer side effects is a major focus of pharmaceutical 
companies. 
 
Four main studies were conducted in this thesis; 1) investigations into the 
mechanism(s) of action of vanilloid-like agents on platelets using TRPV1, CB1 and 
CB2 receptors antagonist (Chapter 2), 2) measuring the end products of ADP 
receptor and AA pathway activation (Chapter 3), 3) determination of the effect of the 
combination of plant-derived vanilloids, CAP and DHC, on in vitro platelet 
aggregation and the AA pathway (Chapter 4), and 4) a pilot clinical study to 
investigate the effect of vanilloids on in vitro platelet aggregation in SLE patients 
(Chapter 5). 
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In neuronal tissue CAP, OLDA and NADA act through TRPV1, a non-selective 
cation channel with some preference for Ca2+ (Caterina et al., 1999, Zhong and 
Wang, 2008). The endovanilloids/endocannabinoids, OLDA and NADA, also have 
an affinity for CB receptors (Hu et al., 2009). Although the expression of CB1 and 
CB2 receptors has previously been demonstrated in platelets, only one study, using 
Western blotting, has shown that TRPV1 is present on platelets (Deusch et al., 2004, 
Harper et al., 2009). For the first time, I was able to confirm the presence of, and 
visualise TRPV1 channels on/in platelets using the highly sensitive technique of 
confocal microscopy, which allowed further investigations of whether these channels 
are involved in the vanilloids induced inhibition of platelet aggregation (Chapter 2). 
 
Subsequently, the possible role of TRPV1 channels, and CB1 and CB2 receptors, on 
the inhibition of platelet aggregation produced by vanilloids and endovanilloids was 
investigated. Platelet aggregation was induced using three agonists, collagen, AA, 
and ADP, in combination with vanilloids and/or endovanilloids. To ensure that 
vanilloids, endovanilloids and receptor antagonists used in this study had no direct 
effect on platelets, platelet numbers were also determined after exposure to these 
agents and shown to have no effect on platelet count (Chapter 2). 
 
The potent antagonists to TRPV1 channels, as well as the CB1 and CB2 receptors 
each had no effect on platelet aggregation. Blocking these receptors did not interfere 
with the inhibitory effects of OLDA and NADA on collagen-induced aggregation or 
CAP and NADA in AA-induced aggregation. However, blocking TRPV1 channels 
with SB452533 enhanced the inhibitory effect of OLDA in collagen-induced 
aggregation and CAP in AA-induced aggregation, which could be due to reduced 
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Ca2+ influx [Ca2+]i and/or intracellular Ca2+ release from platelets (Clapham, 2003, 
Montell et al., 2002, Moran et al., 2004). In addition, blocking the TRPV1 receptor 
may decrease binding of CAP and OLDA to TRPV1, thus increase their 
bioavailability for other anti-aggregating activities. This could be investigated by 
performing functional /pharmacological studies, including Ca2+ flux, and radioligand 
binding. Moreover, the antiplatelet effect of CAP in AA-induced aggrgation was also 
enhanced in the presance of the CB2 antagonist that may result in increased cAMP 
formation (Rueda et al., 2000, Childers and Deadwyler, 1996). The inhibitory 
influence of CAP and OLDA on aggregation induced by ADP was therefore 
independent of CB1 and CB2 receptors (Chapter 2). 
 
Despite the new data presented in this thesis the precise roles of TRPV1 channels in 
platelets remain unclear. These channels may be involved in the pro/inflammatory 
response of platelets, as TRPV1 expression is upregulated in different inflammatory 
diseases and platelets play a pivotal role in many inflammatory conditions (Chan et 
al., 2003, Yiangou et al., 2001, Hansson and Libby, 2006, Robbie and Libby, 2001). 
The results of the current study are in agreement with previous work that 
demonstrated that the CAP inhibition of canine platelet aggregation was not TRPV1 
mediated (Mittelstadt et al., 2012). In contrast, another study demonstrated that 
TRPV1 channels are present in human platelets, but that CAP enhanced platelet 
aggregation in the absence of ADP or other platelet agonists (Harper et al., 2009). 
This effect led to increased intracellular Ca+2 through TRPV1, which was blocked in 
the presence of a TRPV1 antagonist (Harper et al., 2009). The conflicting data 
concerning the effect of CAP platelet aggregation might be due to differences in 
study design where the current study investigated the effect of CAP on exogenously 
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activated platelet aggregation, while in Harper et al. the direct effect of CAP on 
platelet aggregation was tested. Collectively, this data suggests that TRPV1 
channels, and CB1 and CB2 receptors, are not directly involved in the anti-platelet 
actions of vanilloids and endovanilloids/endocannabinoids in humans. 
 
As vanilloid-like agents produced prominent inhibitory effects on AA- and ADP-
induced aggregation (Almaghrabi et al., 2014, Adams et al., 2009), the effects of 
these compounds on the end products of their respective signaling pathways were 
next investigated. Firstly, TXB2 concentration (an end product of AA pathway) was 
measured in the presence and absence of CAP, DHC, NADA and OLDA. Plant-
derived vanilloids, CAP and possibly DHC, appeared to inhibit TXB2 formation in a 
concentration-dependent manner, which paralleled their effect on in vitro platelet 
aggregation (Chapter 3). My results are in agreement with Raghavendra and Naidu 
(2009) who showed that CAP inhibits cyclooxygenase1 (COX1) in the AA pathway, 
which may result in a dampening of platelet aggregation. In contrast, NADA did not 
show any effect on TXB2 levels, although it inhibited AA-induced platelet 
aggregation. NADA may interfere with the ADP receptor, P2Y12, as ADP release 
from platelet granules is a part of the amplification process of AA-induced 
aggregation. Moreover, OLDA had no effect on TXB2 levels, which was expected as 
OLDA has been previously shown to have no effect on AA-induced aggregation 
(Almaghrabi et al., 2014). 
 
Secondly, the effect of  CAP, DHC, OLDA and NADA on ADP-induced !- and 
dense-granules release via the P2Y1 receptor was investigated. Vanilloid-like agents 
do not appear to inhibit platelet aggregation through interfering/blocking the P2Y1 
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receptor, as PF4, β-TG or 5-HT release from ADP-activated platelets were not 
affected (Chapter 3). Hence, whether the inhibitory effects of plant-derived 
vanilloids and endovanilloids through the second ADP receptor (P2Y12) was 
determined by measuring levels of VASP phosphorylation. NADA, and possibly 
OLDA, appeared to inhibit platelet aggregation through interference with the P2Y12 
receptor, as VASP phosphorylation was significantly increased (Chapter 3). In 
contrast, CAP inhibited ADP-induced aggregation but had no effect on VASP 
phosphorylation status. This may be due to a high concentration of ADP used in the 
VASP ELISA kit (which was not supplied by the manufacturer), which was able to 
overcome any inhibitory effect of CAP. As expected, DHC did not show any effect 
on VASP phosphorylation level since it had no effect on ADP-induced aggregation. 
It can be concluded from this data that CAP and DHC may act at least partially 
through suppression of the AA pathway, and NADA and OLDA through interference 
to the P2Y12 receptor, to inhibit platelet aggregation (Chapter 3). The knowledge of 
how vanilloids interact and/or target receptors and pathways in platelets is potentially 
beneficial, in that it might be possible to form a nutraceutical combination of both 
plant-derived vanilloids and endovanilloids that produce a higher antiplatelet effect. 
Finally, lacking of a clear understanding of mechanism(s) of action of vanilloids or 
(any drug) may lead to deleterious outcomes.  
 
Platelet-derived microparticles (PMP) have been increasingly recognised as markers 
of platelet activation, which is associated with increased risk of CVD (Abrams et al., 
1990, Morel et al., 2011a, Keuren et al., 2006, Azevedo et al., 2007, Hartopo et al., 
2016). To my knowledge there are no previous studies that have investigated the 
influence of vanilloids on PMP formation/release. Therefore, the effects of vanilloids 
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on PMP generation/release induced by ADP and AA were determined. Circulating 
levels of CD41b/CD42a-positive PMP in the presence of CAP, DHC, OLDA and 
NADA were not significantly altered. In ADP-stimulated platelets, NADA and 
OLDA appeared to inhibit PMP release whereas with AA-stimulated platelets 
NADA slightly enhanced PMP formation. However, CAP and DHC enhanced PMP 
formation with both ADP and AA, in contrast to their inhibitory effect on platelet 
aggregation (Adams et al., 2009, Almaghrabi et al., 2014). Since platelet activation is 
associated with high levels of PMP release, the safety of using CAP and DHC as 
antiplatelet agents may be questionable, particularly by patients with hyperactive 
platelets, and warrants further investigation (Chapter 3). For example, use an in 
vivo/ex vivo model of CAP and DHC and their interactions with platelets may help 
determine their effects on PMP formation. 
 
Plant-derived vanilloids, CAP and DHC, are the main capsaicinoids in Capsicum 
fruits (Bennett and Kirby, 1968, Kosuge and Furuta, 1970), and contribute ~60% and 
~40%, respectively, to the total capsaicinoid concentration (Garces-Claver et al., 
2006). In previous studies, I investigated the influence of CAP and DHC individually 
on platelet aggregation (Adams et al., 2009, Almaghrabi et al., 2014). Therefore, in 
the next set of experiments, the effect of a combination of CAP and DHC in the 
proportion they are usually present naturally, on AA-, ADP- and collagen-induced 
aggregation, platelet count and TXB2 formation, was investigated (Chapter 4). The 
combination of CAP and DHC had a greater inhibitory effect on in vitro AA-induced 
aggregation compared to their individual effects, suggesting these molecules may act 
synergistically. The combined concentration was lower than the individual CAP and 
DHC concentrations, but the combined effects were greater. In contrast, at the 
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concentrations tested, CAP and DHC individually, and in combination, had no 
significant effect on ADP- or collagen-induced aggregation (Chapter 4). CAP and 
DHC, and their combination, had no direct effect on platelet count. Moreover, the 
low CAP:DHC combination inhibited in vitro platelet aggregation through the AA 
pathway, as TXB2 formation decreased significantly in the presence of combined 
CAP:DHC. In comparison, the effect of 50 µM of CAP and DHC individually on 
TXB2 level was 10.7% and 4.6%, respectively (Chapter 3), while the combination of 
CAP and DHC (7.5:5 µM) was 4.4%, reflecting that low concentrations in 
combination are more effective in inhibiting platelet aggregation than higher 
concentrations of the individual vanilloid. On the contrary, low concentrations of 
individual CAP and DHC (12.5 µM) showed no effect on TXB2 formation (Chapter 
4). These results suggest that CAP and DHC might inhibit different enzymes or act 
synergistically on one of the enzymes in AA pathway, to inhibit TXA2 formation 
and subsequently TXB2. 
 
In addition to the anti-platelet effect of CAP:DHC combination (Chapter 4), it has 
been reported that individuals who regularly consume chilli have a lower incidence 
of peptic ulcers than those who eat chilli less frequently (Kang et al., 1995). Gastric 
injury and peptic ulcers are the most common side effects of aspirin (Singh and 
Triadafilopoulos, 1999, Derry and Loke, 2000, Ivey et al., 1980, Weil et al., 1995). 
Several studies have shown that low doses of CAP have a gastro-protective effect 
through increased mucosal secretion, which prevents gastric mucosal damage caused 
by indomethacin, ethanol and /or aspirin (Debreceni et al., 1999, Mozsik et al., 1999, 
Mozsik, 2014, Szabo et al., 2013, Yeoh et al., 1995). Although CAP inhibits in vitro 
platelet aggregation, a study showed that CAP does not have an additional inhibitory 
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effect in combination with aspirin, compared to aspirin alone, across a 24 hour 
period (Sandor et al., 2014). However, an endoscopic study has reported a lower 
gastric injury in volunteers who ingested chilli with aspirin (Yeoh et al., 1995). 
Given that combined CAP:DHC had a great antiplatelet effect, as well as the 
protective effect that natural chilli appears to have on the gastric mucosa (Yeoh et al., 
1995, Kang et al., 1995), further work should investigate the combined effects of 
CAP and DHC (or chilli) and aspirin, against aspirin only, on platelet aggregation. 
 
The effects of vanilloid-like agents have been tested in all previous studies using 
healthy platelets from different species, i.e., human, rabbits and canine (Almaghrabi 
et al., 2014, Mittelstadt et al., 2012, Hogaboam and Wallace, 1991, Harper et al., 
2009, Adams et al., 2009, Raghavendra and Naidu, 2009). In this thesis however, the 
influence of these compounds on platelets from SLE patients who have a high 
tendency of thrombosis and atherosclerosis were determined, in a pilot study 
(Chapter 5) (Ward, 1999, Gladman and Urowitz, 1987). Plant-derived vanilloids, 
CAP and DHC, and the endovanilloid, OLDA, did not inhibit platelet aggregation 
induced by ADP and collagen. Only NADA inhibited collagen-induced in vitro 
platelet aggregation in a concentration-dependent manner, but no effect on ADP-
induced aggregation was observed. The reason(s) for the differences between the 
effects of vanilloid-like agents on healthy and SLE patients’ platelets are unclear. It 
may be that the pathway(s) by which vanilloid-like agents inhibit platelet 
aggregation in healthy platelets is impaired, blocked or over-stimulated by SLE 
itself, or affected by medication(s).  
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NADA is the only vanilloid that inhibited aggregation induced by ADP, AA and 
collagen using healthy platelets (Almaghrabi et al., 2014), as well as collagen-
induced aggregation using platelets from SLE patients (Chapter 5). Furthermore, 
NADA demonstrated decreased PMP formation, at least with ADP-activated 
platelets (Chapter 3). In addition to NADA’s antiplatelet effect it has also been 
shown to have anti-inflammatory properties and may play an important role in the 
immune system (Wilhelmsen et al., 2014, Sancho et al., 2004). Therefore, it would 
be interesting to further investigate the physiological interactions between NADA 
and platelets through in vivo/ex vivo models of disease, specifically in disorders of 
the cardiovascular system. 
 
The main limitations of these studies were: first, there was a relatively small 
catchment of SLE patients or other patients with thrombophilia around Launceston. 
This was compounded by the absence of a rheumatology clinic at the Launceston 
General Hospital, which made it difficult to recruit a large number of patients. 
Further, the experimental conditions dictated that the blood samples had to be 
processed within four hours of collection to ensure the viability of platelets. Second, 
PRP was used to determine in vitro aggregation in response to various agents, which 
may not accurately reflect in vivo platelet function. Third, higher concentrations of 
the platelet agonists, ADP and AA, could be used in PMP experiments, but 
concentrations of all agonists and vanilloids were kept consistent across all 
experiments to allow comparison of the effect of vanilloids on platelets across 
different studies.  Finally, there may be a variable response of platelets from the 
individual subject to agonists and/or vanilloids. 
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Future directions could include: 1) increasing the SLE cohort to investigate 
expression of TRPV1 in SLE platelets compared to the healthy individuals, 2) use of 
whole blood aggregometry e.g., Multiplate Analyser, and two or more platelet 
agonists together to determine the effects of vanilloids on platelet aggregation, which 
more closely mimic in vivo conditions, 3) use a higher concentration of agonist for 
PMP experiments, 4) investigate the role of fibrinogen receptor (GPIIb/IIIa) on the 
effect of vanilloids on platelet aggregation, 5) explore the potential role of TRPV1, 
CB1 and CB2 receptors in platelets, and 6) determine the in vivo/ex vivo effect of the 
CAP, DHC (or chilli) and aspirin, against aspirin only, on platelet aggregation using 
healthy individual and SLE  patients platelets. 
 
In conclusion, the results from this thesis confirmed the presence of TRPV1 channels 
on healthy platelets. Moreover, the inhibitory influence of plant-derived vanilloids, 
CAP and DHC, and endovanilloids/endocannabinoids, OLDA and NADA, on in 
vitro platelet aggregation are not TRPV1- or CB1- or CB2-mediated. However, 
blocking TRPV1 and CB2 receptors may enhance the anti-aggregating effects of 
OLDA and CAP. CAP and DHC appear to inhibit in vitro platelet aggregation by 
suppression of the AA-pathway, whereas NADA and OLDA do so by interfering 
with and/or blocking the ADP receptor P2Y12. However, none of the vanilloids 
appears to inhibit platelet aggregation by interfering with the P2Y1 receptor or have 
an effect on PMP formation/release. Interestingly, the combination of CAP and DHC 
act synergistically to inhibit aggregation induced by AA and TXB2 formation. In the 
pilot study using platelets from SLE patients only NADA produced an inhibitory 
effect on collagen-induced aggregation, whereas CAP, DHC and OLDA had no 
effect on ADP- or collagen-induced aggregation in the patient samples. Finally, 
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further studies are clearly warranted, especially considering the clinical potential of 
the chilli pepper in healthy and SLE patients, as additional therapeutic nutraceutical 
to reduce cardiovascular risk, and to decrease the side effect/s of conventional 
antiplatelet medication/s.  
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potential vanilloid-1 channels or cannabinoid receptors. Clin Exp Pharmacol 
Physiol, 43, 606-11. 
Link to the manuscript:  
http://onlinelibrary.wiley.com/doi/10.1111/1440-1681.12569/full 
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Agents: Potential Therapeutic Targeting of Platelets? Drug Development Research, 
74, 450-459. 
Link to the manuscript:  
http://onlinelibrary.wiley.com/doi/10.1002/ddr.21102/abstract 
 
Almaghrabi, SY, Geraghty, DP, Ahuja, KDK & Adams, MJ 2014. Vanilloid-like 
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Appendix-3: Manual of VASP/P2Y12 ELISA assay  
 
 
 
CY-QUANT VASP/P2Y12 
For the measurement of specific 
platelet ADP receptor antagonists 
 
Kit contents: 
− 1 microtiter plate of Reagent 1 (96 Anti-VASP coated wells) 
− 3 vials of Reagent 2a (PGE1) 
− 3 vials of Reagent 2b (PGE1 + ADP) 
− 1 vial of Reagent 3 (Lysis buffer) 
− 1 vial of Reagent 4 (Washing solution) 
− 1 vial of Reagent 5 (Dilution buffer) 
− 1 vial of Reagent 6 (Anti-VASP-P peroxidase) 
− 1 vial of Reagent 7 (TMB) 
− 1 vial of Reagent 8 (Stop solution) 
− 1 tool to extract wells from their strips 
 
For In Vitro Diagnostic Use 
 
Ref. 7502 
 
 
        
 
1- INTRODUCTION 
CY-QUANT VASP/P2Y12 is an enzyme-linked immunosorbent 
assay (ELISA) procedure for the determination of serine 239-
phosphorylated VASP (VASP-P) in platelets from fresh human 
whole blood. 
CY-QUANT VASP/P2Y12 kit is dedicated to the measurement of 
specific platelet ADP receptor (P2Y12) antagonists. 
VASP (Vasodilator Stimulated Phosphoprotein) is an intracellular 
platelet protein which is unphosphorylated at basal state. 
Prostaglandin E1 (PGE1) induces phosphorylation of VASP (1) 
whereas the binding of adenosine diphosphate (ADP) to P2Y12 
receptors (2) leads to dephosphorylation of VASP. Under test 
conditions, in the concomitant addition of ADP and PGE1, the effect 
of ADP dominates and leads to VASP dephosphorylation, unless the 
P2Y12 receptor is efficiently blocked by antiplatelet drugs targeting 
this receptor (such as thienopyridines). Thus, the level of VASP 
phosphorylation in this condition reflects the level of P2Y12 receptor 
inhibition. 
Inter-individual variability and resistance to antiplatelet drugs have 
been widely described (a,b). The effect of thienopyridines (3) can be 
demonstrated with CY-QUANT VASP/P2Y12 by the persistence of 
VASP phosphorylation induced by PGE1 despite simultaneous 
addition of ADP. 
CY-QUANT VASP/P2Y12 may also be used to evaluate in vitro 
effects of P2Y12 receptor antagonists. 
 
ADP
PGE1
VASP VASP-P
Activated 
or resting 
platelets
Inhibited 
platelets
Thienopyridine
(1)
(3)
(2)
 
 
 
 
 
 
 
 
 
 
2- TEST PRINCIPLE 
After a first step of parallel whole blood sample activation with PGE1 
and PGE1+ADP (Reagent 2a and 2b), platelets from the sample are 
lysed (Reagent 3), allowing released VASP to be captured by an 
anti-human VASP antibody which is coated in the microtiter plate 
(Reagent 1). Then, a peroxidase-coupled anti-human VASP-P 
antibody (Reagent 6) binds to phosphorylated serine 239 antigenic 
determinant of VASP. The bound enzyme peroxidase is then 
revealed by its activity on TMB substrate (Reagent 7) over a 
predetermined time. After stopping the reaction (Reagent 8), 
absorbance at 450 nm is directly related to the concentration of 
VASP-P contained in the sample. 
A platelet reactivity index (PRI) is calculated using optical density 
(OD450nm) in the presence of PGE1 alone [PGE1] or PGE1 and ADP 
simultaneously [PGE1+ ADP]. 
 
3- REAGENTS 
• Reagent 1: 96-wells microtiter plate composed of 12 breakable 
strips of 8 wells coated with mouse anti-human 
VASP MAb, in a re-sealable pouch. 
• Reagent 2a:  vial, lyophilized PGE1. 
 
• Reagent 2b:  vial, lyophilized PGE1 + ADP. 
 
• Reagent 3:  vial, 15 mL, lysis buffer. 
 
• Reagent 4:  vial, 50 mL, 20 fold-concentrated washing solution. 
 
• Reagent 5:  vial, 50 mL, dilution buffer. 
 
• Reagent 6: vial, 1.6 mL, 20 fold-concentrated specific mouse 
anti-human VASP-P MAb coupled with peroxidase. 
 
• Reagent 7:  vial, 25 mL, TMB (tetramethylbenzidine). 
 
• Reagent 8:  vial, 15 mL, stop solution. 
 
4- MATERIAL REQUIRED BUT NOT PROVIDED 
- Deionized or distilled water, equilibrated at room temperature and 
preferably sterile. 
- Timer. 
- Multi-channel pipettes, pipettes with disposable tips. 
- ELISA plate reader set at 450 nm. 
- Vortex. 
- Absorbent paper. 
 
5- WARNING 
- Follow the conventional laboratory practices. 
- Follow the appropriate regulation for waste disposal. 
- Blood must be considered as potentially infectious. 
- Reagent  5: 
 R43: May cause sensitization by skin contact. 
 S26: In case of contact with eyes, rinse immediately with 
plenty of water and seek medical advice. 
 S28: After contact with skin, wash immediately with plenty of 
water. 
 S36/37/39: Wear suitable protective clothing, gloves and 
eye/face protection. 
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6- REAGENTS PREPARATION AND STORAGE 
Notes: 
- When stored at 2-8° C, unopened kits and contents remain stable 
until the printed expiration date. 
- Before use, all reagents must be equilibrated at room temperature 
(RT, 18-25 °C) for at least 30 minutes. 
 
• Reagent 1  
Ready-to-use. After first use, immediately replace unused strips and 
wells in the re-sealable pouch with the desiccant and store at 2-8°C. 
Stability after opening: 2 months at 2-8°C, when free of 
contamination. 
 
• Reagents 2a and 2b 
Reconstitute each vial with 900 µL of deionized or distilled water 
and homogenize the content using a vortex for 5 seconds. 
Stability after reconstitution: 1 month at 2-8°C, when free of 
contamination. 
 
• Reagents 3, 5 and 8 
Ready-to-use. Stability after opening: 2 months at 2-8°C, when free 
of contamination. 
 
• Reagent 4 
Stability after opening: 2 months at 2-8°C, when free of 
contamination. 
Before use, dilute the reagent 1:20 with deionized or distilled water. 
For one well, dilute 100 µL of Reagent 4 with 1 900 µL of deionized 
or distilled water. 
Stability after dilution: 15 days at 2-8°C, when free of contamination. 
Note: The presence of crystals does not affect the quality of 
the reagent. If necessary, warm at 37°C until all crystals have 
dissolved. Then, homogenize and equilibrate at RT. 
 
• Reagent 6 
Stability after opening: 2 months at 2-8°C, when free of 
contamination. 
Before use, dilute the reagent 1:20 with Reagent 5. 
For one well, dilute 15 µL of Reagent 6 with 285 µL of Reagent 5. 
Stability after dilution: 1 hour at RT. 
Note: Since the vial is filled to capacity, pipette carefully to avoid 
reagent overflow. 
 
• Reagent 7 
Ready-to-use. Stability after opening: 2 months at 2-8°C, when free 
of contamination. 
Note: Avoid exposure to light, heat and contamination with metal 
ions or peroxidase. 
 
7- SPECIMEN COLLECTION AND STORAGE 
- Draw venous whole blood into a 0.109 M trisodium citrate 
collection tube, according to manufacturer's instructions. 
- Maintain platelet integrity. Avoid platelet activation during the 
collection procedure (shaking, heat shock). 
- Blood collection tube must be filled to capacity, stored at RT and 
unopened before the test. 
- Samples must be analyzed within 24 hours from collection. 
 
8- PROCEDURE 
We recommend to test a normal sample in parallel of each series, to 
serve as a control. 
 
Notes: 
- The washing steps can be performed either with an automated 
plate-washing equipment or manually with a multi-channel pipette. 
- During manual washing, first empty all wells by flicking off the 
liquid into an appropriate container and blot the plate on a clean 
absorbent paper. Then, fill each well with 300 µL of diluted 
Reagent 4, flick off the washing solution, and blot the plate on a 
clean adsorbent paper.  
- The number of washing steps must be scrupulously respected.  
- Do not leave the wells dry at any time. 
- Do not expose the strips to strong light. 
- Check the absence of bubbles in the wells before OD 
measurement. 
 
8.1- OPERATING PROCEDURE 
At each step, identical incubation time must be carefully respected 
for each well. 
Distribute the samples to be tested and the blank in duplicate; one 
duplicate blank is enough for a series of samples. 
Pipette directly into precoated wells (Reagent 1): 
 
  Well PGE1 
Well 
PGE1 + ADP 
Well 
Blank 
Reagent: 2a: 40 µL 2b: 40 µL 5: 180 µL  
Whole blood 
sample: 40 µL 40 µL — 
Thoroughly mix the contents of each well by 
pipetting up and down 8-10 times — 
Cover the wells and 
incubate 10 minutes at RT — 
Reagent: 3: 100 µL 3: 100 µL — 
Thoroughly mix the contents of each well by pipetting 
up and down 8-10 times 
AN
TI
GE
N 
CA
PT
UR
E 
Cover the wells and 
incubate 30 minutes at RT 
Wash all wells 3 times with 300 µL of diluted Reagent 4, 
then add immediately: 
Diluted 
Reagent 6: 200 µL 200 µL 200 µL 
CO
NJ
UG
AT
E 
IM
MO
BI
LI
ZA
TI
ON
 
Cover the wells 
and incubate 30 minutes at RT 
Wash all wells 3 times with 300 µL of diluted Reagent 4, 
then add immediately: 
Reagent 7: 200 µL 200 µL 200 µL 
Incubate 5 minutes at RT, 
and then add: 
Reagent 8: 100 µL 100 µL 100 µL CO
LO
R 
DE
VE
LO
PM
EN
T 
Thoroughly homogenize the contents of each well 
OD
 P
LA
TE
 
ME
AS
UR
EM
EN
T 
Measure the absorbance at 450 nm 
up to 4 hours at RT after stopping the reaction 
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8.2- PLATELET REACTIVITY INDEX (PRI) CALCULATION  
A platelet reactivity index (PRI) is calculated using optical density 
(OD450nm) in the presence of PGE1 alone [PGE1] or PGE1 and ADP 
simultaneously [PGE1+ ADP], according to the following formula:  
 
100
][]1[
]1[]1[(%)
450450
450450 ×
−
+−
=
BlankODPGEOD
ADPPGEODPGEODPRI
nmnm
nmnm  
 
Note: Each laboratory must establish its own interpretation 
values depending upon the P2Y12 antagonist to evaluate. 
 
In order to measure the efficiency of a P2Y12 antagonist, apply the 
following recommendations: 
1- Determine the basal PRI range (mean ± 2 standard deviations) 
on a group of patients relevant of the disease of interest and 
not receiving the P2Y12 antagonist to evaluate. As a guide, the 
PRI of untreated healthy donors (n=32) is ranging from 89% to 
99% (data from external study). 
2- Determine the basal PRI value of the patient to be tested 
before the treatment (PRI0) and confirm that this value is 
included in the pre-established basal PRI range. Otherwise, 
refer to the Limitations paragraph (§10) and repeat the test if 
necessary. 
3- Determine the PRI value at a time point T (PRIT) according to 
the pharmacodynamic properties of the P2Y12 antagonist 
evaluated. A PRIT value which is still included in the basal PRI 
range signifies that the patient has not responded to the drug. 
 
In summary, a low PRI corresponds to a good responder patient 
while a high PRI stands either for a healthy subject or a bad 
responder patient. The lower the PRI, the higher P2Y12 receptor 
inhibition. 
 
9- PERFORMANCES  
Repeatability: 
Two samples presenting different levels of PRI are tested 8 times 
with the same kit: 
 
Sample Sample 1 Sample 2 
n 8 8 
(PRI %) 43,69% 97,85% 
SD 2,02 0,57 
CV 4,6% 0,6% 
 
Working range: 
The working range for this method is from 0 up to 100 % of PRI. 
 
Correlation to PLT VASP/P2Y12 (BioCytex ref. 7014, CE ): 
CY-QUANT VASP/P2Y12 test is strongly correlated with the flow 
cytometric PLT VASP/P2Y12 test: n = 96; r = 0.95; p < 0.001. 
 
Interferences: 
- Platelet count: on samples from 50,000 up to 375,000 platelets/µL, 
the platelet count has no significant interference on CY-QUANT 
VASP/P2Y12 assay. 
 
- Red blood cell count: on non treated samples from 1 x 106 up to 
5,8 x 106 red blood cells/µL, the red blood cell count has no 
significant interference on CY-QUANT VASP/P2Y12 assay. 
 
- Aspirin and anti GpIIb/IIIa drugs have no significant interference on 
CY-QUANT VASP/P2Y12 assay since VASP biomarker is specific 
from the P2Y12 signaling pathway. 
10- LIMITATIONS 
CY-QUANT VASP/P2Y12 kit cannot be used on activated and/or 
hemolyzed blood samples. 
11- LIABILITY 
The in vitro diagnostic use is only valid within the strict application of 
the package insert. Any modification of the protocol may influence 
the result of the test. 
Never switch or mix vials originating from different kits.  
In cases where these recommendations are not strictly respected, 
no contestation or replacement of the product will be accepted. 
 
12- REFERENCES 
(a) Gurbel PA. et al. (2007) Thromb Research 120:311-321. 
(b) Angiollilo D. et al. (2007) J Am Coll Cardiol 49:1505-1516. 
(c) Barragan P. et al. (2010) Thromb. Haemost 104(2): 410-11. 
(d) Jakubowski J.A. et al. (2012) Thromb. Haemost 107: 388-395. 
(e) Abtan J. et al. (2013) Thromb Haemost 110(5):1055-64. 
 
13- NOTICE TO PURCHASER 
The CY-QUANT VASP/P2Y12 kit is covered by patent WO 
99/24473. 
 
14- SYMBOLS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BIOCYTEX 
140, CH. DE L'ARMEE D'AFRIQUE 
13010 MARSEILLE 
FRANCE 
TEL: +33 (0) 4 96 12 20 40 
FAX: +33 (0) 4 91 47 24 71 
 
Version March 2014 
Catalogue number 
In Vitro Diagnostic 
 Medical Device 
Temperature limitation 
 
Use By 
 
Contains sufficient  
for "n“ tests 
 
Batch code 
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Appendix-4: Manual of 5-HT ELISA assay 
 
CEA808Ge 96 Tests
Enzyme-linked Immunosorbent Assay Kit
For 5-Hydroxytryptamine (5-HT)
Organism Species: General
Instruction manual
FOR IN VITRO AND RESEARCH USE ONLY
NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES
11th Edition (Revised in July, 2013)
[ INTENDED USE ]
The kit is a competitive inhibition enzyme immunoassay technique for the in vitro quantitative measurement of
5-HT in serum and plasma.
[ REAGENTS AND MATERIALS PROVIDED ]
Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B 1×120μL Assay Diluent B 1×12mL
TMB Substrate 1×9mL Stop Solution 1×6mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1
[ MATERIALS REQUIRED BUT NOT SUPPLIED ]
1. Microplate reader with 450 ± 10nm filter.
2. Precision single or multi-channel pipettes and disposable tips.
3. Eppendorf Tubes for diluting samples.
4. Deionized or distilled water.
5. Absorbent paper for blotting the microtiter plate.
6. Container for Wash Solution
[ STORAGE OF THE KITS ]
1. For unopened kit: All the reagents should be kept according to the labels on vials. The Standard, Detection
Reagent A, Detection Reagent B and the 96-well strip plate should be stored at -20oC upon receipt while
the others should be at 4 oC.
2. For opened kit: When the kit is opened, the remaining reagents still need to be stored according to the
above storage condition. Besides, please return the unused wells to the foil pouch containing the desiccant
pack, and reseal along entire edge of zip-seal.
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Note:
It is highly recommended to use the remaining reagents within 1 month provided this is within the expiration date
of the kit. For the expiration date of the kit, please refer to the label on the kit box. All components are stable until
this expiration date.
[ SAMPLE COLLECTION AND STORAGE ]
Serum - Allow samples to clot for two hours at room temperature or overnight at 4oC before centrifugation for 20
minutes at approximately 1000×g. Assay immediately or store samples in aliquot at -20oC or -80oC. Avoid
repeated freeze/thaw cycles.
Plasma - Collect plasma using EDTA or heparin as an anticoagulant. Centrifuge samples for 15 minutes at
1000×g within 30 minutes of collection. Remove plasma and assay immediately or store samples in aliquot at
-20oC or -80oC. Avoid repeated freeze/thaw cycles.
Note:
1. Samples to be used within 5 days may be stored at 4oC, otherwise samples must be stored at -20oC (≤1
month) or -80oC (≤2 months) to avoid loss of bioactivity and contamination.
2. Sample hemolysis will influence the result, so hemolytic specimen should not be detected.
3. When performing the assay, bring samples to room temperature.
[ REAGENT PREPARATION ]
1. Bring all kit components and samples to room temperature (18-25oC) before use.
2. Standard - Reconstitute the Standard with 0.5mL of Standard Diluent, kept for 10 minutes at room
temperature, shake gently(not to foam). The concentration of the standard in the stock solution is 900ng/mL.
Please prepare 5 tubes containing 0.6mL Standard Diluent and produce a triple dilution series according to
the picture shown below. Mix each tube thoroughly before the next transfer. Set up 5 points of diluted
standard such as 900ng/mL, 300ng/mL, 100ng/mL, 33.33ng/mL, 11.11ng/mL, and the last EP tubes with
Standard Diluent is the blank as 0ng/mL.
Tube 1 2 3 4 5 6
ng/mL 900 300 100 33.33 11.11 0
3. Detection Reagent A and Detection Reagent B - Briefly spin or centrifuge the stock Detection A and
Detection B before use. Dilute to the working concentration with Assay Diluent A and B, respectively
(1:100).
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4. Wash Solution - Dilute 20mL of Wash Solution concentrate (30×) with 580mL of deionized or distilled water
to prepare 600mL of Wash Solution (1×).
5. TMB substrate - Aspirate the needed dosage of the solution with sterilized tips and do not dump the residual
solution into the vial again.
Note:
1. Making serial dilution in the wells directly is not permitted.
2. Prepare standard within 15 minutes before assay. Please do not dissolve the reagents at 37oC directly.
3. Detection Reagent A and B are sticky solutions, therefore, slowly pipette them to reduce the volume errors.
4. Please carefully reconstitute Standards or working Detection Reagent A and B according to the instruction,
and avoid foaming and mix gently until the crystals are completely dissolved. To minimize imprecision caused
by pipetting, use small volumes and ensure that pipettors are calibrated. It is recommended to suck more
than 10μL for once pipetting.
5. The reconstituted Standards, Detection Reagent A and Detection Reagent B can be used only once.
6. If crystals have formed in the Wash Solution concentrate (30×), warm to room temperature and mix gently
until the crystals are completely dissolved.
7. Contaminated water or container for reagent preparation will influence the detection result.
[ SAMPLE PREPARATION ]
1. Cloud-Clone Corp. is only responsible for the kit itself, but not for the samples consumed during the assay.
The user should calculate the possible amount of the samples used in the whole test. Please reserve
sufficient samples in advance.
2. Please predict the concentration before assaying. If values for these are not within the range of the standard
curve, users must determine the optimal sample dilutions for their particular experiments. Sample should be
diluted by 0.01mol/L PBS(PH=7.0-7.2).
3. If the samples are not indicated in the manual, a preliminary experiment to determine the validity of the kit is
necessary.
4. Tissue or cell extraction samples prepared by chemical lysis buffer may cause unexpected ELISA results due
to the impacts from certain chemicals.
5. Due to the possibility of mismatching between antigen from other origin and antibody used in our kits (e.g.,
antibody targets conformational epitope rather than linear epitope), some native or recombinant proteins
from other manufacturers may not be recognized by our products.
6. Influenced by the factors including cell viability, cell number or sampling time, samples from cell culture
supernatant may not be detected by the kit.
7. Fresh samples without long time storage is recommended for the test. Otherwise, protein degradation and
denaturalization may occur in those samples and finally lead to wrong results.
[ ASSAY PROCEDURE ]
1. Determine wells for diluted standard, blank and sample. Prepare 5 wells for standard points, 1 well for blank.
Add 50μL each of dilutions of standard (read Reagent Preparation), blank and samples into the appropriate
wells, respectively. And then add 50μL of Detection Reagent A to each well immediately. Shake the plate
gently (using a microplate shaker is recommended). Cover with a Plate sealer. Incubate for 1 hour at 37oC.
Detection Reagent A may appear cloudy. Warm to room temperature and mix gently until solution appears
uniform.
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2. Aspirate the solution and wash with 350μL of 1X Wash Solution to each well using a squirt bottle,
multi-channel pipette, manifold dispenser or autowasher, and let it sit for 1-2 minutes. Remove the remaining
liquid from all wells completely by snapping the plate onto absorbent paper. Repeat 3 times. After the last
wash, remove any remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against
absorbent paper.
3. Add 100μL of Detection Reagent B working solution to each well. Incubate for 30 minutes at 37oC after
covering it with the Plate sealer.
4. Repeat the aspiration/wash process for total 5 times as conducted in step 2.
5. Add 90μL of Substrate Solution to each well. Cover with a new Plate sealer. Incubate for 15 - 25 minutes at
37oC (Don't exceed 30 minutes). Protect from light. The liquid will turn blue by the addition of Substrate
Solution.
6. Add 50μL of Stop Solution to each well. The liquid will turn yellow by the addition of Stop solution. Mix the
liquid by tapping the side of the plate. If color change does not appear uniform, gently tap the plate to ensure
thorough mixing.
7. Remove any drop of water and fingerprint on the bottom of the plate and confirm there is no bubble on the
surface of the liquid. Then, run the microplate reader and conduct measurement at 450nm immediately.
Note:
1. Assay preparation: Keep appropriate numbers of wells for each experiment and remove extra wells from
microplate. Rest wells should be resealed and stored at -20oC.
2. Samples or reagents addition：Please use the freshly prepared Standard. Please carefully add samples
to wells and mix gently to avoid foaming. Do not touch the well wall. For each step in the procedure, total
dispensing time for addition of reagents or samples to the assay plate should not exceed 10 minutes. This
will ensure equal elapsed time for each pipetting step, without interruption. Duplication of all standards and
specimens, although not required, is recommended. To avoid cross-contamination, change pipette tips
between additions of standards, samples, and reagents. Also, use separated reservoirs for each reagent.
3. Incubation: To ensure accurate results, proper adhesion of plate sealers during incubation steps is
necessary. Do not allow wells to sit uncovered for extended periods between incubation steps. Once
reagents are added to the well strips, DO NOT let the strips DRY at any time during the assay. Incubation
time and temperature must be controlled.
4. Washing: The wash procedure is critical. Complete removal of liquid at each step is essential for good
performance. After the last wash, remove any remaining Wash Solution by aspirating or decanting and
remove any drop of water and fingerprint on the bottom of the plate. Insufficient washing will result in poor
precision and false elevated absorbance reading.
5. Controlling of reaction time: Observe the change of color after adding TMB Substrate (e.g. observation
once every 10 minutes), if the color is too deep, add Stop Solution in advance to avoid excessively strong
reaction which will result in inaccurate absorbance reading.
6. TMB Substrate is easily contaminated. Please protect it from light.
7. The environment humidity which is less than 60% might have some effects on the final performance,
therefore, a humidifier is recommended to be used at that condition.
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[ TEST PRINCIPLE ]
This assay employs the competitive inhibition enzyme immunoassay technique. A monoclonal antibody specific
to 5-HT has been pre-coated onto a microplate. A competitive inhibition reaction is launched between biotin
labeled 5-HT and unlabeled 5-HT (Standards or samples) with the pre-coated antibody specific to 5-HT. After
incubation the unbound conjugate is washed off. Next, avidin conjugated to Horseradish Peroxidase (HRP) is
added to each microplate well and incubated. The amount of bound HRP conjugate is reverse proportional to the
concentration of 5-HT in the sample. After addition of the substrate solution, the intensity of color developed is
reverse proportional to the concentration of 5-HT in the sample.
[ CALCULATION OF RESULTS ]
This assay employs the competitive inhibition enzyme immunoassay technique, so there is an inverse correlation
between 5-HT concentration in the sample and the assay signal intensity.
Average the duplicate readings for each standard, control, and samples. Create a standard curve on log-log or
semi-log graph paper, with the log of 5-HT concentration on the y-axis and absorbance on the x-axis. Draw the
best fit straight line through the standard points and it can be determined by regression analysis. Using some plot
software, for instance, curve expert 1.30, is also recommended. If samples have been diluted, the concentration
read from the standard curve must be multiplied by the dilution factor.
[ TYPICAL DATA ]
In order to make the calculation easier, we plot the O.D. value of the standard (X-axis) against the log of
concentration of the standard (Y-axis), although concentration is the independent variable and O.D. value is the
dependent variable. The O.D. values of the standard curve may vary according to the conditions of assay
performance (e.g. operator, pipetting technique, washing technique or temperature effects). Typical standard
curve below is provided for reference only.
Typical Standard Curve for 5-HT ELISA.
[ DETECTION RANGE ]
11.11-900ng/mL. The standard curve concentrations used for the ELISA’s were 900ng/mL, 300ng/mL, 100ng/mL,
33.33ng/mL, 11.11ng/mL.
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[ SENSITIVITY ]
The minimum detectable dose of 5-HT is typically less than 3.92ng/mL.
The sensitivity of this assay, or Lower Limit of Detection (LLD) was defined as the lowest protein concentration
that could be differentiated from zero. It was determined by subtracting two standard deviations to the mean
optical density value of twenty zero standard replicates and calculating the corresponding concentration.
[ SPECIFICITY ]
This assay has high sensitivity and excellent specificity for detection of 5-HT.
No significant cross-reactivity or interference between 5-HT and analogues was observed.
Note:
Limited by current skills and knowledge, it is impossible for us to complete the cross- reactivity detection between
5-HT and all the analogues, therefore, cross reaction may still exist.
[ RECOVERY ]
Matrices listed below were spiked with certain level of 5-HT and the recovery rates were calculated by comparing
the measured value to the expected amount of 5-HT in samples.
Matrix Recovery range (%) Average(%)
serum(n=5) 96-105 101
EDTA plasma(n=5) 86-98 93
heparin plasma(n=5) 80-101 89
[ LINEARITY ]
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of 5-HT and their
serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample 1：2 1：4 1：8 1：16
serum(n=5) 87-97% 79-104% 98-105% 92-102%
EDTA plasma(n=5) 93-101% 82-91% 78-90% 80-96%
heparin plasma(n=5) 89-103% 95-105% 85-101% 87-104%
[ PRECISION ]
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level 5-HT were tested 20
times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level 5-HT were tested on
3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
[ STABILITY ]
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within
the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room
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temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the
whole assay is performed by the same operator from the beginning to the end.
[ ASSAY PROCEDURE SUMMARY ]
1. Prepare all reagents, samples and standards;
2. Add 50μL standard or sample to each well.
And then add 50μL prepared Detection Reagent A immediately.
Shake and mix. Incubate 1 hour at 37oC;
3. Aspirate and wash 3 times;
4. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;
5. Aspirate and wash 5 times;
6. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;
7. Add 50μL Stop Solution. Read at 450 nm immediately.
[ IMPORTANT NOTE ]
1. Limited by the current condition and scientific technology, we can't completely conduct the comprehensive
identification and analysis on the raw material provided by suppliers. So there might be some qualitative and
technical risks to use the kit.
2. The final experimental results will be closely related to validity of the products, operation skills of the end
users and the experimental environments. Please make sure that sufficient samples are available.
3. Kits from different batches may be a little different in detection range, sensitivity and color developing time.
Please perform the experiment exactly according to the instruction attached in kit while electronic ones from
our website is only for information.
4. Do not mix or substitute reagents from one kit lot to another. Use only the reagents supplied by manufacturer.
5. Protect all reagents from strong light during storage and incubation. All the bottle caps of reagents should be
covered tightly to prevent the evaporation and contamination of microorganism.
6. There may be some foggy substance in the wells when the plate is opened at the first time. It will not have
any effect on the final assay results. Do not remove microtiter plate from the storage bag until needed.
7. Wrong operations during the reagents preparation and loading, as well as incorrect parameter setting for the
plate reader may lead to incorrect results. A microplate plate reader with a bandwidth of 10nm or less and an
optical density range of 0-3 O.D. or greater at 450 ± 10nm wavelength is acceptable for use in absorbance
measurement. Please read the instruction carefully and adjust the instrument prior to the experiment. For
more information, please refer to the operation video (http://www.cloud-clone.us/homepage/operate.htm).
8. Even the same operator might get different results in two separate experiments. In order to get better
reproducible results, the operation of every step in the assay should be controlled. Furthermore, a
preliminary experiment before assay for each batch is recommended.
9. Each kit has been strictly passed Q.C test. However, results from end users might be inconsistent with our
in-house data due to some unexpected transportation conditions or different lab equipments. Intra-assay
variance among kits from different batches might arise from above factors, too.
10. Kits from different manufacturers with the same item might produce different results, since we haven’t
compared our products with other manufacturers.
11. The instruction manual also suits for the kit of 48T, but all reagents of 48T kit are reduced by half.
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[ PRECAUTION ]
The Stop Solution suggested for use with this kit is an acid solution. Wear eye, hand, face, and clothing protection
when using this material.
[ TROUBLE SHOOTING ]
Problem Possible Source Correction Action
Poor
Standard
Curve
Improper standard curve preparation Ensure accurate operation of the dilution
Incomplete washing and aspiration Adequate washing and adequate aspiration
Inaccurate Pipetting Check and Calibrate pipettes
Poor
Precision
Incomplete washing of wells Ensure sufficient washing
Inadequate mixing and aspiration reagents Adequate aspiration and mixing reagents
Reused pipette tips, containers and sealers Change and use new pipette tips, containers and sealers
Inaccurate Pipetting Check and Calibrate pipettes
Low
O.D
Values
Inadequate reagent volumes added to wells Calibrate pipettes and Add adequate reagents
Incorrect incubation times Ensure sufficient incubation times
Incorrect incubation temperature Reagents balanced to room temperature
Conjugate or substrate reagent failure Mix conjugate &substrate,color should develop immediately
No stop solution added Follow the assay protocol in the kit manual
Read beyond suggested reading time Read within the time recommended in the manual
Sample
Values
Improper Sample Storage Store the sample properly and use the fresh sample
Improper sample collection and preparation Take proper sample collection and preparation method
Low quantity of analyte in samples Use new sample and repeat assay
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Appendix-5: Manual of PF4 ELISA assay
 
SEA172Hu 96 Tests
Enzyme-linked Immunosorbent Assay Kit
For Platelet Factor 4 (PF4)
Organism Species: Homo sapiens (Human)
Instruction manual
FOR IN VITRO AND RESEARCH USE ONLY
NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES
11th Edition (Revised in July, 2013)
[ INTENDED USE ]
The kit is a sandwich enzyme immunoassay for in vitro quantitative measurement of PF4 in human serum,
platelet-poor plasma and cell culture supernates.
[ REAGENTS AND MATERIALS PROVIDED ]
Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B 1×120μL Assay Diluent B 1×12mL
TMB Substrate 1×9mL Stop Solution 1×6mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1
[ MATERIALS REQUIRED BUT NOT SUPPLIED ]
1. Microplate reader with 450 ± 10nm filter.
2. Precision single or multi-channel pipettes and disposable tips.
3. Eppendorf Tubes for diluting samples.
4. Deionized or distilled water.
5. Absorbent paper for blotting the microtiter plate.
6. Container for Wash Solution
[ STORAGE OF THE KITS ]
1. For unopened kit: All the reagents should be kept according to the labels on vials. The Standard, Detection
Reagent A, Detection Reagent B and the 96-well strip plate should be stored at -20oC upon receipt while
the others should be at 4 oC.
2. For opened kit: When the kit is opened, the remaining reagents still need to be stored according to the
above storage condition. Besides, please return the unused wells to the foil pouch containing the desiccant
pack, and reseal along entire edge of zip-seal.
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Note:
It is highly recommended to use the remaining reagents within 1 month provided this is within the expiration date
of the kit. For the expiration date of the kit, please refer to the label on the kit box. All components are stable until
this expiration date.
[ SAMPLE COLLECTION AND STORAGE ]
Serum - Allow samples to clot for two hours at room temperature or overnight at 4oC before centrifugation for 20
minutes at approximately 1000×g. Assay immediately or store samples in aliquot at -20oC or -80oC. Avoid
repeated freeze/thaw cycles.
Platelet-Poor Plasma - Collect plasma on ice using EDTA or heparin as an anticoagulant. Centrifuge samples at
4oC for 20 minutes at 2,000×g within 30 minutes of collection. Centrifuge the separated plasma at 4oC for 10
minutes at 10,000×g. Assay immediately or store samples in aliquot at -20oC or -80oC. Avoid repeated
freeze/thaw cycles.
Cell culture supernates - Centrifuge samples for 20 minutes at 1000×g. Remove particulates and assay
immediately or store samples in aliquot at -20oC or -80oC for later use. Avoid repeated freeze/thaw cycles.
Note:
1. Samples to be used within 5 days may be stored at 4oC, otherwise samples must be stored at -20oC (≤1
month) or -80oC (≤2 months) to avoid loss of bioactivity and contamination.
2. Sample hemolysis will influence the result, so hemolytic specimen should not be detected.
3. When performing the assay, bring samples to room temperature.
[ REAGENT PREPARATION ]
1. Bring all kit components and samples to room temperature (18-25oC) before use.
2. Standard - Reconstitute the Standard with 1.0mL of Standard Diluent, kept for 10 minutes at room
temperature, shake gently(not to foam). The concentration of the standard in the stock solution is 400pg/mL.
Please firstly dilute the stock solution to 100pg/mL and the diluted standard serves as the highest standard
(100pg/mL). Then prepare 7 tubes containing 0.5mL Standard Diluent and use the diluted standard to
produce a double dilution series according to the picture shown below. Mix each tube thoroughly before the
next transfer. Set up 7 points of diluted standard such as 100pg/mL, 50pg/mL, 25pg/mL, 12.5pg/mL,
6.25pg/mL, 3.12pg/mL, 1.56pg/mL, and the last EP tubes with Standard Diluent is the blank as 0pg/mL.
3. Detection Reagent A and Detection Reagent B - Briefly spin or centrifuge the stock Detection A and
Detection B before use. Dilute to the working concentration with Assay Diluent A and B, respectively
(1:100).
Tube 1 2 3 4 5 6 7 8 9
pg/mL 400 100 50 25 12.5 6.25 3.12 1.56 0
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4. Wash Solution - Dilute 20mL of Wash Solution concentrate (30×) with 580mL of deionized or distilled water
to prepare 600mL of Wash Solution (1×).
5. TMB substrate - Aspirate the needed dosage of the solution with sterilized tips and do not dump the residual
solution into the vial again.
Note:
1. Making serial dilution in the wells directly is not permitted.
2. Prepare standard within 15 minutes before assay. Please do not dissolve the reagents at 37oC directly.
3. Please carefully reconstitute Standards or working Detection Reagent A and B according to the instruction,
and avoid foaming and mix gently until the crystals are completely dissolved. To minimize imprecision caused
by pipetting, use small volumes and ensure that pipettors are calibrated. It is recommended to suck more
than 10μL for once pipetting.
4. The reconstituted Standards, Detection Reagent A and Detection Reagent B can be used only once.
5. If crystals have formed in the Wash Solution concentrate (30×), warm to room temperature and mix gently
until the crystals are completely dissolved.
6. Contaminated water or container for reagent preparation will influence the detection result.
[ SAMPLE PREPARATION ]
1. Cloud-Clone Corp. is only responsible for the kit itself, but not for the samples consumed during the assay.
The user should calculate the possible amount of the samples used in the whole test. Please reserve
sufficient samples in advance.
2. Please predict the concentration before assaying. If values for these are not within the range of the standard
curve, users must determine the optimal sample dilutions for their particular experiments.
3. Serum/plasma samples require about a 2,000 fold dilution. For example, to prepare a 1:2,000 dilution of
sample, transfer 20μL of sample to 380μL PBS. This yields a 1:20 dilution. Next, dilute the 1:20 sample by
transferring 10μL to 990μL PBS. You now have a 1:2,000 dilution of your sample. Mix thoroughly at each
stage. Sample should be diluted by 0.01mol/L PBS(PH=7.0-7.2).
4. If the samples are not indicated in the manual, a preliminary experiment to determine the validity of the kit is
necessary.
5. Tissue or cell extraction samples prepared by chemical lysis buffer may cause unexpected ELISA results due
to the impacts from certain chemicals.
6. Due to the possibility of mismatching between antigen from other origin and antibody used in our kits (e.g.,
antibody targets conformational epitope rather than linear epitope), some native or recombinant proteins
from other manufacturers may not be recognized by our products.
7. Influenced by the factors including cell viability, cell number or sampling time, samples from cell culture
supernatant may not be detected by the kit.
8. Fresh samples without long time storage is recommended for the test. Otherwise, protein degradation and
denaturalization may occur in those samples and finally lead to wrong results.
[ ASSAY PROCEDURE ]
1. Determine wells for diluted standard, blank and sample. Prepare 7 wells for standard, 1 well for blank.
Add 100μL each of dilutions of standard (read Reagent Preparation), blank and samples into the appropriate
wells. Cover with the Plate sealer. Incubate for 2 hours at 37oC.
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2. Remove the liquid of each well, don’t wash.
3. Add 100μL of Detection Reagent A working solution to each well. Incubate for 1 hour at 37oC after covering
it with the Plate sealer.
4. Aspirate the solution and wash with 350μL of 1× Wash Solution to each well using a squirt bottle,
multi-channel pipette, manifold dispenser or autowasher, and let it sit for 1~2 minutes. Remove the remaining
liquid from all wells completely by snapping the plate onto absorbent paper. Totally wash 3 times. After the
last wash, remove any remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against
absorbent paper.
5. Add 100μL of Detection Reagent B working solution to each well. Incubate for 30 minutes at 37oC after
covering it with the Plate sealer.
6. Repeat the aspiration/wash process for total 5 times as conducted in step 4.
7. Add 90μL of Substrate Solution to each well. Cover with a new Plate sealer. Incubate for 15 - 25 minutes at
37oC (Don't exceed 30 minutes). Protect from light. The liquid will turn blue by the addition of Substrate
Solution.
8. Add 50μL of Stop Solution to each well. The liquid will turn yellow by the addition of Stop solution. Mix the
liquid by tapping the side of the plate. If color change does not appear uniform, gently tap the plate to ensure
thorough mixing.
9. Remove any drop of water and fingerprint on the bottom of the plate and confirm there is no bubble on the
surface of the liquid. Then, run the microplate reader and conduct measurement at 450nm immediately.
Note:
1. Assay preparation: Keep appropriate numbers of wells for each experiment and remove extra wells from
microplate. Rest wells should be resealed and stored at -20oC.
2. Samples or reagents addition：Please use the freshly prepared Standard. Please carefully add samples
to wells and mix gently to avoid foaming. Do not touch the well wall. For each step in the procedure, total
dispensing time for addition of reagents or samples to the assay plate should not exceed 10 minutes. This
will ensure equal elapsed time for each pipetting step, without interruption. Duplication of all standards and
specimens, although not required, is recommended. To avoid cross-contamination, change pipette tips
between additions of standards, samples, and reagents. Also, use separated reservoirs for each reagent.
3. Incubation: To ensure accurate results, proper adhesion of plate sealers during incubation steps is
necessary. Do not allow wells to sit uncovered for extended periods between incubation steps. Once
reagents are added to the well strips, DO NOT let the strips DRY at any time during the assay. Incubation
time and temperature must be controlled.
4. Washing: The wash procedure is critical. Complete removal of liquid at each step is essential for good
performance. After the last wash, remove any remaining Wash Solution by aspirating or decanting and
remove any drop of water and fingerprint on the bottom of the plate. Insufficient washing will result in poor
precision and false elevated absorbance reading.
5. Controlling of reaction time: Observe the change of color after adding TMB Substrate (e.g. observation
once every 10 minutes), if the color is too deep, add Stop Solution in advance to avoid excessively strong
reaction which will result in inaccurate absorbance reading.
6. TMB Substrate is easily contaminated. Please protect it from light.
7. The environment humidity which is less than 60% might have some effects on the final performance,
therefore, a humidifier is recommended to be used at that condition.
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[ TEST PRINCIPLE ]
The microtiter plate provided in this kit has been pre-coated with an antibody specific to PF4. Standards or
samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to PF4.
Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After
TMB substrate solution is added, only those wells that contain PF4, biotin-conjugated antibody and
enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the
addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of
450nm ± 10nm. The concentration of PF4 in the samples is then determined by comparing the O.D. of the
samples to the standard curve.
[ CALCULATION OF RESULTS ]
Average the duplicate readings for each standard, control, and samples and subtract the average zero standard
optical density. Construct a standard curve by plotting the mean O.D. and concentration for each standard and
draw a best fit curve through the points on the graph or create a standard curve on log-log graph paper with PF4
concentration on the y-axis and absorbance on the x-axis. Using some plot software, for instance, curve expert
1.30, is also recommended. If samples have been diluted, the concentration read from the standard curve must
be multiplied by the dilution factor.
[ TYPICAL DATA ]
In order to make the calculation easier, we plot the O.D. value of the standard (X-axis) against the known
concentration of the standard (Y-axis), although concentration is the independent variable and O.D. value is the
dependent variable. However, the O.D. values of the standard curve may vary according to the conditions of
assay performance (e.g. operator, pipetting technique, washing technique or temperature effects), plotting log of
the data to establish standard curve for each test is recommended. Typical standard curve below is provided for
reference only.
Typical Standard Curve for PF4, Human ELISA.
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[ DETECTION RANGE ]
1.56 -100pg/mL. The standard curve concentrations used for the ELISA’s were 100pg/mL, 50pg/mL, 25pg/mL,
12.5pg/mL, 6.25pg/mL, 3.12pg/mL, 1.56pg/mL.
[ SENSITIVITY ]
The minimum detectable dose of PF4 is typically less than 0.68pg/mL.
The sensitivity of this assay, or Lower Limit of Detection (LLD) was defined as the lowest protein concentration
that could be differentiated from zero. It was determined by adding two standard deviations to the mean optical
density value of twenty zero standard replicates and calculating the corresponding concentration.
[ SPECIFICITY ]
This assay has high sensitivity and excellent specificity for detection of PF4.
No significant cross-reactivity or interference between PF4 and analogues was observed.
Note:
Limited by current skills and knowledge, it is impossible for us to complete the cross- reactivity detection between
PF4 and all the analogues, therefore, cross reaction may still exist.
[ RECOVERY ]
Matrices listed below were spiked with certain level of recombinant PF4 and the recovery rates were calculated
by comparing the measured value to the expected amount of PF4 in samples.
Matrix Recovery range (%) Average(%)
serum(n=5) 85-98 92
EDTA plasma(n=5) 88-101 95
heparin plasma(n=5) 91-105 99
[ LINEARITY ]
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of PF4 and their
serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample 1：2 1：4 1：8 1：16
serum(n=5) 89-98% 86-104% 80-98% 90-107%
EDTA plasma(n=5) 78-92% 80-93% 92-103% 88-99%
heparin plasma(n=5) 96-103% 85-99% 90-106% 81-95%
[ PRECISION ]
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level PF4 were tested 20
times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level PF4 were tested on
3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
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[ STABILITY ]
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within
the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room
temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the
whole assay is performed by the same operator from the beginning to the end.
[ ASSAY PROCEDURE SUMMARY ]
1. Prepare all reagents, samples and standards;
2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;
3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;
4. Aspirate and wash 3 times;
5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;
6. Aspirate and wash 5 times;
7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;
8. Add 50μL Stop Solution. Read at 450nm immediately.
[ IMPORTANT NOTE ]
1. Limited by the current condition and scientific technology, we can't completely conduct the comprehensive
identification and analysis on the raw material provided by suppliers. So there might be some qualitative and
technical risks to use the kit.
2. The final experimental results will be closely related to validity of the products, operation skills of the end
users and the experimental environments. Please make sure that sufficient samples are available.
3. Kits from different batches may be a little different in detection range, sensitivity and color developing time.
Please perform the experiment exactly according to the instruction attached in kit while electronic ones from
our website is only for information.
4. Do not mix or substitute reagents from one kit lot to another. Use only the reagents supplied by manufacturer.
5. Protect all reagents from strong light during storage and incubation. All the bottle caps of reagents should be
covered tightly to prevent the evaporation and contamination of microorganism.
6. There may be some foggy substance in the wells when the plate is opened at the first time. It will not have
any effect on the final assay results. Do not remove microtiter plate from the storage bag until needed.
7. Wrong operations during the reagents preparation and loading, as well as incorrect parameter setting for the
plate reader may lead to incorrect results. A microplate plate reader with a bandwidth of 10nm or less and an
optical density range of 0-3 O.D. or greater at 450 ± 10nm wavelength is acceptable for use in absorbance
measurement. Please read the instruction carefully and adjust the instrument prior to the experiment. For
more information, please refer to the operation video (http://www.cloud-clone.us/homepage/operate.htm).
8. Even the same operator might get different results in two separate experiments. In order to get better
reproducible results, the operation of every step in the assay should be controlled. Furthermore, a
preliminary experiment before assay for each batch is recommended.
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9. Each kit has been strictly passed Q.C test. However, results from end users might be inconsistent with our
in-house data due to some unexpected transportation conditions or different lab equipments. Intra-assay
variance among kits from different batches might arise from above factors, too.
10. Kits from different manufacturers with the same item might produce different results, since we haven’t
compared our products with other manufacturers.
11. The instruction manual also suits for the kit of 48T, but all reagents of 48T kit are reduced by half.
[ PRECAUTION ]
The Stop Solution suggested for use with this kit is an acid solution. Wear eye, hand, face, and clothing protection
when using this material.
[ TROUBLE SHOOTING ]
Problem Possible Source Correction Action
Poor
Standard
Curve
Improper standard curve preparation Ensure accurate operation of the dilution
Incomplete washing and aspiration Adequate washing and adequate aspiration
Inaccurate Pipetting Check and Calibrate pipettes
Poor
Precision
Incomplete washing of wells Ensure sufficient washing
Inadequate mixing and aspiration reagents Adequate aspiration and mixing reagents
Reused pipette tips, containers and sealers Change and use new pipette tips, containers and sealers
Inaccurate Pipetting Check and Calibrate pipettes
Low
O.D
Values
Inadequate reagent volumes added to wells Calibrate pipettes and Add adequate reagents
Incorrect incubation times Ensure sufficient incubation times
Incorrect incubation temperature Reagents balanced to room temperature
Conjugate or substrate reagent failure Mix conjugate &substrate,color should develop immediately
No stop solution added Follow the assay protocol in the kit manual
Read beyond suggested reading time Read within the time recommended in the manual
Sample
Values
Improper Sample Storage Store the sample properly and use the fresh sample
Improper sample collection and preparation Take proper sample collection and preparation method
Low quantity of analyte in samples Use new sample and repeat assay
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Appendix-6: Manual of β-TG ELISA assay 
 
SEA370Hu 96 Tests
Enzyme-linked Immunosorbent Assay Kit
For Beta-Thromboglobulin (bTG)
Organism Species: Homo sapiens (Human)
Instruction manual
FOR IN VITRO AND RESEARCH USE ONLY
NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES
11th Edition (Revised in July, 2013)
[ INTENDED USE ]
The kit is a sandwich enzyme immunoassay for in vitro quantitative measurement of bTG in human serum,
plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.
[ REAGENTS AND MATERIALS PROVIDED ]
Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B 1×120μL Assay Diluent B 1×12mL
TMB Substrate 1×9mL Stop Solution 1×6mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1
[ MATERIALS REQUIRED BUT NOT SUPPLIED ]
1. Microplate reader with 450 ± 10nm filter.
2. Precision single or multi-channel pipettes and disposable tips.
3. Eppendorf Tubes for diluting samples.
4. Deionized or distilled water.
5. Absorbent paper for blotting the microtiter plate.
6. Container for Wash Solution
[ STORAGE OF THE KITS ]
1. For unopened kit: All the reagents should be kept according to the labels on vials. The Standard, Detection
Reagent A, Detection Reagent B and the 96-well strip plate should be stored at -20oC upon receipt while
the others should be at 4 oC.
2. For opened kit: When the kit is opened, the remaining reagents still need to be stored according to the
above storage condition. Besides, please return the unused wells to the foil pouch containing the desiccant
pack, and reseal along entire edge of zip-seal.
Note:
It is highly recommended to use the remaining reagents within 1 month provided this is within the expiration date
of the kit. For the expiration date of the kit, please refer to the label on the kit box. All components are stable until
this expiration date.
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[ SAMPLE COLLECTION AND STORAGE ]
Serum - Use a serum separator tube and allow samples to clot for two hours at room temperature or overnight at
4oC before centrifugation for 20 minutes at approximately 1000×g. Assay freshly prepared serum
immediately or store samples in aliquot at -20oC or -80oC for later use. Avoid repeated freeze/thaw cycles.
Plasma - Collect plasma using EDTA or heparin as an anticoagulant. Centrifuge samples for 15 minutes at
1000×g at 2 - 8oC within 30 minutes of collection. Remove plasma and assay immediately or store samples
in aliquot at -20oC or -80oC for later use. Avoid repeated freeze/thaw cycles.
Tissue homogenates - The preparation of tissue homogenates will vary depending upon tissue type. For this
assay, tissues were rinsed in ice-cold PBS(0.01mol/L,pH 7.0-7.2) to remove excess blood thoroughly and
weighed before homogenization. Minced the tissues to small pieces and homogenized them in 5-10mL of
PBS with a glass homogenizer on ice(Micro Tissue Grinders woks, too). The resulting suspension was
sonicated with an ultrasonic cell disrupter or subjected to two freeze-thaw cycles to further break the cell
membranes. After that, the homogenates were centrifugated for 5 minutes at 5000×g. Remove the supernate
and assay immediately or aliquot and store at ≤-20oC.
Cell Lysates - Cells must be lysed before assaying according to the following directions.
1. Adherent cells should be detached with trypsin and then collected by centrifugation (suspension cells can
be collected by centrifugation directly).
2. Wash cells three times in cold PBS.
3. Resuspend cells in PBS (1×) and the cells was subject to ultrasonication for 4 times (or Freeze cells at ≤
-20oC. Thaw cells with gentle mixing. Repeat the freeze/thaw cycle for 3 times.)
4. Centrifuge at 1500×g for 10 minutes at 2 - 8oC to remove cellular debris.
Cell culture supernates and other biological fluids - Centrifuge samples for 20 minutes at 1000×g. Remove
particulates and assay immediately or store samples in aliquot at -20oC or -80oC for later use. Avoid repeated
freeze/thaw cycles.
Note:
1. Samples to be used within 5 days may be stored at 4oC, otherwise samples must be stored at -20oC (≤1
month) or -80oC (≤2 months) to avoid loss of bioactivity and contamination.
2. Sample hemolysis will influence the result, so hemolytic specimen should not be detected.
3. When performing the assay, bring samples to room temperature.
[ REAGENT PREPARATION ]
1. Bring all kit components and samples to room temperature (18-25oC) before use.
2. Standard - Reconstitute the Standard with 1.0mL of Standard Diluent, kept for 10 minutes at room
temperature, shake gently(not to foam). The concentration of the standard in the stock solution is
80,000pg/mL. Please firstly dilute the stock solution to 8,000pg/mL and the diluted standard serves as the
highest standard (8,000pg/mL). Then prepare 7 tubes containing 0.5mL Standard Diluent and use the diluted
standard to produce a double dilution series according to the picture shown below. Mix each tube thoroughly
before the next transfer. Set up 7 points of diluted standard such as 8,000pg/mL, 4,000pg/mL, 2,000pg/mL,
1,000pg/mL, 500pg/mL, 250pg/mL, 125pg/mL, and the last EP tubes with Standard Diluent is the blank as
0pg/mL.
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3. Detection Reagent A and Detection Reagent B - Briefly spin or centrifuge the stock Detection A and
Detection B before use. Dilute to the working concentration with Assay Diluent A and B, respectively
(1:100).
4. Wash Solution - Dilute 20mL of Wash Solution concentrate (30×) with 580mL of deionized or distilled water
to prepare 600mL of Wash Solution (1×).
5. TMB substrate - Aspirate the needed dosage of the solution with sterilized tips and do not dump the residual
solution into the vial again.
Note:
1. Making serial dilution in the wells directly is not permitted.
2. Prepare standard within 15 minutes before assay. Please do not dissolve the reagents at 37oC directly.
3. Please carefully reconstitute Standards or working Detection Reagent A and B according to the instruction,
and avoid foaming and mix gently until the crystals are completely dissolved. To minimize imprecision caused
by pipetting, use small volumes and ensure that pipettors are calibrated. It is recommended to suck more
than 10μL for once pipetting.
4. The reconstituted Standards, Detection Reagent A and Detection Reagent B can be used only once.
5. If crystals have formed in the Wash Solution concentrate (30×), warm to room temperature and mix gently
until the crystals are completely dissolved.
6. Contaminated water or container for reagent preparation will influence the detection result.
[ SAMPLE PREPARATION ]
1. Cloud-Clone Corp. is only responsible for the kit itself, but not for the samples consumed during the assay.
The user should calculate the possible amount of the samples used in the whole test. Please reserve
sufficient samples in advance.
2. Please predict the concentration before assaying. If values for these are not within the range of the standard
curve, users must determine the optimal sample dilutions for their particular experiments.
3. Serum/plasma samples require about a 50 fold dilution. A suggested 50-fold dilution is 10μL Sample + 490μL
PBS. Sample should be diluted by 0.01mol/L PBS(PH=7.0-7.2).
4. If the samples are not indicated in the manual, a preliminary experiment to determine the validity of the kit is
necessary.
5. Tissue or cell extraction samples prepared by chemical lysis buffer may cause unexpected ELISA results due
to the impacts from certain chemicals.
Tube 1 2 3 4 5 6 7 8 9
pg/mL 80,000 8,000 4,000 2,000 1,000 500 250 125 0
  187 
 
6. Due to the possibility of mismatching between antigen from other origin and antibody used in our kits (e.g.,
antibody targets conformational epitope rather than linear epitope), some native or recombinant proteins
from other manufacturers may not be recognized by our products.
7. Influenced by the factors including cell viability, cell number or sampling time, samples from cell culture
supernatant may not be detected by the kit.
8. Fresh samples without long time storage is recommended for the test. Otherwise, protein degradation and
denaturalization may occur in those samples and finally lead to wrong results.
[ ASSAY PROCEDURE ]
1. Determine wells for diluted standard, blank and sample. Prepare 7 wells for standard, 1 well for blank.
Add 100μL each of dilutions of standard (read Reagent Preparation), blank and samples into the appropriate
wells. Cover with the Plate sealer. Incubate for 2 hours at 37oC.
2. Remove the liquid of each well, don’t wash.
3. Add 100μL of Detection Reagent A working solution to each well. Incubate for 1 hour at 37oC after covering
it with the Plate sealer.
4. Aspirate the solution and wash with 350μL of 1× Wash Solution to each well using a squirt bottle,
multi-channel pipette, manifold dispenser or autowasher, and let it sit for 1~2 minutes. Remove the remaining
liquid from all wells completely by snapping the plate onto absorbent paper. Totally wash 3 times. After the
last wash, remove any remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against
absorbent paper.
5. Add 100μL of Detection Reagent B working solution to each well. Incubate for 30 minutes at 37oC after
covering it with the Plate sealer.
6. Repeat the aspiration/wash process for total 5 times as conducted in step 4.
7. Add 90μL of Substrate Solution to each well. Cover with a new Plate sealer. Incubate for 15 - 25 minutes at
37oC (Don't exceed 30 minutes). Protect from light. The liquid will turn blue by the addition of Substrate
Solution.
8. Add 50μL of Stop Solution to each well. The liquid will turn yellow by the addition of Stop solution. Mix the
liquid by tapping the side of the plate. If color change does not appear uniform, gently tap the plate to ensure
thorough mixing.
9. Remove any drop of water and fingerprint on the bottom of the plate and confirm there is no bubble on the
surface of the liquid. Then, run the microplate reader and conduct measurement at 450nm immediately.
Note:
1. Assay preparation: Keep appropriate numbers of wells for each experiment and remove extra wells from
microplate. Rest wells should be resealed and stored at -20oC.
2. Samples or reagents addition：Please use the freshly prepared Standard. Please carefully add samples
to wells and mix gently to avoid foaming. Do not touch the well wall. For each step in the procedure, total
dispensing time for addition of reagents or samples to the assay plate should not exceed 10 minutes. This
will ensure equal elapsed time for each pipetting step, without interruption. Duplication of all standards and
specimens, although not required, is recommended. To avoid cross-contamination, change pipette tips
between additions of standards, samples, and reagents. Also, use separated reservoirs for each reagent.
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3. Incubation: To ensure accurate results, proper adhesion of plate sealers during incubation steps is
necessary. Do not allow wells to sit uncovered for extended periods between incubation steps. Once
reagents are added to the well strips, DO NOT let the strips DRY at any time during the assay. Incubation
time and temperature must be controlled.
4. Washing: The wash procedure is critical. Complete removal of liquid at each step is essential for good
performance. After the last wash, remove any remaining Wash Solution by aspirating or decanting and
remove any drop of water and fingerprint on the bottom of the plate. Insufficient washing will result in poor
precision and false elevated absorbance reading.
5. Controlling of reaction time: Observe the change of color after adding TMB Substrate (e.g. observation
once every 10 minutes), if the color is too deep, add Stop Solution in advance to avoid excessively strong
reaction which will result in inaccurate absorbance reading.
6. TMB Substrate is easily contaminated. Please protect it from light.
7. The environment humidity which is less than 60% might have some effects on the final performance,
therefore, a humidifier is recommended to be used at that condition.
[ TEST PRINCIPLE ]
The microtiter plate provided in this kit has been pre-coated with an antibody specific to bTG. Standards or
samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to bTG.
Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After
TMB substrate solution is added, only those wells that contain bTG, biotin-conjugated antibody and
enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the
addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of
450nm ± 10nm. The concentration of bTG in the samples is then determined by comparing the O.D. of the
samples to the standard curve.
[ CALCULATION OF RESULTS ]
Average the duplicate readings for each standard, control, and samples and subtract the average zero standard
optical density. Construct a standard curve by plotting the mean O.D. and concentration for each standard and
draw a best fit curve through the points on the graph or create a standard curve on log-log graph paper with bTG
concentration on the y-axis and absorbance on the x-axis. Using some plot software, for instance, curve expert
1.30, is also recommended. If samples have been diluted, the concentration read from the standard curve must
be multiplied by the dilution factor.
[ TYPICAL DATA ]
In order to make the calculation easier, we plot the O.D. value of the standard (X-axis) against the known
concentration of the standard (Y-axis), although concentration is the independent variable and O.D. value is the
dependent variable. However, the O.D. values of the standard curve may vary according to the conditions of
assay performance (e.g. operator, pipetting technique, washing technique or temperature effects), plotting log of
the data to establish standard curve for each test is recommended. Typical standard curve below is provided for
reference only.
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Typical Standard Curve for bTG, Human ELISA.
[ DETECTION RANGE ]
125-8,000pg/mL. The standard curve concentrations used for the ELISA’s were 8,000pg/mL, 4,000pg/mL,
2,000pg/mL, 1,000pg/mL, 500pg/mL, 250pg/mL, 125pg/mL.
[ SENSITIVITY ]
The minimum detectable dose of bTG is typically less than 53pg/mL.
The sensitivity of this assay, or Lower Limit of Detection (LLD) was defined as the lowest protein concentration
that could be differentiated from zero. It was determined by adding two standard deviations to the mean optical
density value of twenty zero standard replicates and calculating the corresponding concentration.
[ SPECIFICITY ]
This assay has high sensitivity and excellent specificity for detection of bTG.
No significant cross-reactivity or interference between bTG and analogues was observed.
Note:
Limited by current skills and knowledge, it is impossible for us to complete the cross- reactivity detection between
bTG and all the analogues, therefore, cross reaction may still exist.
[ RECOVERY ]
Matrices listed below were spiked with certain level of recombinant bTG and the recovery rates were calculated
by comparing the measured value to the expected amount of bTG in samples.
Matrix Recovery range (%) Average(%)
serum(n=5) 78-92 85
EDTA plasma(n=5) 87-103 97
heparin plasma(n=5) 90-99 95
[ LINEARITY ]
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of bTG and their
serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
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Sample 1：2 1：4 1：8 1：16
serum(n=5) 86-94% 82-101% 89-104% 80-94%
EDTA plasma(n=5) 91-105% 83-98% 80-94% 84-97%
heparin plasma(n=5) 84-97% 79-95% 96-105% 85-99%
[ PRECISION ]
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level bTG were tested 20
times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level bTG were tested on
3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
[ STABILITY ]
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within
the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room
temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the
whole assay is performed by the same operator from the beginning to the end.
[ ASSAY PROCEDURE SUMMARY ]
1. Prepare all reagents, samples and standards;
2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;
3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;
4. Aspirate and wash 3 times;
5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;
6. Aspirate and wash 5 times;
7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;
8. Add 50μL Stop Solution. Read at 450nm immediately.
[ IMPORTANT NOTE ]
1. Limited by the current condition and scientific technology, we can't completely conduct the comprehensive
identification and analysis on the raw material provided by suppliers. So there might be some qualitative and
technical risks to use the kit.
2. The final experimental results will be closely related to validity of the products, operation skills of the end
users and the experimental environments. Please make sure that sufficient samples are available.
3. Kits from different batches may be a little different in detection range, sensitivity and color developing time.
Please perform the experiment exactly according to the instruction attached in kit while electronic ones from
our website is only for information.
4. Do not mix or substitute reagents from one kit lot to another. Use only the reagents supplied by manufacturer.
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5. Protect all reagents from strong light during storage and incubation. All the bottle caps of reagents should be
covered tightly to prevent the evaporation and contamination of microorganism.
6. There may be some foggy substance in the wells when the plate is opened at the first time. It will not have
any effect on the final assay results. Do not remove microtiter plate from the storage bag until needed.
7. Wrong operations during the reagents preparation and loading, as well as incorrect parameter setting for the
plate reader may lead to incorrect results. A microplate plate reader with a bandwidth of 10nm or less and an
optical density range of 0-3 O.D. or greater at 450 ± 10nm wavelength is acceptable for use in absorbance
measurement. Please read the instruction carefully and adjust the instrument prior to the experiment. For
more information, please refer to the operation video (http://www.cloud-clone.us/homepage/operate.htm).
8. Even the same operator might get different results in two separate experiments. In order to get better
reproducible results, the operation of every step in the assay should be controlled. Furthermore, a
preliminary experiment before assay for each batch is recommended.
9. Each kit has been strictly passed Q.C test. However, results from end users might be inconsistent with our
in-house data due to some unexpected transportation conditions or different lab equipments. Intra-assay
variance among kits from different batches might arise from above factors, too.
10. Kits from different manufacturers with the same item might produce different results, since we haven’t
compared our products with other manufacturers.
11. The instruction manual also suits for the kit of 48T, but all reagents of 48T kit are reduced by half.
[ PRECAUTION ]
The Stop Solution suggested for use with this kit is an acid solution. Wear eye, hand, face, and clothing protection
when using this material.
[ TROUBLE SHOOTING ]
Problem Possible Source Correction Action
Poor
Standard
Curve
Improper standard curve preparation Ensure accurate operation of the dilution
Incomplete washing and aspiration Adequate washing and adequate aspiration
Inaccurate Pipetting Check and Calibrate pipettes
Poor
Precision
Incomplete washing of wells Ensure sufficient washing
Inadequate mixing and aspiration reagents Adequate aspiration and mixing reagents
Reused pipette tips, containers and sealers Change and use new pipette tips, containers and sealers
Inaccurate Pipetting Check and Calibrate pipettes
Low
O.D
Values
Inadequate reagent volumes added to wells Calibrate pipettes and Add adequate reagents
Incorrect incubation times Ensure sufficient incubation times
Incorrect incubation temperature Reagents balanced to room temperature
Conjugate or substrate reagent failure Mix conjugate &substrate,color should develop immediately
No stop solution added Follow the assay protocol in the kit manual
Read beyond suggested reading time Read within the time recommended in the manual
Sample
Values
Improper Sample Storage Store the sample properly and use the fresh sample
Improper sample collection and preparation Take proper sample collection and preparation method
Low quantity of analyte in samples Use new sample and repeat assay
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Appendix-7: Manual of TXB2 ELISA assay 
The assay protocol link: 
http://www.abcam.com/ps/products/133/ab133022/documents/ab133022%20-
%20Thromboxane%20B2%20ELISA%20Kit%20v7%20(website).pdf  
 
 
 
